10-K 1 ctlt-20220630.htm 10-K ctlt-20220630
FALSE2022FY179895677.0008873--06-3000015967830.010.011,000,000,0001,000,000,000179,302,032162,788,0430.010.01100,000,000100,000,000384,777650000384,7776500002912P20YP3Yhttp://fasb.org/us-gaap/2022#DefinedBenefitPensionPlanLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2022#DefinedBenefitPensionPlanLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2022#DefinedBenefitPensionPlanLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2022#DefinedBenefitPensionPlanLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2022#DefinedBenefitPensionPlanLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2022#DefinedBenefitPensionPlanLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitieshttp://fasb.org/us-gaap/2022#OtherLiabilitieshttp://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentNethttp://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentNethttp://fasb.org/us-gaap/2022#OtherAssetsNoncurrent00015967832021-07-012022-06-3000015967832021-12-31iso4217:USD00015967832022-08-19xbrli:shares00015967832022-06-3000015967832021-06-300001596783us-gaap:FairValueInputsLevel1Member2022-06-30iso4217:USDxbrli:shares00015967832020-07-012021-06-3000015967832019-07-012020-06-300001596783us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-07-012022-06-300001596783ctlt:ACOIAccumulatedGainLossMarketableSecuritiesMember2021-07-012022-06-300001596783ctlt:ACOIAccumulatedGainLossMarketableSecuritiesMember2020-07-012021-06-300001596783ctlt:ACOIAccumulatedGainLossMarketableSecuritiesMember2019-07-012020-06-300001596783us-gaap:CommonStockMember2019-06-300001596783us-gaap:AdditionalPaidInCapitalMember2019-06-300001596783us-gaap:RetainedEarningsMember2019-06-300001596783us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-06-3000015967832019-06-300001596783us-gaap:CommonStockMember2019-07-012020-06-300001596783us-gaap:AdditionalPaidInCapitalMember2019-07-012020-06-300001596783us-gaap:RetainedEarningsMember2019-07-012020-06-300001596783us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-07-012020-06-300001596783us-gaap:CommonStockMember2020-06-300001596783us-gaap:AdditionalPaidInCapitalMember2020-06-300001596783us-gaap:RetainedEarningsMember2020-06-300001596783us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-3000015967832020-06-300001596783us-gaap:CommonStockMember2020-07-012021-06-300001596783us-gaap:AdditionalPaidInCapitalMember2020-07-012021-06-300001596783us-gaap:RetainedEarningsMember2020-07-012021-06-300001596783us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-07-012021-06-300001596783us-gaap:CommonStockMember2021-06-300001596783us-gaap:AdditionalPaidInCapitalMember2021-06-300001596783us-gaap:RetainedEarningsMember2021-06-300001596783us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300001596783us-gaap:CommonStockMember2021-07-012022-06-300001596783us-gaap:AdditionalPaidInCapitalMember2021-07-012022-06-300001596783us-gaap:RetainedEarningsMember2021-07-012022-06-300001596783us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012022-06-300001596783us-gaap:CommonStockMember2022-06-300001596783us-gaap:AdditionalPaidInCapitalMember2022-06-300001596783us-gaap:RetainedEarningsMember2022-06-300001596783us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300001596783srt:MinimumMemberctlt:BuildingAndImprovementsMember2021-07-012022-06-300001596783ctlt:BuildingAndImprovementsMembersrt:MaximumMember2021-07-012022-06-300001596783srt:MinimumMemberus-gaap:MachineryAndEquipmentMember2021-07-012022-06-300001596783us-gaap:MachineryAndEquipmentMembersrt:MaximumMember2021-07-012022-06-300001596783srt:MinimumMemberus-gaap:FurnitureAndFixturesMember2021-07-012022-06-300001596783us-gaap:FurnitureAndFixturesMembersrt:MaximumMember2021-07-012022-06-300001596783ctlt:BiologicsMemberctlt:ManufacturingCommercialProductSupplyMember2021-07-012022-06-300001596783ctlt:SoftgelAndOralTechnologiesMemberctlt:ManufacturingCommercialProductSupplyMember2021-07-012022-06-300001596783ctlt:OralAndSpecialtyDeliveryMemberctlt:ManufacturingCommercialProductSupplyMember2021-07-012022-06-300001596783ctlt:ClinicalSupplyServicesMemberctlt:ManufacturingCommercialProductSupplyMember2021-07-012022-06-300001596783ctlt:TotalCatalentbeforeintersegmentrevenueeliminationMemberctlt:ManufacturingCommercialProductSupplyMember2021-07-012022-06-300001596783ctlt:BiologicsMemberctlt:DevelopmentServicesMember2021-07-012022-06-300001596783ctlt:SoftgelAndOralTechnologiesMemberctlt:DevelopmentServicesMember2021-07-012022-06-300001596783ctlt:OralAndSpecialtyDeliveryMemberctlt:DevelopmentServicesMember2021-07-012022-06-300001596783ctlt:ClinicalSupplyServicesMemberctlt:DevelopmentServicesMember2021-07-012022-06-300001596783ctlt:TotalCatalentbeforeintersegmentrevenueeliminationMemberctlt:DevelopmentServicesMember2021-07-012022-06-300001596783ctlt:BiologicsMemberctlt:ClinicalSupplyServicesMember2021-07-012022-06-300001596783ctlt:SoftgelAndOralTechnologiesMemberctlt:ClinicalSupplyServicesMember2021-07-012022-06-300001596783ctlt:OralAndSpecialtyDeliveryMemberctlt:ClinicalSupplyServicesMember2021-07-012022-06-300001596783ctlt:ClinicalSupplyServicesMemberctlt:ClinicalSupplyServicesMember2021-07-012022-06-300001596783ctlt:ClinicalSupplyServicesMemberctlt:TotalCatalentbeforeintersegmentrevenueeliminationMember2021-07-012022-06-300001596783ctlt:BiologicsMember2021-07-012022-06-300001596783ctlt:SoftgelAndOralTechnologiesMember2021-07-012022-06-300001596783ctlt:OralAndSpecialtyDeliveryMember2021-07-012022-06-300001596783ctlt:ClinicalSupplyServicesMember2021-07-012022-06-300001596783ctlt:TotalCatalentbeforeintersegmentrevenueeliminationMember2021-07-012022-06-300001596783ctlt:BiologicsMemberctlt:ManufacturingCommercialProductSupplyMember2020-07-012021-06-300001596783ctlt:SoftgelAndOralTechnologiesMemberctlt:ManufacturingCommercialProductSupplyMember2020-07-012021-06-300001596783ctlt:OralAndSpecialtyDeliveryMemberctlt:ManufacturingCommercialProductSupplyMember2020-07-012021-06-300001596783ctlt:ClinicalSupplyServicesMemberctlt:ManufacturingCommercialProductSupplyMember2020-07-012021-06-300001596783ctlt:TotalCatalentbeforeintersegmentrevenueeliminationMemberctlt:ManufacturingCommercialProductSupplyMember2020-07-012021-06-300001596783ctlt:BiologicsMemberctlt:DevelopmentServicesMember2020-07-012021-06-300001596783ctlt:SoftgelAndOralTechnologiesMemberctlt:DevelopmentServicesMember2020-07-012021-06-300001596783ctlt:OralAndSpecialtyDeliveryMemberctlt:DevelopmentServicesMember2020-07-012021-06-300001596783ctlt:ClinicalSupplyServicesMemberctlt:DevelopmentServicesMember2020-07-012021-06-300001596783ctlt:TotalCatalentbeforeintersegmentrevenueeliminationMemberctlt:DevelopmentServicesMember2020-07-012021-06-300001596783ctlt:BiologicsMemberctlt:ClinicalSupplyServicesMember2020-07-012021-06-300001596783ctlt:SoftgelAndOralTechnologiesMemberctlt:ClinicalSupplyServicesMember2020-07-012021-06-300001596783ctlt:OralAndSpecialtyDeliveryMemberctlt:ClinicalSupplyServicesMember2020-07-012021-06-300001596783ctlt:ClinicalSupplyServicesMemberctlt:ClinicalSupplyServicesMember2020-07-012021-06-300001596783ctlt:ClinicalSupplyServicesMemberctlt:TotalCatalentbeforeintersegmentrevenueeliminationMember2020-07-012021-06-300001596783ctlt:BiologicsMember2020-07-012021-06-300001596783ctlt:SoftgelAndOralTechnologiesMember2020-07-012021-06-300001596783ctlt:OralAndSpecialtyDeliveryMember2020-07-012021-06-300001596783ctlt:ClinicalSupplyServicesMember2020-07-012021-06-300001596783ctlt:TotalCatalentbeforeintersegmentrevenueeliminationMember2020-07-012021-06-300001596783ctlt:BiologicsMemberctlt:ManufacturingCommercialProductSupplyMember2019-07-012020-06-300001596783ctlt:SoftgelAndOralTechnologiesMemberctlt:ManufacturingCommercialProductSupplyMember2019-07-012020-06-300001596783ctlt:OralAndSpecialtyDeliveryMemberctlt:ManufacturingCommercialProductSupplyMember2019-07-012020-06-300001596783ctlt:ClinicalSupplyServicesMemberctlt:ManufacturingCommercialProductSupplyMember2019-07-012020-06-300001596783ctlt:TotalCatalentbeforeintersegmentrevenueeliminationMemberctlt:ManufacturingCommercialProductSupplyMember2019-07-012020-06-300001596783ctlt:BiologicsMemberctlt:DevelopmentServicesMember2019-07-012020-06-300001596783ctlt:SoftgelAndOralTechnologiesMemberctlt:DevelopmentServicesMember2019-07-012020-06-300001596783ctlt:OralAndSpecialtyDeliveryMemberctlt:DevelopmentServicesMember2019-07-012020-06-300001596783ctlt:ClinicalSupplyServicesMemberctlt:DevelopmentServicesMember2019-07-012020-06-300001596783ctlt:TotalCatalentbeforeintersegmentrevenueeliminationMemberctlt:DevelopmentServicesMember2019-07-012020-06-300001596783ctlt:BiologicsMemberctlt:ClinicalSupplyServicesMember2019-07-012020-06-300001596783ctlt:SoftgelAndOralTechnologiesMemberctlt:ClinicalSupplyServicesMember2019-07-012020-06-300001596783ctlt:OralAndSpecialtyDeliveryMemberctlt:ClinicalSupplyServicesMember2019-07-012020-06-300001596783ctlt:ClinicalSupplyServicesMemberctlt:ClinicalSupplyServicesMember2019-07-012020-06-300001596783ctlt:ClinicalSupplyServicesMemberctlt:TotalCatalentbeforeintersegmentrevenueeliminationMember2019-07-012020-06-300001596783ctlt:BiologicsMember2019-07-012020-06-300001596783ctlt:SoftgelAndOralTechnologiesMember2019-07-012020-06-300001596783ctlt:OralAndSpecialtyDeliveryMember2019-07-012020-06-300001596783ctlt:ClinicalSupplyServicesMember2019-07-012020-06-300001596783ctlt:TotalCatalentbeforeintersegmentrevenueeliminationMember2019-07-012020-06-300001596783ctlt:geographicalMember2021-07-012022-06-300001596783country:US2021-07-012022-06-300001596783country:US2020-07-012021-06-300001596783country:US2019-07-012020-06-300001596783srt:EuropeMember2021-07-012022-06-300001596783srt:EuropeMember2020-07-012021-06-300001596783srt:EuropeMember2019-07-012020-06-300001596783ctlt:InternationalOtherMember2021-07-012022-06-300001596783ctlt:InternationalOtherMember2020-07-012021-06-300001596783ctlt:InternationalOtherMember2019-07-012020-06-300001596783ctlt:SkeletalCellTherapySupportSAMember2020-11-162020-11-160001596783ctlt:AcordaTherapeuticsIncMember2021-02-112021-02-110001596783ctlt:AcordaTherapeuticsIncMember2021-02-110001596783ctlt:DelphiGeneticsSAMember2021-02-232021-02-230001596783ctlt:DelphiGeneticsSAMember2021-02-230001596783ctlt:HepaticCellTherapySupportSA2021-02-232021-02-230001596783ctlt:HepaticCellTherapySupportSAMember2021-03-310001596783ctlt:RheinCellTherapeuticsMember2021-08-012021-08-010001596783ctlt:RheinCellTherapeuticsMember2021-08-010001596783ctlt:BetteraHoldingsLLCMember2021-10-012021-10-010001596783ctlt:A3500SeniorUSDenominatedNotesMemberMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Member2022-06-300001596783ctlt:A3500SeniorUSDenominatedNotesMemberMember2022-06-30xbrli:pure0001596783ctlt:BetteraHoldingsLLCMember2021-10-010001596783ctlt:BetteraHoldingsLLCMember2021-10-012021-10-310001596783ctlt:CoreTechnologyMemberctlt:BetteraHoldingsLLCMember2021-10-010001596783us-gaap:CustomerRelationshipsMemberctlt:BetteraHoldingsLLCMember2021-10-010001596783ctlt:CoreTechnologyBetteraMember2021-07-012022-06-300001596783ctlt:VaccineManufacturingAndInnovationCentreMember2022-04-012022-04-300001596783ctlt:VaccineManufacturingAndInnovationCentreMember2022-04-300001596783ctlt:PrincetonCellTherapyMember2022-04-012022-04-300001596783ctlt:PrincetonCellTherapyMember2022-04-300001596783ctlt:BlowFillSealBusinessWoodstockMember2021-07-012022-06-300001596783ctlt:BlowFillSealBusinessWoodstockMember2022-06-300001596783ctlt:BlowFillSealBusinessWoodstockMember2022-01-012022-03-310001596783ctlt:BlowFillSealBusinessWoodstockMember2020-07-012021-06-300001596783ctlt:BiologicsMember2020-06-300001596783ctlt:SoftgelAndOralTechnologiesMember2020-06-300001596783ctlt:OralAndSpecialtyDeliveryMember2020-06-300001596783ctlt:ClinicalSupplyServicesMember2020-06-300001596783ctlt:BiologicsMember2021-06-300001596783ctlt:SoftgelAndOralTechnologiesMember2021-06-300001596783ctlt:OralAndSpecialtyDeliveryMember2021-06-300001596783ctlt:ClinicalSupplyServicesMember2021-06-300001596783ctlt:BiologicsMember2022-06-300001596783ctlt:SoftgelAndOralTechnologiesMember2022-06-300001596783ctlt:OralAndSpecialtyDeliveryMember2022-06-300001596783ctlt:ClinicalSupplyServicesMember2022-06-300001596783ctlt:CoreTechnologyMember2021-07-012022-06-300001596783ctlt:CoreTechnologyMember2022-06-300001596783us-gaap:CustomerRelationshipsMember2021-07-012022-06-300001596783us-gaap:CustomerRelationshipsMember2022-06-300001596783ctlt:ProductRelationshipsMember2021-07-012022-06-300001596783ctlt:ProductRelationshipsMember2022-06-300001596783us-gaap:OtherIntangibleAssetsMember2021-07-012022-06-300001596783us-gaap:OtherIntangibleAssetsMember2022-06-300001596783ctlt:CoreTechnologyMember2020-07-012021-06-300001596783ctlt:CoreTechnologyMember2021-06-300001596783us-gaap:CustomerRelationshipsMember2020-07-012021-06-300001596783us-gaap:CustomerRelationshipsMember2021-06-300001596783ctlt:ProductRelationshipsMember2020-07-012021-06-300001596783ctlt:ProductRelationshipsMember2021-06-300001596783us-gaap:OtherIntangibleAssetsMember2020-07-012021-06-300001596783us-gaap:OtherIntangibleAssetsMember2021-06-300001596783ctlt:BoltonCSMembersrt:MaximumMember2021-07-012022-06-30ctlt:employees0001596783ctlt:BoltonCSMembersrt:MaximumMember2022-06-300001596783ctlt:BoltonCSMember2021-07-012022-06-300001596783ctlt:TermLoanThreeFacilityDollarDenominatedMember2022-06-300001596783ctlt:TermLoanThreeFacilityDollarDenominatedMember2021-06-300001596783us-gaap:CarryingReportedAmountFairValueDisclosureMemberctlt:USDollarDenominated500SeniorNotesMemberus-gaap:FairValueInputsLevel2Member2022-06-300001596783us-gaap:CarryingReportedAmountFairValueDisclosureMemberctlt:USDollarDenominated500SeniorNotesMemberus-gaap:FairValueInputsLevel2Member2021-06-300001596783ctlt:A2375SeniorEuroDenominatedNotesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Member2022-06-300001596783ctlt:A2375SeniorEuroDenominatedNotesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Member2021-06-300001596783ctlt:A3125SeniorUSDenominatedNotesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Member2022-06-300001596783ctlt:A3125SeniorUSDenominatedNotesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Member2021-06-300001596783ctlt:A3500SeniorUSDenominatedNotesMemberMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Member2021-06-300001596783ctlt:SeniorUnsecuredTermLoanFacilityMember2022-06-300001596783ctlt:SeniorUnsecuredTermLoanFacilityMember2021-06-300001596783us-gaap:CapitalLeaseObligationsMember2022-06-300001596783us-gaap:CapitalLeaseObligationsMember2021-06-300001596783ctlt:OtherObligationsMember2022-06-300001596783ctlt:OtherObligationsMember2021-06-300001596783ctlt:DebtIssuanceCostsMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-06-300001596783ctlt:DebtIssuanceCostsMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2021-06-300001596783us-gaap:CarryingReportedAmountFairValueDisclosureMember2022-06-300001596783us-gaap:CarryingReportedAmountFairValueDisclosureMember2021-06-300001596783ctlt:TermLoanTwoFacilityDollarDenominatedMember2021-02-280001596783ctlt:TermLoanThreeFacilityDollarDenominatedMembersrt:MinimumMemberus-gaap:LondonInterbankOfferedRateLIBORMember2021-07-012022-06-300001596783ctlt:TermLoanThreeFacilityDollarDenominatedMemberus-gaap:LondonInterbankOfferedRateLIBORMember2021-07-012022-06-300001596783us-gaap:LondonInterbankOfferedRateLIBORMemberus-gaap:RevolvingCreditFacilityMember2021-07-012022-06-300001596783srt:MinimumMemberus-gaap:LondonInterbankOfferedRateLIBORMemberus-gaap:RevolvingCreditFacilityMember2021-07-012022-06-300001596783ctlt:USDollarDenominated500SeniorNotesMember2022-06-300001596783ctlt:A2375SeniorEuroDenominatedNotesMember2022-06-30iso4217:EUR0001596783ctlt:FourPointSevenFivePercentSeniorEuroDenominatedNotesMember2022-06-300001596783ctlt:A3125SeniorUSDenominatedNotesMember2022-06-300001596783ctlt:U.S.Dollardenominated4.875SeniorNotesMember2017-10-180001596783us-gaap:AccruedLiabilitiesMember2017-10-012017-10-2300015967832017-10-012017-10-230001596783ctlt:SeniorSecuredCreditFacilityMember2021-07-012022-06-300001596783us-gaap:EstimateOfFairValueFairValueDisclosureMemberctlt:USDollarDenominated500SeniorNotesMemberus-gaap:FairValueInputsLevel2Member2022-06-300001596783us-gaap:EstimateOfFairValueFairValueDisclosureMemberctlt:USDollarDenominated500SeniorNotesMemberus-gaap:FairValueInputsLevel2Member2021-06-300001596783ctlt:A2375SeniorEuroDenominatedNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Member2022-06-300001596783ctlt:A2375SeniorEuroDenominatedNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Member2021-06-300001596783ctlt:A3125SeniorUSDenominatedNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Member2022-06-300001596783ctlt:A3125SeniorUSDenominatedNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Member2021-06-300001596783ctlt:A3500SeniorUSDenominatedNotesMemberMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Member2022-06-300001596783us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberctlt:SeniorSecuredCreditFacilitiesOtherMember2022-06-300001596783us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberctlt:SeniorSecuredCreditFacilitiesOtherMember2022-06-300001596783us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberctlt:SeniorSecuredCreditFacilitiesOtherMember2021-06-300001596783us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberctlt:SeniorSecuredCreditFacilitiesOtherMember2021-06-300001596783us-gaap:EstimateOfFairValueFairValueDisclosureMember2022-06-300001596783us-gaap:EstimateOfFairValueFairValueDisclosureMember2021-06-300001596783ctlt:DebtIssuanceCostsMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-06-300001596783ctlt:DebtIssuanceCostsMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-06-3000015967832020-11-232020-11-2300015967832020-11-2300015967832021-11-182021-11-1800015967832021-11-180001596783us-gaap:SeriesAPreferredStockMember2021-07-012022-06-300001596783us-gaap:SeriesAPreferredStockMember2020-07-012021-06-300001596783us-gaap:SeriesAPreferredStockMember2019-07-012020-06-300001596783ctlt:USDenominatedTermLoanMember2022-06-300001596783us-gaap:FairValueInputsLevel2Member2022-06-300001596783us-gaap:FairValueInputsLevel3Member2022-06-300001596783us-gaap:FairValueInputsLevel1Member2021-06-300001596783us-gaap:FairValueInputsLevel2Member2021-06-300001596783us-gaap:FairValueInputsLevel3Member2021-06-300001596783us-gaap:DomesticCountryMember2022-06-300001596783us-gaap:StateAndLocalJurisdictionMember2022-06-300001596783us-gaap:StateAndLocalJurisdictionMember2021-07-012022-06-300001596783us-gaap:ForeignCountryMember2022-06-300001596783us-gaap:ForeignCountryMember2021-07-012022-06-300001596783ctlt:ForeignNetOperatingLossEstablishedMember2021-07-012022-06-300001596783us-gaap:PensionPlansDefinedBenefitMember2021-07-012022-06-300001596783us-gaap:PensionPlansDefinedBenefitMember2022-06-300001596783us-gaap:PensionPlansDefinedBenefitMember2021-06-300001596783us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-06-300001596783us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-06-300001596783us-gaap:PensionPlansDefinedBenefitMember2020-06-300001596783us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-06-300001596783us-gaap:PensionPlansDefinedBenefitMember2020-07-012021-06-300001596783us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-07-012022-06-300001596783us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-07-012021-06-300001596783us-gaap:PensionPlansDefinedBenefitMemberus-gaap:EquitySecuritiesMember2022-06-300001596783us-gaap:PensionPlansDefinedBenefitMemberus-gaap:EquitySecuritiesMember2021-06-300001596783us-gaap:EquitySecuritiesMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-06-300001596783us-gaap:EquitySecuritiesMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-06-300001596783us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:PensionPlansDefinedBenefitMember2022-06-300001596783us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:PensionPlansDefinedBenefitMember2021-06-300001596783us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-06-300001596783us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-06-300001596783us-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2022-06-300001596783us-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2021-06-300001596783us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2022-06-300001596783us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2021-06-300001596783us-gaap:PensionPlansDefinedBenefitMemberus-gaap:RealEstateMember2022-06-300001596783us-gaap:PensionPlansDefinedBenefitMemberus-gaap:RealEstateMember2021-06-300001596783us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:RealEstateMember2022-06-300001596783us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:RealEstateMember2021-06-300001596783ctlt:InsuranceContractsMemberus-gaap:PensionPlansDefinedBenefitMember2022-06-300001596783ctlt:InsuranceContractsMemberus-gaap:PensionPlansDefinedBenefitMember2021-06-300001596783ctlt:InsuranceContractsMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-06-300001596783ctlt:InsuranceContractsMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-06-300001596783us-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherAssetsMember2022-06-300001596783us-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherAssetsMember2021-06-300001596783us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:OtherAssetsMember2022-06-300001596783us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:OtherAssetsMember2021-06-300001596783us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel1Member2022-06-300001596783us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-06-300001596783us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Member2022-06-300001596783us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:EquitySecuritiesMember2022-06-300001596783us-gaap:EquitySecuritiesMember2022-06-300001596783us-gaap:FairValueInputsLevel1Memberus-gaap:DebtSecuritiesMember2022-06-300001596783us-gaap:DebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-06-300001596783us-gaap:DebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2022-06-300001596783us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:DebtSecuritiesMember2022-06-300001596783us-gaap:DebtSecuritiesMember2022-06-300001596783us-gaap:FairValueInputsLevel1Memberus-gaap:RealEstateMember2022-06-300001596783us-gaap:FairValueInputsLevel2Memberus-gaap:RealEstateMember2022-06-300001596783us-gaap:FairValueInputsLevel3Memberus-gaap:RealEstateMember2022-06-300001596783us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:RealEstateMember2022-06-300001596783us-gaap:RealEstateMember2022-06-300001596783us-gaap:FairValueInputsLevel1Memberus-gaap:OtherAssetsMember2022-06-300001596783us-gaap:OtherAssetsMemberus-gaap:FairValueInputsLevel2Member2022-06-300001596783us-gaap:OtherAssetsMemberus-gaap:FairValueInputsLevel3Member2022-06-300001596783us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:OtherAssetsMember2022-06-300001596783us-gaap:OtherAssetsMember2022-06-300001596783us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2022-06-300001596783us-gaap:FairValueInputsLevel2Memberus-gaap:HedgeFundsMember2022-06-300001596783us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel1Member2021-06-300001596783us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel2Member2021-06-300001596783us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Member2021-06-300001596783us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:EquitySecuritiesMember2021-06-300001596783us-gaap:EquitySecuritiesMember2021-06-300001596783us-gaap:FairValueInputsLevel1Memberus-gaap:DebtSecuritiesMember2021-06-300001596783us-gaap:DebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2021-06-300001596783us-gaap:DebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2021-06-300001596783us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:DebtSecuritiesMember2021-06-300001596783us-gaap:DebtSecuritiesMember2021-06-300001596783us-gaap:FairValueInputsLevel1Memberus-gaap:RealEstateMember2021-06-300001596783us-gaap:FairValueInputsLevel2Memberus-gaap:RealEstateMember2021-06-300001596783us-gaap:FairValueInputsLevel3Memberus-gaap:RealEstateMember2021-06-300001596783us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:RealEstateMember2021-06-300001596783us-gaap:RealEstateMember2021-06-300001596783us-gaap:FairValueInputsLevel1Memberus-gaap:OtherAssetsMember2021-06-300001596783us-gaap:OtherAssetsMemberus-gaap:FairValueInputsLevel2Member2021-06-300001596783us-gaap:OtherAssetsMemberus-gaap:FairValueInputsLevel3Member2021-06-300001596783us-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:OtherAssetsMember2021-06-300001596783us-gaap:OtherAssetsMember2021-06-300001596783us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2021-06-300001596783us-gaap:FairValueInputsLevel2Memberus-gaap:HedgeFundsMember2021-06-300001596783ctlt:EberbachPensionPromissoryNoteOrLoanMember2022-06-300001596783ctlt:InsuranceContractsMemberus-gaap:FairValueInputsLevel3Member2021-06-300001596783ctlt:OtherUnobservableAssetsMemberus-gaap:FairValueInputsLevel3Member2021-06-300001596783us-gaap:FairValueInputsLevel3Member2021-07-012022-06-300001596783ctlt:InsuranceContractsMemberus-gaap:FairValueInputsLevel3Member2021-07-012022-06-300001596783ctlt:OtherUnobservableAssetsMemberus-gaap:FairValueInputsLevel3Member2021-07-012022-06-300001596783ctlt:InsuranceContractsMemberus-gaap:FairValueInputsLevel3Member2022-06-300001596783ctlt:OtherUnobservableAssetsMemberus-gaap:FairValueInputsLevel3Member2022-06-300001596783us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberctlt:Post65Member2022-06-300001596783us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberctlt:Post65Member2021-06-300001596783us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberctlt:Post65Member2021-07-012022-06-300001596783us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberctlt:Post65Member2020-07-012021-06-3000015967832020-06-152020-06-1500015967832020-06-1500015967832020-02-062020-02-0600015967832020-02-060001596783ctlt:DesignatedSharesMember2020-06-3000015967832019-05-170001596783us-gaap:AdditionalPaidInCapitalMember2020-11-232020-11-230001596783us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-3100015967832021-07-012022-03-310001596783us-gaap:AccumulatedTranslationAdjustmentMember2019-06-300001596783us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-06-300001596783us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember2019-06-300001596783ctlt:ACOIAccumulatedGainLossMarketableSecuritiesMember2019-06-300001596783us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2019-06-300001596783us-gaap:AccumulatedTranslationAdjustmentMember2019-07-012020-06-300001596783us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-07-012020-06-300001596783us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember2019-07-012020-06-300001596783us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2019-07-012020-06-300001596783us-gaap:AccumulatedTranslationAdjustmentMember2020-06-300001596783us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-06-300001596783us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember2020-06-300001596783ctlt:ACOIAccumulatedGainLossMarketableSecuritiesMember2020-06-300001596783us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-06-300001596783us-gaap:AccumulatedTranslationAdjustmentMember2020-07-012021-06-300001596783us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-07-012021-06-300001596783us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember2020-07-012021-06-300001596783us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-07-012021-06-300001596783us-gaap:AccumulatedTranslationAdjustmentMember2021-06-300001596783us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-06-300001596783us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember2021-06-300001596783ctlt:ACOIAccumulatedGainLossMarketableSecuritiesMember2021-06-300001596783us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-06-300001596783us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-07-012022-06-300001596783us-gaap:AccumulatedTranslationAdjustmentMember2022-06-300001596783us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-06-300001596783us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember2022-06-300001596783ctlt:ACOIAccumulatedGainLossMarketableSecuritiesMember2022-06-300001596783us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-06-300001596783ctlt:StockCompensationPlanOmnibusMember2021-07-012022-06-300001596783ctlt:StockCompensationPlanOmnibusMember2020-07-012021-06-300001596783ctlt:StockCompensationPlanOmnibusMember2019-07-012020-06-300001596783us-gaap:EmployeeStockOptionMembersrt:MinimumMember2021-07-012022-06-300001596783us-gaap:EmployeeStockOptionMembersrt:MinimumMember2020-07-012021-06-300001596783us-gaap:EmployeeStockOptionMembersrt:MinimumMember2019-07-012020-06-300001596783us-gaap:EmployeeStockOptionMembersrt:MaximumMember2019-07-012020-06-300001596783us-gaap:EmployeeStockOptionMembersrt:MaximumMember2021-07-012022-06-300001596783us-gaap:EmployeeStockOptionMembersrt:MaximumMember2020-07-012021-06-300001596783ctlt:TimeMember2021-06-300001596783ctlt:TimeMember2020-07-012021-06-300001596783ctlt:TimeMember2021-07-012022-06-300001596783ctlt:PerformanceMember2022-06-300001596783ctlt:TimeMember2022-06-300001596783ctlt:TimeBasedRestrictedStockUnitsMember2021-06-300001596783ctlt:TimeBasedRestrictedStockUnitsMember2021-07-012022-06-300001596783ctlt:TimeBasedRestrictedStockUnitsMember2022-06-300001596783us-gaap:PerformanceSharesMember2021-06-300001596783us-gaap:PerformanceSharesMember2021-07-012022-06-300001596783us-gaap:PerformanceSharesMember2022-06-300001596783us-gaap:PerformanceSharesMembersrt:MinimumMember2021-07-012022-06-300001596783us-gaap:PerformanceSharesMembersrt:MaximumMember2021-07-012022-06-300001596783us-gaap:PerformanceSharesMembersrt:MinimumMember2020-07-012021-06-300001596783us-gaap:PerformanceSharesMembersrt:MaximumMember2020-07-012021-06-300001596783ctlt:RTSRPerformanceShareUnitsMember2021-06-300001596783ctlt:RTSRPerformanceShareUnitsMember2021-07-012022-06-300001596783ctlt:RTSRPerformanceShareUnitsMember2022-06-300001596783us-gaap:RestrictedStockUnitsRSUMember2022-06-300001596783us-gaap:RestrictedStockUnitsRSUMember2021-07-012022-06-300001596783us-gaap:RestrictedStockUnitsRSUMember2020-07-012021-06-300001596783us-gaap:RestrictedStockUnitsRSUMember2019-07-012020-06-300001596783ctlt:TotalCatalentSubTotalOfSegmentReportingMember2021-07-012022-06-300001596783ctlt:TotalCatalentSubTotalOfSegmentReportingMember2020-07-012021-06-300001596783ctlt:TotalCatalentSubTotalOfSegmentReportingMember2019-07-012020-06-300001596783ctlt:CorporateAndEliminationsMember2022-06-300001596783ctlt:CorporateAndEliminationsMember2021-06-300001596783us-gaap:CorporateMember2021-07-012022-06-300001596783us-gaap:CorporateMember2020-07-012021-06-300001596783us-gaap:CorporateMember2019-07-012020-06-300001596783country:US2022-06-300001596783country:US2021-06-300001596783srt:EuropeMember2022-06-300001596783srt:EuropeMember2021-06-300001596783ctlt:RestofWorldMember2022-06-300001596783ctlt:RestofWorldMember2021-06-3000015967832022-10-012022-12-3100015967832022-08-092022-08-09

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM10-K
ýANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended June 30, 2022
or
¨TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission File Number: 001-36587
ctlt-20220630_g1.jpg
CATALENT, INC.
(Exact name of registrant as specified in its charter)
Delaware20-8737688
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
14 Schoolhouse Road
08873
Somerset,New Jersey
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (732) 537-6200
____________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.01 par value per shareCTLTNew York Stock Exchange
Securities registered pursuant to Section 12(g) of the Act: None
____________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.   Yes   No   ¨ 
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ¨  No  
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes       No  ¨
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).   Yes     No ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company and emerging growth company in Rule 12b-2 of the Exchange Act.
Large accelerated filer
ý
Accelerated filer
¨
Non-accelerated filer
¨
Smaller reporting company
¨
Emerging growth company
¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).    ¨ Yes     No 
1


As of December 31, 2021, the aggregate market value of the registrant’s voting and non-voting common equity held by non-affiliates was $21.84 billion. On August 25, 2022, there were 179,895,677 shares of the Registrant’s Common Stock, par value $0.01 per share, issued and outstanding.

DOCUMENTS INCORPORATED BY REFERENCE
Portions of the Registrant's Proxy Statement relating to the 2022 Annual Meeting of Shareholders are incorporated by reference into Part III of this report.

CATALENT, INC.
INDEX TO ANNUAL REPORT ON FORM 10-K
For the Fiscal Year Ended June 30, 2022
ItemPage
PART I
Item 1.
Item 1A.
Item 1B.
Item 2.
Item 3.
Item 4.
PART II
Item 5.
Item 6.
Item 7.
Item 7A.
Item 8.
Item 9.
Item 9A.
Item 9B.
Item 9C.
PART III
Item 10.
Item 11.
Item 12.
Item 13.
Item 14.
PART IV
Item 15.
Item 16.

2


PART I
Special Note Regarding Forward-Looking Statements
In addition to historical information, this Annual Report on Form 10-K for the fiscal year ended June 30, 2022 (this Annual Report) of Catalent, Inc. (Catalent or the Company) contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), which are subject to the safe harbor created by those sections. All statements, other than statements of historical facts, included in this Annual Report are forward-looking statements. In some cases, you can identify these forward-looking statements by the use of words such as outlook, believes, expects, potential, continues, may, will, should, could, seeks, predicts, intends, plans, estimates, anticipates, future, forward, sustain or the negative version of these words or other comparable words.
These statements are based on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments, and other factors they believe to be appropriate. Any forward-looking statement is subject to various risks and uncertainties. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements.
Some of the factors that may cause actual results, developments, and business decisions to differ materially from those contemplated by such forward-looking statements include, but are not limited to, those described under the section entitled Risk Factors in this Annual Report, which are summarized below:
Summary of Principal Risk Factors
Any investment, including an investment in our common stock, par value $0.01 (the “Common Stock”), involves risk. The following summary highlights certain risks that an investor in our Common Stock should consider. The following should be read in conjunction with the fuller discussion of risk factors we face set forth in "Item 1A. Risk Factors."
Risks Relating to Our Business and the Industry in Which We Operate
Our business, financial condition, and operations may be adversely affected by global health epidemics, including the pandemic resulting from the SARS-Co-V-2 strain of coronavirus and its variants (“COVID-19”).
The continually evolving nature of the COVID-19 pandemic and the resulting public health response, including the changing demand for various COVID-19 vaccines and treatments from both patients and governments around the world, may affect sales of the COVID-19 products we manufacture.
We participate in a highly competitive market, and increased competition may adversely affect our business.
The demand for our offerings depends in part on our customers’ research and development and the clinical and market success of their products.
We are subject to product and other liability risks that could exceed our anticipated costs or adversely affect our results of operations, financial condition, liquidity, and cash flows.
We are a part of the highly regulated healthcare industry, subject to stringent regulatory standards and other applicable laws and regulations, which can change unexpectedly and may adversely impact our business.
Any failure to implement fully, monitor, and improve our quality management strategy could lead to quality or safety issues and expose us to significant costs, potential liability and adverse publicity.
If we cannot keep pace with rapid technological advances, our services may become uncompetitive or obsolete.
Any failure to protect or maintain our intellectual property may adversely affect our competitive edge and result in loss of revenue and reputation.
Future price fluctuations, material shortages of raw materials, or changes in healthcare policies may have an adverse effect on our results of operations and financial conditions.
Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.
We may be unable to attract or retain key personnel.
We may be unsuccessful in integrating our acquisitions, and we may expend substantial amounts of cash and incur debt in making acquisitions.
3


Our global operations are subject to economic and political risks that could affect the profitability of our operations or require costly changes to our procedures.
As a global enterprise, fluctuations in the exchange rates of the United States ("U.S.") dollar, our reporting currency, against other currencies could have a material adverse effect on our financial performance and results of operations.
Tax legislative or regulatory initiatives, new interpretations or developments concerning existing tax laws, or challenges to our tax positions could adversely affect our results of operations and financial condition.
We use advanced information and communication systems to run our operations, compile and analyze financial and operational data, and communicate among our employees, customers, and counter-parties, and the risks generally associated with information and communications systems could adversely affect our results of operations. We continuously work to install new, and upgrade existing, systems and provide employee awareness training around phishing, malware, and other cybersecurity risks to enhance the protections available to us, but such protections may be inadequate to address malicious attacks or inadvertent compromises affecting data security or the operability of such systems.
We provide services incorporating various advanced modalities, including protein and plasmid production and cell and gene therapies, and these modalities relate to relatively new modes of treatment that may be subject to changing public opinion, continuing research, and increased regulatory scrutiny, each of which may affect our customers' ability to conduct their businesses, or obtain regulatory approvals for their therapies, and thereby adversely affect these offerings.
Risks Relating to Our Indebtedness
The size of our indebtedness and the obligations associated with it could limit our ability to operate our business and to finance future operations or acquisitions that would enhance our growth.
Our debt agreements contain restrictions that may limit our flexibility in conducting certain current and future operations.
We may not be able to pay our indebtedness when it becomes due.
Our current and potential future use of derivative financial instruments may expose us to economic losses in the event of price or currency fluctuations.
Risks Relating to Ownership of Our Common Stock
Our stock price has historically been and may continue to be volatile.
Because we have no plan to pay cash dividends on our Common Stock for the foreseeable future, receiving a return on an investment in our Common Stock may require a sale for a net price greater than was paid for it.
Provisions in our organizational documents could delay or prevent a change of control.
We caution you that the risks, uncertainties, and other factors referenced above may not contain all of the risks, uncertainties, and other factors that are important to you. In addition, we cannot assure you that we will realize the results, benefits, or developments that we expect or anticipate or, even if substantially realized, that they will result in the consequences or affect us or our business in the way expected. There can be no assurance that (i) we have correctly measured or identified all of the factors affecting our business or the extent of these factors’ likely impact, (ii) the available information with respect to these factors on which such analysis is based is complete or accurate, (iii) such analysis is correct, or (iv) our strategy, which is based in part on this analysis, will be successful. All forward-looking statements in this report apply only as of the date of this report or as of the date they were made, and we undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as required by law.
4


We file annual, quarterly, and current reports and other information with and furnish additional information to the U.S. Securities and Exchange Commission (the SEC). Our filings with the SEC are available to the public on the SEC’s website at www.sec.gov. Those filings are also available to the public on, or accessible through, our website (catalent.com) for free via the Investors section as soon as reasonably practicable after we file such material, or furnish it to, the SEC. We also use our website, Facebook page (facebook.com/CatalentPharmaSolutions), LinkedIn page (linkedin.com/company/catalent-pharma-solutions/) and Twitter account (@catalentpharma) as channels of distribution of information concerning our activities, our offerings, our various businesses, and other related matters. The information we post through these channels may be deemed material. Accordingly, investors should monitor these channels, in addition to following our press releases, SEC filings, and public conference calls and webcasts. The information we file with or furnish to the SEC (other than the information set forth or incorporated in this Annual Report) or contained on or accessible through our website, our social media channels, or any other website that we may maintain is not a part of this Annual Report.
Catalent References and Fiscal Year
Unless the context otherwise requires, in this Annual Report, the terms “Catalent,” “the company,” “we,” “us,” and “our” refer to Catalent, Inc. and its subsidiaries. All references to years in this Annual Report, unless otherwise stated, refer to fiscal years beginning July 1 and ending June 30. All references to quarters, unless otherwise stated, refer to fiscal quarters. Fiscal years are referred to by the calendar year in which they end. For example, “fiscal 2022” refers to the fiscal year ended June 30, 2022.
Trademarks and Service Marks
We have U.S. or foreign registrations for the following marks, among others: Bettera®, Catalent®, Clinicopia®, CosmoPod®, Easyburst®, FastChain®, FlexDirect®, Follow the Molecule®, Galacorin®, GPEx®, GPEx® Boost, GPEx® Lightning, Graphicaps®, Liqui-Gels®, Manufacturing Miracles®, Micron Technologies®, OmegaZero®, OneBio®, OneXpres Solution®, OptiDose®, OptiForm®, OptiGel®, OptiGel® Bio, OptiGel® DR, OptiMelt®, OptiShell®, PEEL-ID®, Pharmatek®, RP Scherer®, Savorgel®, Scherer®, SMARTag®, Softdrop®, Staby®, StabyExpress®, SupplyFlex®, Vegicaps®, Zydis®, and Zydis Ultra®. This Annual Report also includes trademarks and trade names owned by other parties, and these trademarks and trade names are the property of their respective owners. We use certain other trademarks and service marks, including, FlexDose™, Catalent Xpress Pharmaceutics™, OptiPact™, StartScore, and Uptempo Virtuoso and on an unregistered basis in the U.S. and abroad.
Solely for convenience, the trademarks, service marks, and trade names identified in this Annual Report may appear without the ®, SM, and ™ symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensors to these trademarks, service marks, and trade names.
5


ITEM 1.    BUSINESS
Overview

We provide differentiated development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, vaccines, and consumer health products at over fifty facilities across four continents under rigorous quality and operational standards. Our oral, injectable, and respiratory delivery technologies, along with our state-of-the-art protein, plasmid, viral, and cell and gene therapy manufacturing capacity, address a wide and growing range of modalities and therapeutic and other categories across the biopharmaceutical and consumer health industries. Through our extensive capabilities, growth-enabling capacity, and deep expertise in product development, regulatory compliance, and clinical trial and commercial supply, we can help our customers take products to market faster, including more than half of new drug products approved by the U.S. Food and Drug Administration (the FDA) in the last decade. Our development and manufacturing platforms, our proven formulation, supply, and regulatory expertise, and our broad and deep development and manufacturing know-how enable our customers to advance and then bring to market more products and better treatments for patients and consumers. Our commitment to reliably supply our customers’ and their patients’ needs is the foundation for the value we provide; annually, we produce nearly 80 billion doses for nearly 8,000 customer products, or approximately 1 in every 23 doses of such products taken each year by patients and consumers around the world. We believe that, through our investments in state-of-the-art facilities and capacity expansion, including investments in facilities focused on new treatment modalities and other attractive market segments, our continuous improvement activities devoted to operational and quality excellence, the sales of existing and introduction of new customer products, and, in some cases, our innovation activities and patents, we will continue to attract premium opportunities and realize the growth potential from these areas.

We continue to invest in both our product and service offerings and our sales and marketing activities, leading to growth in the number of active commercial manufacturing and development programs for our customers. This has further enhanced our extensive, long-duration relationships and long-term contracts with a broad and diverse range of industry-leading customers. In fiscal 2022, we conducted business with 87 of the top 100 branded drug marketers, 21 of the top 25 generics marketers, 24 of the top 25 biologics marketers, and 21 of the top 25 consumer health marketers globally. Selected key customers include AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Johnson & Johnson, Moderna, Pfizer, and Sarepta Therapeutics. We have many long-standing relationships with our customers, particularly those with commercial products, as we provide support and reliable supply through each stage of a product's lifecycle. Our relationship with an innovator of a prescription pharmaceutical product will often last many years—in several cases, two decades or more—extending from pre-clinical development through more mature stages of the product's life cycle. We serve customers requiring some combination of innovative product development, superior quality, state-of-the-art manufacturing, and skilled technical services to support their development and marketed product needs. Our broad and diverse range of technologies closely integrates with all aspects of our customers’ final formulations and dose forms, and this generally results in the inclusion of our facilities as manufacturing and testing sites in our customers’ prescription product regulatory filings. Both factors frequently translate to long-duration supply relationships at an individual product level.

We believe our customers value us because our depth of development solutions and state-of-the-art manufacturing technologies, continuous innovations and improvements, consistent and reliable supply, geographic reach, and substantial expertise enable us to create a broad range of business and product solutions that can be customized to fit their individual needs. Today we employ more than 9,000 highly trained direct manufacturing associates, as well as more than 3,000 formulation, analytical development, and process scientists and technicians. Our customers can also benefit from more than 1,400 patents and patent applications in advanced delivery platforms, drug and biologics formulation, and manufacturing. The aim of our offerings is to reliably supply their commercial needs and also allow our customers to bring more products to market faster and develop and market differentiated products that improve patient outcomes. We believe our leading market position and diversity of customers, offerings, regulatory categories, products, and geographies reduce our exposure to potential strategic and product shifts within our industries.

We provide a wide variety of proprietary and non-proprietary, differentiated technologies, products, and service offerings to our customers across our development and manufacturing platforms, which we have advanced and grown over more than 90 years through internal development, strategic alliances, in-licensing, and acquisitions. We initially introduced our softgel capsule technologies in the 1930s and have continuously expanded our range of offerings. In recent years, we have launched more than a dozen internally developed new technology platform offerings. We have also augmented our portfolio through acquisitions. Among the technologies we currently offer are softgel capsules, including both gelatin and non-gelatin formulations, our Zydis orally disintegrating tablets, gummy and soft chew oral forms, protein production using advanced mammalian cell lines, adeno-associated virus (“AAV”) vectors, induced pluripotent stem cells (“iPSCs”), plasmid DNA (“pDNA”), and a range of other oral, injectable, and respiratory delivery technologies. The technologies and service offerings within our development solution platforms span the full drug development process, ranging from our OptiForm Solution Suite
6


for enhancement of bioavailability and other characteristics of early-stage small molecules, Gene Product Expression (“GPEx”), GPEx Boost, GPEx Lightning for advanced cell line development, pDNA development and production and SMARTag platforms for development of biologics and antibody-drug conjugates (“ADCs”), to formulation, analytical services, early-stage clinical development, drug-device combination development and supply, fill and finish operations for injectable products, and clinical trials supply, including our unique FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions. Our offerings serve a critical need in the development and manufacture of products across a broad range of product types. We focus on serving as an accelerator for new therapeutic modalities and formulation, delivery, and manufacturing technologies. Our expertise enables us to bring advanced products to market at scale, faster.

In large part due to our recent acquisitions and their subsequent organic growth, the revenue contribution from our Biologics segment has grown from approximately 17% in fiscal 2016 to 53% in fiscal 2022. We believe our own internal innovation and investments, supplemented by current and future external partnerships and acquisitions, will continue to strengthen and extend our leadership positions in the development, reliable supply, and delivery of drugs, protein-based biologics, cell and gene therapies, and consumer health products.
History

We trace our history to the 1933 founding of the R.P. Scherer Corporation, which developed the first rotary die machine for the manufacture of soft gelatin capsules, and assumed our current form in April 2007. We regularly review our portfolio of offerings and operations in the context of our strategic growth plan, and, where appropriate, have added to or divested from our portfolio of offering and sites, which has led to significant growth of the overall business. In July 2014, we completed the initial public offering of our Common Stock, which is listed on the New York Stock Exchange (the “NYSE”) under the symbol “CTLT.”

We are a holding company that indirectly owns Catalent Pharma Solutions, Inc. (“Operating Company”), which owns, directly or indirectly, all of our operating assets.
Our Competitive Strengths

Available, State-of-the-art Manufacturing Capacity in Attractive Market Segments

We have invested several billion dollars over the last few years, and plan to continue to invest, to broaden our portfolio of offerings and expand our capacity with state-of-the-art manufacturing and development capabilities that focus on anticipating and meeting the needs of the evolving biopharmaceutical and consumer health industries. In addition, we have hired and trained thousands of new direct manufacturing associates in our rigorous, quality-focused culture of operational excellence. The capacity and capabilities we have built and purchased have enabled, and our further planned expansions will continue to enable, us to secure, along with our operational and quality excellence, attractive new business opportunities in the expanding market for outsourced product development and supply.

Vibrant, Patient First-Driven Culture

From the manufacturing line to the executive suite, for all our critical decisions, we ask the question, “What would the impact be to the patient?”, and our culture is built on our cornerstone value of Patient First. We believe this mindset, which aligns closely with our customers’ values, enables a pervasive focus on patient safety, impact, and outcomes, and an uncompromising approach to product quality and compliance, by reminding us of those who depend upon our vigilance concerning the safety, quality, reliability, and sustainability of our product supply. Along with other key cultural strengths, including our commitments to diversity and inclusion and to science-based environmental sustainability, we believe our culture brings us both a unique reputation and an operating capability that is difficult to replicate.

Diversified Operating Platform

We are diversified by virtue of our broad range of product and service offerings, our geographic scope, our large customer portfolio, the extensive range of products we produce, and our ability to provide solutions at every stage of a product’s lifecycle. In fiscal 2022, we produced nearly 8,000 distinct products across multiple categories. Our fiscal 2022 net revenue was distributed as follows: biologics 55%, branded drugs 28%, generic prescription drugs 3%, over-the-counter drugs 6%, and consumer health and other 8% combined. In fiscal 2022, our top 20 products represented approximately 44% of our total net revenue, with one customer accounting for greater than 10% of net revenue whose largest individual product accounted for less than 9% of our net revenue. We serve more than 1,200 customers in approximately 80 countries, with 36% of our fiscal 2022 net revenue coming from outside the U.S. This diversity, combined with long product lifecycles and close customer
7


relationships, has contributed to the stability of our business. It has also allowed us to reduce our exposure to the risks associated with potential strategic, customer, and product shifts as well as to payer-driven pricing pressures experienced by our drug and biologic customers.

Longstanding, Extensive Relationships with a Diverse Customer Portfolio

We have longstanding, extensive relationships with leading pharmaceutical, biotechnology, and consumer health customers. In fiscal 2022, we did business with 87 of the top 100 branded drug marketers, 21 of the top 25 generics marketers, 24 of the top 25 biologics marketers, and 21 of the top 25 consumer health marketers globally, as well as with more than 1,200 other customers, including emerging and specialty biotech and pharmaceutical companies, which are often more reliant on outside partners as a result of their more virtual business models. Regardless of size, our customers seek innovative product development, superior quality, advanced manufacturing, and skilled technical services to support their development and marketed product needs.

We believe our customers value us because our broad range of product and service offerings, expanding capacity in state-of-the-art manufacturing facilities, including facilities offering new treatment modalities, reliable supply, geographic reach, commitment to operational and quality excellence, and substantial expertise that enable us to create a broad range of tailored solutions, many of which are unavailable from other individual providers.
Deep, Broad, and Growing Advanced Technology Foundation
Our breadth of offerings employing advanced technologies and state-of-the-art manufacturing systems and long track record of innovation substantially differentiate us from other industry participants. Our leading softgel platforms, including Liqui-Gels, OptiShell, OptiGel DR, and Vegicaps capsules, our new gummy and soft chew oral forms, and our modified release technologies, including the Zydis family of orally disintegrating tablets, our spray drying capabilities, and our OptiPact and OptiMelt technologies, provide formulation expertise to solve complex delivery challenges for our customers. We offer advanced technologies for delivery of small molecules and biologics via oral, respiratory, and injectable routes and also provide advanced biologics formulation options, including GPEx, GPEx Boost, and GPEx Lightning mammalian cell lines for protein production, SMARTag ADC technology, AAV vectors for cell and gene therapies, and pDNA development and commercial manufacturing. We have a leadership position within respiratory delivery, including dry powder inhalers and intra-nasal forms. We have reinforced our leadership position in advanced technologies over the last three years, as we have launched more than a dozen new technology platforms and applications, and recently purchased or expanded our businesses developing and manufacturing consumer health products, protein-based biologics, fill and finish for injectable drugs and biologics, cell and gene therapies, and other new therapeutic modalities. Our culture of creativity, problem-solving, and innovation is grounded in our advanced technologies, the substantial expertise and experience of our scientists and engineers, and, in some cases, our patents and proprietary manufacturing processes. Our global product development and innovation teams drive a focused application of resources to opportunities for both new customer product introductions and platform technology development. As of June 30, 2022, we had more than 1,500 product development programs in active development across our businesses.
Long-Duration Relationships Provide Sustainability

Our broad and diverse range of technologies closely integrates with our customers’ molecules to yield safe and effective final formulations and dose forms, and this generally results in the inclusion of Catalent in our customers’ prescription product regulatory filings. Both factors translate to long-duration supply relationships at an individual product level, to which we apply our expertise in contracting to produce long-duration commercial supply agreements. These agreements typically have initial terms of three to seven years with regular renewals of one to three years (see “—Contractual Arrangements for more detail). Approximately two-thirds of our fiscal 2022 net revenue from our product development and delivery offerings and related services were covered by such long-term contractual arrangements. We believe this base provides us with a sustainable competitive advantage.
Significant Recent Growth Investments

We have made over time, and expect to continue to make, significant investments in our manufacturing network, which is capable of serving customers and patients worldwide, and today employ approximately 8 million square feet of manufacturing, laboratory, and related space across four continents. We have deployed approximately $2.21 billion in the last five fiscal years in gross capital expenditures, not including approximately $4.06 billion spent in acquiring new facilities and businesses. Growth-related investments in facilities, capacity, and capabilities across our businesses have positioned us for future growth in areas aligned with anticipated future demand, including in pDNA, cell and gene therapies, fill and finish for injectable drugs and biologics, and other new therapeutic modalities. Through our focus on operational, quality, and regulatory excellence, we drive continuous improvements in safety, productivity, sustainability and reliable supply, which we believe further differentiate
8


us. Our manufacturing network and capabilities allow us the flexibility to reliably supply the changing needs of our customers while consistently meeting their quality, delivery, sustainability, and regulatory compliance expectations.

High Standards of Regulatory Compliance and Operational and Quality Excellence

We operate our plants in accordance with current good manufacturing practices (cGMP) or other applicable requirements, following our own high standards that are consistent with those of many of our large global pharmaceutical and biotechnology customers. We have approximately 1,900 employees around the globe focused on quality and regulatory compliance. All of our facilities are registered where required with the FDA or other applicable regulatory agencies, such as the European Medicines Agency (the “EMA”). In many cases, our facilities are registered with multiple food, drug, or biologics regulatory agencies around the world. In fiscal 2022, we were subject to 54 regulatory audits, and, over the last five fiscal years, we successfully completed approximately 300 regulatory audits. We also undergo more than 700 customer and internal audits annually. We believe our quality and regulatory track record to be a favorable competitive differentiator.

Strong and Experienced Management Team

Our executive leadership team collectively has approximately 600 years of combined and diverse experience within the pharmaceutical and healthcare industries. With an average of approximately 29 years of functional experience, this team possesses deep knowledge and a wide network of industry relationships.

Our Strategy

Our strategic ambition, guided by and operationalized through our values, is to power the innovation and growth of the life science industry by becoming its leading development and commercial partner in reliable supply, conventional and advanced technologies, first-to-scale innovation, and therapeutic modalities, and integrated solutions. To achieve this, we continue to pursue the following key growth initiatives:
Capabilities & Capacity Continued Expansion in Biologics and Other Attractive Markets

Recognizing the strategic importance of protein-based biologics, cell and gene therapies, pDNA, and other new biopharmaceutical modalities, we began to build a differentiated biologics platform in 2002. Since 2017, we have invested over $4.23 billion in our biologics business, including capital investments and approximately $2.81 billion for acquisitions of biologics-focused businesses and sites. Today, we are a recognized leader in biologics, including AAV vectors for gene therapies; development and supply for cell therapies; advanced cell-line development; formulation and fill-finish into vials, pre-filled syringes, and cartridges; specialized manufacturing of biologic drug substances; and bioanalytical analysis. We have partnered with customers from around the world to develop advanced cell expression for more than 1,000 cell lines, many using our advanced GPEx, GPEx Boost, and GPEx Lightning technologies, and have actively collaborated on developing and scaling up more than 125 cell and gene therapies. In the last two fiscal years, we expanded our existing cell therapy development and manufacturing capabilities and began offering pDNA production services. In the same period, we acquired a commercial-scale cell therapy manufacturing facility in Princeton, New Jersey, a developer and manufacturer of iPSCs located near Dusseldorf, Germany, and a manufacturing facility for biologic therapies and vaccines near Oxford, U.K. We have also invested in a second-generation ADC technology, SMARTag, and see continued progress in this technology’s capabilities and our customers’ SMARTag product-development activities.

In addition to our expansion in biologics, we have invested additional capital in several other existing facilities in order to expand in attractive markets, including ongoing significant expansion of our oral solid controlled release production capacity in Winchester, Kentucky, and the scaling-up of commercial manufacturing capacity for our next-generation orally disintegrating tablet (“ODT”) technology, Zydis Ultra. We have also added specialized new capabilities and capacity in early development over the last several fiscal years. We acquired a leading position in consumer-preferred gummy and soft-chew formats for consumer health products with our acquisition of Bettera Holdings, LLC (“Bettera Wellness”) in fiscal 2022. We expanded our capacity for oral and injectable products via our fiscal 2020 acquisition of a facility in Anagni, Italy, and our capacity for spray dried dispersion and dry powder inhaler manufacturing via our fiscal 2021 acquisition of a facility located near Boston, Massachusetts.
Use Our Proprietary Technologies and Substantial Expertise to Help Our Customers Develop New Products
We have broad and diverse technology platforms that are supported by deep scientific expertise, extensive know-how, and more than 1,400 patents and patent applications in approximately 140 families across advanced delivery, drug and biologics formulation, and manufacturing. For example, we have significant softgel fill and formulation know-how, databases of formulated products, and substantial softgel regulatory approval expertise. As a result, approximately 90% of approvals by the FDA over the last 25 years of new chemical entities presented in a softgel format have been developed and supplied by us.
9



In addition to resolving delivery challenges for our customers’ products, we apply our technology platforms and development expertise to proactively develop proof-of-concept products, whether improved versions of existing drugs, new generic formulations, or innovative consumer health products. In the consumer health area, we file product dossiers with regulators in relevant jurisdictions for self-created products, which help contribute sustainable growth to our consumer health business. We expect to continue to seek proactive development opportunities and other non-traditional relationships to increase demand for and value realized from our technology platforms. These activities have provided us with opportunities to capture an increased share of end-market value through out-licensing, profit-sharing, and other arrangements.
Operational Leverage Deploy Existing Infrastructure and Operational Discipline to Drive Profitable Growth
Through our existing infrastructure, including our global network of operating locations and programs, we promote operational discipline and drive margin expansion. With our active focus on continuous improvement and sustainability enhancement, global procurement function, and conversion cost productivity metrics in place, we have created a culture of functional excellence and cost accountability. Along with the ongoing increase in the share of revenues from higher margin biologics offerings, we expect this discipline to further leverage our operational network for profitable growth. Since fiscal 2017, we have expanded gross margin by 250 basis points and Adjusted EBITDA margin by over 400 basis points. Note that “Adjusted EBITDA” is a financial metric that is not prepared in accordance with the accounting principles generally accepted in the U.S. (U.S. GAAP), and that further explanations of this measure and comparisons to the most directly comparable U.S. GAAP measures are set forth below at Management’s Discussion and Analysis of Financial Condition and Results of Operations—Non-GAAP Metrics.
Strategic Acquisitions and Licensing Build on our Existing Platform
We operate in the markets for outsourced development solutions and commercial supply, where we estimate current spending at approximately $70 billion globally. Our broad platform, global infrastructure, and diversified customer portfolio provide us with a strong foundation from which to consolidate within these markets, to enter new markets, and generate operating leverage through acquisitions. Since fiscal 2013, we have executed 21 transactions, investing approximately $4.44 billion, and have demonstrated an ability to efficiently and effectively integrate these acquisitions.

While we are rigorously focused on driving our organic growth, we have in recent years substantially increased our participation in biologics, including protein-based biologics, cell and gene therapies, pDNA production, and drug product fill and finish, via strategy-driven inorganic transactions. We intend to continue opportunistically to source and execute strategic acquisitions within our existing business areas, as well as to undertake transactions that provide us with expansion opportunities within emerging treatment modalities, new geographic markets, or related market segments. We have a dedicated corporate development team in place to identify these opportunities and have a rigorous and financially disciplined process for evaluating, executing, and integrating such acquisitions.
“Follow the Molecule”® by Providing Solutions to our Customers across all Phases of the Product Lifecycle
We intend to continue to use our development and manufacturing solutions across the entire lifecycle of our customers’ products to drive future growth. Our development solutions span the drug development process, starting with our platforms for early pre-clinical development of small molecules, protein-based biologics, and cell and gene therapies; through formulation and analytical services, development and manufacturing of clinical trial supplies, and fill and finish of injectable products; to regulatory consulting. Once a molecule is ready for clinical trials and subsequent commercialization, we provide our customers with a range of advanced technologies and expert, state-of-the-art manufacturing solutions that allow them to deliver their molecules to the end-users in safe, effective, and, in some cases, patient-preferred dosage forms, and to produce biologic drug substances needed for protein-based biologics and cell and gene therapies. Our relationship with a molecule typically starts with developing and manufacturing the innovator product and can extend throughout the molecule’s commercial life. For prescription products, we are typically the sole or primary outsourced provider and are frequently reflected in customers’ product approval applications. Our revenue from our development and manufacturing activities are primarily driven by volumes, and, as a result, the loss of an innovator drug’s market exclusivity may be mitigated if we supply customers offering generic or biosimilar equivalents.

An example of the long and mutually productive relationships we foster can be found in a leading over-the-counter anti-allergy brand, which today uses both our Zydis ODTs and our Liqui-Gels softgel technology. We originally began development of the prescription format of this product for our multinational pharmaceutical company partner in 1992 to address specific patient sub-segment needs. After four years of development, we then commercially supplied the prescription product in our Zydis ODT format for six years, and we have continued to provide the Zydis form since the switch to over-the-counter status in the U.S. and other markets in the early 2000s. Subsequently, we proactively brought a softgel product concept for the brand to
10


the customer, which the customer elected to develop and launch as well. By following this molecule, we have built a strong, 30-year-long relationship across multiple formats and markets.
Customer Product Pipeline Continuing to Grow Through New Projects and Product Launches
We intend to continue to supplement our existing diverse base of commercialized customer products with new development programs. As of June 30, 2022, our product development teams were working on more than 1,500 active customer development programs. Our base of active development programs has expanded in recent years from growing market demand, as well as from our expanded capabilities and technology platforms. Although there are many complex factors that affect the development and commercialization of pharmaceutical, protein-based biologic, cell and gene therapy, and consumer health products, we expect that a portion of these programs will reach full development and market approval in the future and thereby add to our long-duration commercial revenues under long-term contracts and grow our existing product base. In fiscal 2022, we introduced 153 new products for our customers.

Catalent continues to be a leader in providing chemistry, manufacturing, and controls-based product development services to the global pharmaceutical, biotechnology, and consumer health industries, driven by thousands of projects annually. In fiscal 2022, we recognized $2.36 billion of net revenue related to the development of products, up 34% from the prior year. In addition, substantially all of the revenue associated with the Clinical Supply Services segment relates to our support of customer products in development.
Our Reporting Segments
In fiscal 2022, we operated in four operating segments, which also constitute our four reporting segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services, as further described below. Immediately following the end of fiscal 2022, we adopted a new operating structure, with two operating segments: (1) Biologics, and (2) Pharma and Consumer Health (discussed further in Note 20, Subsequent Events to our Consolidated Financial Statements). Set forth below is a summary description of our four fiscal 2022 segments.
Biologics
Our Biologics segment provides development and manufacturing for protein, pDNA, mRNA, cell therapy, viral vaccines and viral-based gene therapies; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. The business has extensive expertise in development, scale up, and commercial manufacturing. Representative customers of Biologics include Moderna, Johnson & Johnson, BMS, AstraZeneca, and Sarepta Therapeutics, along with a broad range of innovative small and mid-tier biopharmaceutical customers.
Our growing biologics offering includes cell-line development based on our advanced, patented GPEx suite of technologies, which are used to develop stable, high-yielding mammalian cell lines for both innovator and biosimilar biologic compounds. GPEx technology can provide rapid cell-line development, high biologics production yields, flexibility, and versatility. Our development and manufacturing facility in Madison, Wisconsin has the capability and capacity to produce cGMP quality biologics drug substance from 250L to 4000L scale using single-use technology to provide maximum efficiency and flexibility. Our Bloomington, Indiana facility brings additional biologics development, clinical, and commercial drug substance manufacturing, and formulation capabilities and capacity. Both Bloomington and our Anagni, Italy facility add substantial capacity for finished-dose biologics drug product manufacturing and packaging. We have continued to expand drug substance production capacity in Madison, bringing on-line fourth and fifth manufacturing suites, and have expanded drug product manufacturing and packaging capacity in Bloomington and Anagni. We recently acquired a new facility near Oxford, U.K., which will house development and manufacturing capabilities for proteins, nucleic acid therapeutics and other advanced modalities. Our SMARTag next-generation ADC technology, based in Emeryville, California, is a clinical-stage technology that enables development of ADCs and other protein conjugates with improved efficacy, safety, and manufacturability.
At our pDNA, cell therapy, and gene therapy global centers of excellence in Belgium, Maryland, New Jersey, and Texas, we develop and manufacture advanced therapeutics, including CAR-T, AAV, lentivirus, oncolytic virus and other cell or virus modalities together with critical pDNA biological starting material for cell, mRNA, and viral-based therapies and next-generation vaccines. Through continued inorganic investment in fiscal 2022, we acquired a fully operational, commercial-scale cell therapy campus in Princeton, New Jersey with 16 suites available for both autologous and allogeneic clinical and commercial manufacturing with potential further expansion. The Princeton, New Jersey campus works in conjunction with our Gosselies, Belgium cell therapy center of excellence, our iPSC manufacturing center of excellence in Dusseldorf Germany, and our clinical cell therapy center of excellence in Houston, further expanding our global cell therapy footprint. Additionally, we expanded our gene therapy flagship manufacturing campus in Harmans, Maryland with the addition of three commercial-scale viral vector suites, creating a total of 18 penthouse-style suites on the campus. At our gene therapy development campus in
11


Maryland, we expanded our portfolio with the release of the UpTempo Virtuoso™ AAV platform that reduces AAV development time by half, providing an advantage to our innovator customers across expanded gene therapy indications, enabling them to reach first-in-human studies faster. Our specialized expertise in AAV vectors, the most commonly used delivery system for gene therapies and iPSCs for next-generation allogeneic cell therapy manufacturing, together with our expanded global cell therapy manufacturing, capacity for clinical- through commercial-scale batches, and our expanded capabilities in mRNA and pDNA manufacturing, position us to capitalize on strong industry demand and expansions in treatment indications and the use of newer modalities in the cell and gene therapy market.
Our range of injectable manufacturing offerings includes manufacturing drug substance and filling small molecules or biologics into vials, syringes, and cartridges, with flexibility to accommodate other formats within our existing network. In addition to primary packaging, our network provides secondary packaging capabilities, including auto-injector and safety device assembly for commercial launch and life-cycle management. Our clinical supply services business provides a global network for clinical distribution, as well as labeling, packaging and cold-chain storage for clinical trial and commercial supply of biotherapeutics and cell and gene therapies. Our fill and finish services are largely focused on complex pharmaceuticals and biologics. With our range of technologies, we are able to meet a wide range of specifications, timelines, and budgets. We believe that the complexity of the manufacturing process, the importance of experience and know-how, regulatory compliance, and substantial capital requirements provide us with a meaningful competitive advantage in the market.
We also offer analytical development and testing services for large molecules, including bioassay, biophysical characterization, and cGMP release and stability testing. Our OneBio Suite provides customers the potential to seamlessly integrate drug substance, drug product, and clinical supply management for products in development, and for integrated commercial supply across both drug substance and drug product. We provide a broad range of technologies and services supporting the development and launch of new biologic entities, biosimilars, biobetters, and cell and gene therapies to bring a product from gene to commercialization, faster.
Our Biologics segment represented 53%, 48%, and 33% of our aggregate net revenue before inter-segment eliminations for fiscal 2022, 2021, and 2020, respectively.
Softgel and Oral Technologies
Through our Softgel and Oral Technologies segment, we provide formulation, development, and manufacturing services for soft capsules, or softgels, as well as large-scale manufacturing of oral solid dose forms for pharmaceutical and consumer health markets, along with supporting ancillary services. Following our fiscal 2022 acquisition of Bettera Wellness, we also provide formulation, development, and manufacturing of various experiential dose forms for the delivery of dietary supplements and other nutraceuticals.
Our softgel manufacturing technology was first commercialized by our predecessor in the 1930s, and we have continually enhanced the platform since then. We are the market leader in overall softgel development and manufacturing and hold the leading market position in innovator drug softgels. Our principal softgel technologies include traditional softgel capsules, in which the shell is made of animal-derived gelatin, and Vegicaps and OptiShell capsules, in which the shell is made from plant-derived materials. Softgel capsules are used in a broad range of customer products, including prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. Softgel capsules encapsulate liquid, paste, or oil-based formulations of active compounds in solution or suspension within an outer shell. In the manufacturing process, the capsules are formed, filled, and sealed simultaneously. We typically perform encapsulation for a product within one of our softgel facilities, with active ingredients provided by customers or sourced directly by us. Softgels have historically been used to solve formulation challenges or technical issues for a specific drug, to help improve the clinical performance of compounds, to provide important market differentiation, particularly for over-the-counter medications, and to provide safe handling of hormonal, highly potent, and cytotoxic drugs. We also participate in the softgel vitamin, mineral, and supplement business in selected regions around the world. Our plant-derived softgel shells, available as Vegicaps and OptiShell capsules, allow innovators and consumer health customers to extend the softgel dose form to a broader range of active ingredients and serve patient and consumer populations that were previously inaccessible due to religious, dietary, or cultural preferences. Our Vegicaps and OptiShell capsules are protected by patents in most major global markets. Physician and patient studies we have conducted have demonstrated a preference for softgels versus traditional tablet and hard capsule dose forms in terms of ease of swallowing, real or perceived speed of delivery, ability to remove or eliminate unpleasant odor or taste, and, for physicians, perceived improved patient adherence with dosing regimens.
Our large-scale cGMP manufacturing of oral solid dose forms typically includes late-stage clinical trial supplies, registration batches, and commercial production across a broad range of formats, and may also involve finished dose packaging or advanced processing of intermediates to achieve the desired clinical performance of the prescription or over-the-counter pharmaceutical product. Finished dose forms include traditional and advanced complex oral solid-doses, including coated and uncoated tablets, pellet/bead/powder-filled two-piece hard capsules, granulated powders, and other immediate and modified
12


release forms. Advanced intermediate processing may include coating, extrusion, or spheronization to achieve specific functional outcomes, including site- or time-specific drug release, taste masking, or enhanced bioavailability. We have deep experience at managing complex technical transfers of clinical or commercial programs, whether from Catalent’s early development network in the Oral and Specialty Delivery segment, other contract development sites, or from customers directly.

We conduct formulation, development, and manufacturing of gummies, soft chews, and lozenges in a variety of sizes and shapes serving the dietary supplements market at four facilities in the United States. We use dietary and food ingredients provided by our customers or sourced directly by us, and we also provide ancillary services such as analytical testing and packaging.
Representative customers of Softgel and Oral Technologies include Pfizer, Novartis, Bayer, GlaxoSmithKline, and Procter & Gamble.
Our Softgel and Oral Technologies segment represented 26%, 25%, and 34% of our aggregate net revenue before inter-segment eliminations for fiscal 2022, 2021, and 2020, respectively.
Oral and Specialty Delivery
Our Oral and Specialty Delivery segment provides advanced analytical and formulation development and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. The technologies cover a broad range of oral (including our proprietary fast-dissolve Zydis tablets and many bioavailability enhancement technologies for both immediate and controlled-release tablets and capsules), respiratory and inhaled dose forms, including metered dose inhalers, dry powder inhalers, and nasal delivery devices.
Our oral delivery solutions platform provides comprehensive pre-clinical screening, formulation, and analytical development, and cGMP manufacturing at both clinical and commercial scale for both traditional and advanced complex oral solid-dose formats. We have substantial proven experience in developing and scaling up orphan and rare disease oral products, especially those requiring accelerated development timelines, solubility enhancement, specialized handling (e.g., potent or controlled substance materials), complex technology transfer and specialized manufacturing processes. We provide spray drying, hot melt extrusion, micronization, and lipid formulation capabilities, all of which are used to enhance a drug’s bioavailability and clinical performance. We offer comprehensive analytical method development and scientific capabilities, including stability testing and global regulatory services to support both fully integrated development programs or standalone fee-for-service work. In recent years, we have expanded our network of early development sites focused on earlier phase compounds (i.e., pre-clinical and Phase I) to engage with more customer molecules earlier in their development, with the intent to also support these molecules downstream as they progress towards commercial approval and supply. Demand for our offerings is driven by the need for scientific expertise, the depth and breadth of integrated services offered, as well as the reliability of our supply performance across quality and operational parameters.
Our ODT business began with the introduction of Zydis, a unique proprietary freeze-dried tablet that disintegrates in the mouth, without water, typically in less than three seconds. The platform is often used for drugs that benefit from rapid oral dissolution and buccal absorption and for drugs for specialized patient groups, including geriatric or pediatric populations, that have difficulty swallowing (dysphagia). We can adapt the Zydis technology to a wide range of molecules and indications, including prescription treatments for a variety of central nervous system-related conditions such as migraine, Parkinson’s disease, and schizophrenia, and also for a range of consumer healthcare products targeting broader indications such as pain or allergy relief. We continue to invest in and develop Zydis ODTs in different ways with our customers as we extend the application of the technology to new therapeutic categories, including immunotherapy, vaccines, and biologic molecule delivery.
Our respiratory platform provides integrated molecule screening, formulation development, and commercial manufacturing services for inhaled products delivered via metered dose inhalers, dry powder inhalers, and intra-nasal sprays. Delivery of these inhaled combination device products requires specialized capabilities to account for both the molecule and the device, to ensure accurate repeatable dose delivery.
Representative customers of Oral and Specialty Delivery include Johnson & Johnson, Pfizer, Bayer, AbbVie, and Biohaven, along with many small and mid-sized emerging biopharma companies involved in the clinical development space.
Our Oral and Specialty Delivery segment represented 13%, 17%, and 22% of our aggregate net revenue before inter-segment eliminations for fiscal 2022, 2021, and 2020, respectively.
13


Clinical Supply Services
Our Clinical Supply Services segment provides manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials. We offer customers flexible solutions for clinical supplies production and provide distribution and inventory management support for both simple and complex clinical trials. This includes over-encapsulation where needed; supplying placebos, comparator drug procurement, and clinical packages and kits for physicians and patients; inventory management; investigator kit ordering and fulfillment; and return supply reconciliation and reporting. We support trials in all regions of the world through our facilities and distribution network. In recent years, we have continued to expand and extend our network, with significant expansions at our Philadelphia, Pennsylvania and Shanghai China free trade zone locations and new facilities in California, China, and Japan. We also continue to develop new solutions for the evolving clinical trial environment, including FlexDirect direct-to-patient, CT Success clinical supply planning, and extensive cold chain investments. We are the leading provider of integrated development solutions and one of the leading providers of clinical trial supplies.
Representative customers of Clinical Supply Services include Eli Lilly, AbbVie, Beigene, Johnson & Johnson, and Incyte Corporation.
Our Clinical Supply Services segment represented 8%, 10%, and 11% of our aggregate net revenue before inter-segment eliminations for fiscal 2022, 2021, and 2020, respectively.
Integrated Development and Product Supply Chain Solutions
In addition to our proprietary offerings, we are also differentiated in the market by our ability to bring together our development solutions and state-of-the-art product manufacturing to offer integrated development and product supply solutions that can be combined or tailored in many ways to enable our customers to take their drugs, biologics, and consumer health products from laboratory to market, faster. Once a product is on the market, we can provide comprehensive, integrated product supply, from the sourcing or supply of the bulk active ingredient to comprehensive manufacturing and packaging, to the testing required for release, and to cold-chain or ambient temperature distribution. The customer- and product-specific solutions we develop are flexible, scalable, and creative, so that they meet the unique needs of both large and emerging biopharma and consumer health companies and are appropriate for products of all sizes. We believe that our development and product supply solutions, such as OptiForm Solution Suite and OneBio Suite, will continue to contribute to our future growth.
Sales and Marketing
Our target customers include large pharmaceutical and biotechnology companies, mid-size, emerging, and specialty pharmaceutical and biotechnology companies, and consumer health companies, along with companies in other selected healthcare market segments such as animal health and medical devices, and companies in adjacent industries, such as cosmetics. We have longstanding, extensive relationships with leading pharmaceutical, biotechnology, and consumer health customers. In fiscal 2022, we did business with 87 of the top 100 branded drug marketers, 21 of the top 25 generics marketers, 24 of the top 25 biologics marketers, and 21 of the top 25 consumer health marketers globally, as well as with more than 1,200 other customers. Faced with access, pricing, and reimbursement pressures as well as other market challenges, large pharmaceutical and biotechnology companies have increasingly sought partners to enhance the clinical competitiveness of their drugs and biologics and improve the productivity of their research and development activities, while reducing their fixed cost bases. Many mid-size, emerging, and specialty pharmaceutical and biotechnology companies, while facing the same pricing and market pressures, have chosen not to build a full infrastructure, but rather to partner with other companies through licensing agreements or outsourcing to access the critical skills, technologies, and services required to bring their products to market. Consumer health companies require rapidly developed, innovative dose forms and formulations to keep up with the fast-paced over-the-counter medication, dietary supplement, and personal care markets. These market segments are all important to our growth, but require distinct solutions, marketing and sales approaches, and market strategy.

We follow a hybrid demand-generation organization model, with strategic account teams offering the full breadth of Catalent’s solutions, and technical specialist teams providing the in-depth technical knowledge and practical experience essential for each individual offering, both supported by dedicated team of deeply experienced scientific advisors. Our sales organization currently consists of approximately 190 full-time, experienced sales professionals, supported by inside sales and sales operations. We also have built a dedicated strategic marketing team, providing strategic market and product planning and management for our offerings. As part of our marketing efforts, we participate in major trade shows relevant to our offerings globally and ensure adequate visibility to our offerings and solutions through a comprehensive print and on-line advertising and publicity program. We believe that Catalent is a strong brand with high overall awareness in our established markets and universe of target customers, and that our brand identity is a competitive advantage for us.
14


Global Accounts
We manage select accounts globally due to their substantial current business or growth potential. We recorded approximately 43% of our total net revenue in fiscal 2022 from these global accounts. Each global account is assigned a lead business development professional with substantial industry experience. These account leaders, along with other members of the sales and executive leadership teams, are responsible for managing and extending the overall account relationship. Account leaders work closely with the rest of the sales organization as well as operational, quality, and project management personnel to ensure alignment around critical priorities for the accounts.

Emerging, Specialty, and Virtual Accounts

Emerging, specialty, and virtual pharmaceutical and biotechnology companies are expected to be critical drivers of industry growth globally and account for more than three-quarters of the active drug and biologic development pipeline. Historically, many of these companies have chosen not to build a full infrastructure, but rather partner with other companies to formulate, develop, analyze, test, and manufacture their products. We expect them to continue to do so in the future, providing a critical source for future integrated solutions demand. We expect to continue to increase our penetration of geographic clusters of emerging companies in North America, Europe, Central and South America, and Asia. We regularly use active pipeline and product screening and customer targeting to identify the optimal candidates for partnering based on product profiles, funding status, and relationships, to ensure that our technical sales specialists and field sales representatives develop custom solutions designed to address the specific needs of these customers. In order to reach these emerging, specialty, and virtual companies, we actively partner with leading venture capital investors and biotech incubators.

Seasonality; Fluctuations in Operation Results

Our annual financial reporting period ends on June 30. Excluding the impact from COVID-19, as discussed further in "Item 7 - Management's Discussion and Analysis of Financial Condition and Results of Operations - Factors Affecting our Performance," our revenue and net earnings are generally higher in the third and fourth quarters of each fiscal year, with our first fiscal quarter typically generating our lowest revenue of any quarter, and our last fiscal quarter typically generating our highest revenue. These fluctuations are primarily the result of the timing of our, and our customers’, annual operational maintenance periods at locations in the U.S. and Europe, the seasonality associated with pharmaceutical and biotechnology budgetary spending decisions, clinical trial and research and development schedules, the timing of new product launches and length of time needed to obtain full market penetration, and, to a lesser extent, the time of the year some of our customers’ products are in higher demand.
Contractual Arrangements
We generally enter into a broad range of contractual arrangements with our customers, including agreements with respect to feasibility, development, supply, licenses, quality, and confidentiality. The terms of these contracts vary significantly depending on the offering and customer requirements. Some of our agreements may include a variety of revenue arrangements, such as fee-for-service, unit pricing in one or more tiers, minimum volume commitments, royalties, manufacturing preparation services, profit-sharing, and fixed fees. We generally secure pricing and other contract mechanisms in our supply agreements to allow for periodic resetting of pricing terms, and, in some cases, these agreements permit us to raise or renegotiate pricing in the event of certain price increases for the raw materials we use to make products. Our typical supply agreements include indemnification from our customers for product liability and intellectual property matters and caps on our contractual liabilities, subject in each case to negotiated exclusions. The terms of our manufacturing supply agreements range from three to seven years with regular renewals of one to three years, although some of our agreements are terminable upon much shorter notice periods, such as 30 or 45 days. For our development solutions offerings, we may enter into master service agreements, which provide for standardized terms and conditions and make it easier and faster for customers with multiple development needs to access our offerings.
Backlog
While we generally have long-term supply agreements that provide for a revenue stream over a period of years, our backlog represents, as of a point in time, future service revenues from work not yet completed. For our Softgel and Oral Technologies, Biologics, and Oral and Specialty Delivery segments, backlog represents firm orders for manufacturing services and includes minimum volumes, where applicable. For our Clinical Supply Services segment, backlog represents estimated future service revenues from work not yet completed under signed contracts. Using these methods of reporting backlog, as of June 30, 2022, our backlog was $2,850 million compared to $3,767 million as of June 30, 2021, including $549 million and $501 million, respectively, related to our Clinical Supply Services segment. We expect to recognize as revenue by the end of fiscal 2023 approximately 80% of the value of the backlog in existence as of June 30, 2022.
15



To the extent projects are delayed, the timing of our revenue could be affected. If a customer cancels an order, we may be reimbursed for the costs we have incurred. For orders that are placed inside a contractual firm period or that involve minimum volume commitments, we generally have a contractual right to payment in the event of cancellation. Fluctuations in our reported backlog levels also result from the timing and order pattern of our customers, which often seek to manage their level of inventory on hand. Because of customer ordering patterns, the matters discussed in this paragraph, and other factors, our backlog reported for certain periods may fluctuate and may not be indicative of future results.
Manufacturing Capabilities
We operate manufacturing facilities, development centers, and sales offices throughout the world. As of June 30, 2022, we had 58 facilities (5 geographical locations operate as multiple facilities because they support more than one reporting segment, with one location including both a manufacturing facility and our corporate headquarters) on four continents with approximately 8 million square feet of manufacturing, laboratory, office, and related space. Our manufacturing capabilities generally include the full suite of competencies relevant to the support of each site’s activities, including regulatory, quality assurance, and in-house validation.
We operate our manufacturing facilities and development centers in accordance with cGMP or other applicable requirements. All of these sites are registered where required with the FDA or other applicable regulatory agencies, such as the EMA. In some cases, our sites are registered with multiple regulatory agencies.
We have invested $1.81 billion in our manufacturing and development facilities since fiscal 2020 for improvements and expansions, including $660 million in capital expenditures during fiscal 2022. We believe that our sites and equipment are in good condition, are well maintained, and are able to operate at or above present levels for the foreseeable future, in all material respects.
Our manufacturing operations are focused on employee health and safety, regulatory compliance, operational excellence, continuous improvement, and process standardization across the organization. In fiscal 2022, we achieved approximately 95% on-time shipment delivery versus customer request date across our network as a result of this focus. Our manufacturing operations are structured around an enterprise management philosophy and methodology that utilizes principles and tools common to a number of quality management programs, including Lean Six Sigma and Lean Manufacturing.
Raw Materials
We use a broad and diverse range of raw materials in the design, development, and manufacture of our products. This includes, but is not limited to, key materials such as gelatin, starch, and iota carrageenan; packaging films; single-use production components for drug substance production, and glass vials and syringes for drug product. The raw materials that we use are sourced externally on a global basis. Globally, our supplier relationships could be interrupted due to natural disasters and international supply disruptions, including those caused by pandemics or geopolitical and other issues. For example, commercially usable gelatin is available from a limited number of sources. In addition, much of the gelatin we use is bovine-derived. Past concerns of contamination from Bovine Spongiform Encephalopathy (BSE) have narrowed the number of possible sources of particular types of gelatin. If there were a future disruption in the supply of gelatin from any one or more key suppliers, there can be no assurance that we could obtain an alternative supply from our other suppliers. Any future restriction that were to emerge on the use of bovine-derived gelatin from certain geographic sources due to concerns of contamination from BSE could hinder our ability to timely supply our customers with products and the use of alternative non-bovine-derived gelatin for specific customer products could be subject to lengthy formulation, testing and regulatory approval periods.

We work very closely with our suppliers to assure continuity of supply while maintaining excellence in material quality and reliability. We continually evaluate alternate sources of supply, although we do not frequently pursue regulatory qualification of alternative sources for key raw materials due to the strength of our existing supplier relationships, the reliability of our current supplier base, and the time and expense associated with the regulatory process, since regulators usually must approve changes to prescription product ingredient sources. Although a change in suppliers could require significant effort or investment by us in circumstances where the items supplied are integral to the performance of our products or incorporate specialized material such as gelatin, we do not believe that the loss of any existing supply arrangement would have a material adverse effect on our business. See Risk Factors—Risks Relating to Our Business and the Industry in Which We Operate—Our future results of operations are subject to fluctuations in the costs, availability, and suitability of the components of the products we manufacture, including active pharmaceutical ingredients, excipients, purchased components, and raw materials. In addition, the COVID-19 pandemic and the ongoing supply-chain disruptions triggered by a combination of the pandemic and the Ukrainian-Russian war may interfere with the operations of certain of our direct or indirect suppliers or with
16


international trade for these supplies, which may either raise our costs or reduce the productivity or slow the timing of our operations."
Competition
We compete with multiple companies as to each of our offerings and in every region of the globe in which we operate, including with other companies that offer conventional and advanced technologies for the development, supply, and delivery of medicinal products, clinical trials support, outsourced dose form, protein-based biologics or cell or gene therapy manufacturing, or development services to pharmaceutical, biotechnology, and consumer health companies based in North America, Central and South America, Europe, and the Asia-Pacific region. We also compete in some cases with the internal operations of those pharmaceutical, biotechnology, and consumer health customers that also have manufacturing capabilities and choose to source these services internally. Some of our competitors are substantially larger than we are and have access to more substantial resources, which could be deployed to expand their range of offerings or capacity.

Competition is driven by proprietary technologies and know-how (where relevant), capabilities, consistency of operational performance, availability of equipment, quality, price, value, responsiveness, and speed. While we have competitors that compete with us in our individual offerings, and a few competitors that compete across many of our offerings, we do not believe we have competition from any directly comparable company.
Research and Development Costs
Our research activities are primarily directed toward the development of new offerings and manufacturing process improvements. Research and development costs amounted to $23 million, $21 million, and $21 million for fiscal 2022, 2021, and 2020, respectively.
Employees
As of June 30, 2022, we had approximately 19,000 individuals providing services to us at 58 facilities on 4 continents, of which certain employees at two of our 27 U.S. facilities are represented by a labor union, with their terms and conditions of employment being subject to collective bargaining agreements. Some combination of national works councils, labor unions, and other labor organizations is active at all of our European facilities consistent with labor environments and laws in European countries. Similar relationships with labor organizations or national works councils exist at our plants in Argentina, Brazil, and Canada. Our management believes that our relations with our workforce are satisfactory. Most of our individual service providers are full-time employees, while approximate 1,100 of our workers as of June 30, 2022 are contingent workers who are either self-employed or employed by external services organizations.
North AmericaEuropeSouth AmericaAsia PacificTotal
Approximate number of workers as of June 30, 202211,7005,7001,00060019,000
Human Capital Management

Our employees share common goals: to put patients first and to help people around the world live better, healthier lives. Our global workforce is united by our values: Patient First, commitment to our people, customer dedication, innovation, integrity, and excellence. Together, our values provide the foundation for our culture. We believe that an engaged, diverse workforce, empowered by inclusive leaders, will unlock our full potential as a company and as a leader in our sector. Our employees’ success is Catalent’s success.

We focus on employee development, engagement, and diversity and inclusion (“D&I”) to hire, develop, and retain the best talent. As of June 30, 2022, we had nearly 19,000 individuals providing services to us globally, with women representing 44% of our employees and holding 39% of roles at the manager level or higher. In fiscal 2022, ethnically diverse talent represented 32% of our U.S. employees.

Catalent, like many others, experienced the effects of "the great resignation," in fiscal 2022. Our turnover rate increased to 19% as of June 30, 2022, including 15% voluntary turnover, substantially driven by voluntary turnover in the U.S. Reducing attrition is now one of our top priorities. We continue to implement initiatives to build upon our values-based and inclusive culture, improve our employees' experiences at Catalent, and better develop and engage internal talent. We continuously monitor local talent markets and provide differentiated pay arrangements and benefits to attract and retain talent. Additionally, we provide flexible work arrangements where possible, broader leadership development programs, an employee wellness program, and access to employee recognition programs at all levels.

17


We continue to take steps to assure that Catalent is a company where all employees can develop a fulfilling career with support from our leadership team. We believe that our diverse pool of internal talent and our employees’ passion for excellence make a difference in the way we grow and deliver results.

Talent Acquisition

We have strong human resources processes and practices in place to support our employees through their careers at Catalent. This starts with an aggressive recruiting strategy and a strong employer brand. We attracted more than 4,600 new employees in fiscal 2022, continuously working to reduce the time it takes to fill open positions and reduce our cost per hire, while striving for a best-in-class candidate experience.

We offer competitive compensation and a comprehensive suite of benefits, which, in the U.S., range from medical, dental, and vision coverage to retirement, disability, employee stock purchase, and life insurance programs, we also provide health promotion and wellness programs, remote work flexibility, tuition assistance, and employee assistance programs in several countries.

Our recruitment strategy aims to attract talent representing diverse backgrounds, perspectives, and ideas. This approach includes:

•    engaging with potential top talent early in the career path through our college internship program;
•    developing future leaders and enhancing their skills through several programs, including various mentoring programs and our Global Organization Leadership Development (“GOLD”), Next Generation Global Leaders, and General Manager Excellence programs, as discussed further below;
•    providing competitive compensation and benefits;
•    continuously improving recruitment processes and platforms;
•    working with several recruitment partners to attract diverse profiles and advertise open positions; and
incorporating unconscious bias workshops for hiring managers.

Catalent was recognized as a TOP EMPLOYER USA for 2020, 2021, and 2022 and as a TOP EMPLOYER in the U.K. in 2022. We differentiate ourselves as a preferred employer to candidates through our reputation as a great place to work, offering a fast-paced work environment, and as a result of our continued role as a critical part of the global biopharmaceutical effort to combat the COVID-19 pandemic.

Talent Development

We are also committed to the growth, development, and engagement of our people once they have joined our family. Through a strong learning and development culture, we provide opportunities for specialized technical training, leadership development, and high-potential growth opportunities to endow our employees with the knowledge and expertise needed to grow their careers here.

Our primary goal is to develop our people from within, thereby establishing a strong successor bench to help support company growth. In fiscal 2022, over 3,400 employees moved to a new role within the organization, (of which 47% were women) whether as a developmental move or a promotion to a more senior position. Our senior leaders are committed to talent development and dedicate time each fiscal quarter to perform formalized talent reviews to discuss the development of key talent and to update succession plans for critical roles.

We strongly believe that the combination of experience (70%), exposure (20%), and education (10%) is the best recipe for personal development and career progression here. We have a library of tools and resources available for our employees within that framework, including access to a variety of tools and resources to learn new or expand existing skills.

Given our growth and high volume of new hires, we continue to redesign our employee experience. We have upgraded our on-boarding experience to span employees' first twelve months with Catalent.

We also offer four formal development programs to employees. All programs aim to prepare our talent to fill critical internal leadership roles. Through these programs, we have created a bench of leaders who model our values and are ready to take on more responsibility.
(1)    Entry-level GOLD program. The GOLD program is a two-year rotational program for recent graduates from universities around the world in which the employee participates in three rotations at different sites in our network
18


to learn about us and our varied offerings. GOLD employees receive assignments to perform strategic roles in key business initiatives. We provide them with coaching and opportunities to interact with senior executives, which both develop the skills and experience of our GOLD employees and provide a platform through which they contribute fresh ideas that challenge the status quo. The GOLD program operates in the U.S. and has been relaunched in Europe following a pause in the program during the U.K.'s withdrawal from the European Union ("E.U.").

(2)    Manager-level Next Generation Global Leader program. Our Next Generation Global Leader program for employees at the manager level is a 15-month on-the-job program focused on preparing high-potential managers for director-level roles. In fiscal 2022, 39 employees graduated from this program and 47 new employees joined the program.

(3)    Senior leader General Manager Excellence program. Our general managers run our operating sites and have substantial and wide-ranging responsibilities. This program enhances the skills of our general managers by giving them exposure to industry best practices and opportunities to network internally and receive personalized career coaching, including a 3-day business simulation. In fiscal 2022, 35 general managers were selected for this program and 24 additional general managers will start in fiscal 2023.

(4)    Front-line leader level Lead Now program. Beginning in fiscal 2023, Lead Now is a Catalent-wide leadership offering targeted for those who are new to people leadership. During the first 3 months of a new leadership role, this program teaches employees the fundamentals of leadership and identifies tools to inspire their teams while role modeling Catalent values.

Diversity and Inclusion

At Catalent, we cultivate a workplace that respects and welcomes all people; celebrates the unique backgrounds and experiences of our workforce; encourages all employees to bring their true, authentic selves to work; and leverages our diversity to drive innovation, inclusion, and excellence in every aspect of our business. By closing diversity and inclusion gaps, we energize our people to do their best work.

Our commitment to D&I starts at the top with a diverse board of directors and an executive management team (representing 8 different countries around the world) that present a broad spectrum of backgrounds and perspectives. Our Global Office of Diversity & Inclusion (the “D&I Office”) oversees our D&I efforts globally, and reports to a Global D&I Council of executives and senior leaders from across Catalent. The work of the D&I Office is supported by regional D&I committees composed of leaders at a variety of levels who oversee the implementation of local programs around the world.

We are committed to identifying and acknowledging gaps in our D&I mission and taking action to address them. To drive progress within Catalent, we focus on four strategic initiatives:

• Strengthening our culture of inclusion, supported by our eight employee resource groups;
• Promoting inclusive leadership;
• Accelerating talent acquisition and development, including with support from external partners; and
• Activating a data- and accountability-driven strategy.

The D&I Office oversees our efforts, guided by our Global D&I Council. The Council coordinates with executive-led regional D&I committees to implement local programs. Our board of directors reviews our D&I strategy and progress at least twice a year.

Key D&I performance highlights are captured in our Corporate Responsibility and Environmental, Social, and Governance Strategy section below.

Engagement

Our employee-focused practices have made a clear impact on our employee engagement. Through increased engagement, we can grow our business by relying on strong, engaged leaders and professionals willing to ensure we can overcome and thrive during any challenge.

We periodically administer a company-wide engagement survey to garner direct feedback from our employees regarding how we can more deeply and meaningfully engage them, enabling us to focus on improving specific areas where we can
19


support our people. Our most recent engagement survey in fiscal 2021 showed overall improvement compared to the immediately prior survey taken two years earlier, with the most important improvement among the senior leadership and manager employee populations, and a notable increase in engagement as a result of our enhanced rewards and recognition programs.

We are changing our approach to employee engagement surveys and will launch a "pulse survey" approach in fiscal 2023, using artificial intelligence to deliver an updated engagement score at least every 6 months. The first pulse survey will be launched in the first half of fiscal 2023.

Our COVID-19 Response

We have continued to adapt our processes and policies during the COVID-19 pandemic in order to support our employees, customers, and our local communities.

We recognize that we have a unique responsibility to help respond to the COVID-19 pandemic and are committed to supporting and protecting our employees and their families, ensuring that our supply of COVID-19 related products and our other life-saving and life-enhancing products reach patients, contributing our scientific expertise to the continued development of COVID-19 treatments and vaccines, and supporting health care providers and the communities in which they serve. We continue to keep our employees safe by using the best-available expertise to modify our process flows and people movement, employing masks, physical barriers, and physical distancing when appropriate to minimize exposure. We communicate regularly with our leaders and operating personnel regarding our actions and motivations to assure transparency and the incorporation of useful suggestions from every level of the organization.

In response to the COVID-19 pandemic, we implemented virtual recruitment platforms and streamlined procedures to accelerate onboarding amid varying local guidelines and restrictions. We continue to ensure the safety of new hires through training on our COVID-19 protocols. We continue to provide employees with easy and regular access to information, including details regarding our COVID-19 tracking process, guidance around hygiene measures and travel, and best practices for working from home. We also provide extensive information to support our employees as they continue to make vaccination decisions.

Corporate Responsibility ("CR") and Environmental, Social, and Governance (“ESG”) Strategy

Our CR strategy, which includes our ESG strategy, is integrated into our company-wide strategic plan, ensuring that we operate in alignment with our values, meet our commitments to all our stakeholders, and contribute to the long-term success of the broader pharmaceutical, biopharmaceutical, and consumer health industries and the communities where we operate. Our approach to ESG focuses on three areas of society relevant to our business, prioritizing our impact on (i) people, (ii) the environment, and (iii) our communities. We focus on ESG areas that are the most significant to our business, and our strategy is informed by our employees, customers, investors, communities, and other key stakeholders. Our fiscal 2022 ESG performance, described below, demonstrates our contribution to the long-term success of the industries we serve and the communities where we operate, as we continue to invest in a corporate culture that understands and prioritizes our impact on people in our operations and employee-related decision-making.

Fiscal 2022 brought new and continued challenges for our operations, including the on-going response to global and local surges of the COVID-19 pandemic, the Ukrainian-Russian war, and the on-going supply chain challenges amid rising global inflation. Through it all, our mission and values continued to provide steady, critical orientation and focus. Amid these fiscal 2022 challenges, our business continued to expand as our workforce of nearly 19,000 across more than 50 sites worked hard, with our Patient First value guiding the way, to ensure that we met our commitments to our customers and their patients.

Our ESG performance demonstrates how we are contributing to the long-term success of the broader biopharmaceutical industry and the communities where we operate, as we continue to invest in a corporate culture that understands and prioritizes our impact on people in our operations and decision-making.

Governance

We are committed to ensuring strong corporate governance practices on behalf of our shareholders and other stakeholders. We believe strong corporate governance and an independent board of directors provide the foundation for financial integrity and shareholder confidence. More information about our corporate governance features can be found in our Proxy Statement for the 2022 Annual Meeting of Shareholders (the Proxy Statement”), which will be filed within 120 days after June 30, 2022, the close of our fiscal year covered by this Annual Report.

In addition, we have established a CR council that reports to the CEO and is composed of senior leaders from various parts of our business. Our CR council guides our CR efforts and sets our overall CR strategy. Management, including members
20


of the CR Council, provide regular CR updates to our board of directors which regularly reviews material aspects of our CR strategy and performance as a full board and through its several committees, including a formal annual review of our overall CR strategy and performance.

Business Benefits

Beyond being the right thing to do, our focus on CR strengthens our business by reducing risks, meeting customer and investor expectations, and positioning us to attract top talent. CR performance is an important contributor to our business success. It informs our risk management process, protects our reputation, and alerts us to regulatory, environmental, and societal threats to our business. Our CR activities also align with many of our customers’ CR programs and strengthen our relationships.

Our future success depends on our highly skilled and dedicated global team of employees, who are passionate about improving health outcomes. We compete for top talent in our industry and recognize that our culture and reputation as a responsible company can be a differentiator for attracting job candidates and keeping and motivating our existing employees.

ESG progress in fiscal 2022

We made significant progress in several ESG focus areas in fiscal 2022.

In March 2022, we published our third annual Corporate Responsibility report (covering fiscal 2021), which includes an evaluation of our performance against the standards set by the Sustainability Accounting Standards Board (SASB) for Biotechnology and Pharmaceuticals and, for the first time, the recommendations of the Task Force on Climate-Related Financial Disclosures (TCFD). Some highlights of our progress include:
the achievement of our initial Scope 1 and 2 carbon reduction target and the establishment of a new science-based target to reduce Scope 1 and 2 emissions by 42% by 2030 (from a fiscal 2020 baseline);
our commitment to new water efficiency and waste reduction targets for fiscal 2024;
the initiation of a third-party human rights assessment, in line with the United Nations Guiding Principles on Business and Human Rights, and development of a follow-up plan to integrate key assessment recommendations into our operations and supply chain;
philanthropic giving that exceeded $1 million, donated to communities and organizations supporting COVID-19 recovery and, our on-going commitment to science, technology, engineering, and math (STEM) education, and nonprofits that serve patients, with a focus on underserved communities;
the launch and promotion of two new Catalent Cares programs: Employee Volunteer Grants and an Employee Relief Fund; and
moderately increased diversity of Company leadership and expanded employee resource groups (ERGs), while recognizing that we have gaps that need to be closed.
We experienced another year of philanthropic growth in fiscal 2022, inspired by our Company's and employees' response to the Ukrainian-Russian war. We also established a refugee working group that is mapping refugee communities to job opportunities at Catalent sites and further identifying more nonprofit partners to support relief and refugee efforts.
We continued to drive D&I by (1) investing in the inclusive capabilities of our leaders, (2) working with partners who share our values and help enable our strategy, (3) accelerating diverse talent acquisition and development, and (4) curating an even more inclusive culture. Some highlights of our progress include:
a significant increase in the number of employees of Latin or Hispanic heritage;
an increase in the self-identification of employees with disability, non-binary genders, and veterans, demonstrating our increasingly inclusive and safe company culture;
the completion of a new EDGE (women in the workplace (U.S.)) assessment and the integration of its findings into our D&I strategy, which assessment confirmed that Catalent has closed its gender pay gap in the U.S.;
being named among the 2022 Best Places to Work for People with Disabilities, following submission to the Disability Equality Index;
the growth of our strong ERG network by 25%;
the publication of a supplier diversity policy; and
the on-going rollout of our inclusive leadership workshops for site and functional leadership teams and conversations hosted by our leaders following challenging current events in the U.S.

Looking ahead

21


We are determined to play an integral role in moving our industry toward more responsible and sustainable business practices as we continue to be at the cutting edge of developing and reliably supplying drugs, biologics and consumer health products.

We continue to reduce our carbon emissions measured against our current Scope 1 and 2 science-based target reductions and will share our Scope 3 footprint and reduction plan by the end of fiscal 2023. We committed to new water and waste reduction goals by fiscal 2024, namely, to decrease water intensity to 500 cubic meters per $1 million in revenue, to eliminate waste sent to landfill at all of our facilities, and a bold goal to ensure no residual API above Predicted No Effect Concentration (PNEC) in our wastewater.

We will strengthen our supply chain by expanding our supplier assessment and auditing program, including continued use of our third-party vetting and due diligence platform in alignment with the Pharmaceutical Supply Chain Initiative (PSCI) principles and the U.N. Guiding Principles. Our diverse supplier network and spend will continue to increase, as outlined in our new Diverse Supplier Policy.

Measuring against our baseline D&I statistics, we will work to progress on our goal of recruiting, retaining and developing more diverse talent, including in leadership roles. In fiscal 2023, each of our sites will develop a D&I action plan, outlining localized strategies and goals to help us meet our targets. We will continue to participate in external benchmarks, including the Corporate Equality Index (LGBTQ+ inclusion), to guide our goals and progress. Through training, forums, and internal performance metrics, we will continue to combat our unconscious biases that can blind us from hiring and promoting diverse talent. Our employee surveys reveal that our employees are energized and engaged by our CR and D&I initiatives. In fiscal 2023, we will assess our employees’ overall engagement and inclusion in our next corporate engagement survey.

Further information on our CR program is available at catalent.com/cr, but this website is not part of our public disclosures and is not incorporated by reference into this Annual Report.
Intellectual Property
We use a combination of know-how, trade secrets, patents, copyrights, trademarks, and other intellectual property, nondisclosure and other contractual provisions, and technical measures to protect certain innovative aspects of our offerings, services, and intangible assets that we have developed. These proprietary rights can be important to aspects of our ongoing operations. Many of our operations and products are covered by intellectual property licenses from third parties, particularly our customers that provide licenses to their proprietary active ingredients or formulations as part of our development or supply agreements with them, and in certain instances we license our technology to third parties.

We also have a long track record of innovation across our lines of business, and, to further encourage active innovation, we have developed incentive compensation systems linked to patent filings and other recognition and reward programs for scientists and non-scientists alike. We have applied in the U.S. and certain other countries for registration of a number of trademarks, service marks, and patents, some of which have been registered and issued, and also hold common law rights in various trademarks and service marks. We hold more than 1,400 patents and patent applications worldwide relating to advanced drug delivery and biologics formulations and technologies, as well as manufacturing and other areas relevant to our business.

We hold patents and license rights relating to certain aspects of our formulations, pharmaceutical and nutritional dosage forms, mammalian cell engineering, antibody-drug conjugation, iPSCs, and plasmid DNA manufacturing. We also hold patents relating to certain processes and products. We have pending patent applications in the U.S. and certain other countries and intend to pursue additional patents as appropriate. We have enforced and will continue to enforce our intellectual property rights in the U.S. and worldwide in appropriate circumstances.

We do not consider any particular patent, trademark, license, franchise, or concession to be material to our overall business.
Regulatory Matters
The manufacture, distribution, and marketing of healthcare products and the provision of certain services for development-stage pharmaceutical and biotechnology products are subject to extensive ongoing regulation by the FDA, other U.S. governmental authorities, and similar regulatory authorities in other countries. Certain of our subsidiaries are required to register for permits or licenses with, and must comply with the operating, cGMP, quality, and security standards of, applicable domestic and foreign healthcare regulators, including the FDA, the U.S. Drug Enforcement Agency (the DEA), the U.S. Department of Health and Human Services (the DHHS), the equivalent agencies of the E.U. and its member states, and various state boards of pharmacy, state health departments, and comparable agencies in other jurisdictions, as well as various
22


accrediting bodies, each depending upon the type of operations and the locations of distribution and sale of the products manufactured or services provided by those subsidiaries.

In addition, certain of our subsidiaries are subject to other healthcare laws, including the U.S. Federal Food, Drug, and Cosmetic Act, the Public Health Service Act, the Controlled Substances Act, and comparable state and foreign laws and regulations in certain of their activities.

We are also subject to various federal, state, local, national, and transnational laws, regulations, and requirements, both in the U.S. and other countries, relating to safe working conditions, laboratory and distribution practices, and the use, transportation, and disposal of hazardous or potentially hazardous substances. In addition, applicable import and export laws and regulations require us to abide by certain standards relating to the cross-border transit of finished goods, raw materials, and supplies and the handling of information. We are also subject to various other laws and regulations concerning the conduct of our non-U.S. operations, including the U.S. Foreign Corrupt Practices Act, the U.K. Anti-Bribery Act, and other anti-bribery laws and laws pertaining to the accuracy of our internal books and records.

The costs associated with complying with the various applicable federal, state, local, national, and transnational regulations could be significant, and the failure to comply with such legal requirements could have an adverse effect on our results of operations and financial condition. See Risk Factors—Risks Relating to Our Business and the Industry in Which We Operate—Failure to comply with existing and future regulatory requirements, including changing standards or changing interpretations of existing standards, could adversely affect our results of operations and financial condition or result in claims from customers. In addition, changes to our procedures or additional procedures, implemented to comply with public health orders or best practice guidelines as a result of the COVID-19 pandemic, may increase our costs or reduce our productivity and thereby affect our business, financial condition, or results of operations, for additional discussion of the costs associated with complying with the various regulations.
In fiscal 2022, we were subject to 54 regulatory audits, and, over the last five fiscal years, we completed approximately 300 regulatory audits.
Quality Assurance
We are committed to ensuring and maintaining the highest standard of regulatory compliance while providing high quality products to our customers, supported by our core value of Patient First. To meet these commitments, we have developed and implemented a Catalent-wide quality management system. We have employees around the globe focusing on quality and regulatory compliance. Our senior management team is actively involved in setting quality policies, standards, and internal position papers as well as managing internal and external quality performance. Our quality assurance department provides quality leadership and supervises our quality systems programs. An internal audit program monitors compliance with applicable regulations, standards, and internal policies. In addition, our facilities are subject to periodic inspection by the FDA, the DEA, and other equivalent local, state, and foreign regulatory authorities as well as our customers. All FDA, DEA, and other regulatory inspection observations have been resolved or are on track to be completed at the prescribed timeframe provided in commitments to the applicable agency in all material respects. We believe that our operations are in compliance in all material respects with the regulations under which our facilities are governed.
Environmental, Health & Safety Matters
Our operations are subject to a variety of environmental, health, and safety laws and regulations, including those of the U.S. Environmental Protection Agency (the EPA”), the U.S. Occupational Safety & Health Administration (“OSHA”), and equivalent state, local, and national regulatory agencies in each of the jurisdictions in which we operate. These laws and regulations govern, among other things, air emissions, wastewater discharges, the use, handling, and disposal of hazardous substances and wastes, soil and groundwater contamination, and employee health and safety. Our manufacturing facilities use, in varying degrees, hazardous substances in their processes. These substances include, among others, chlorinated solvents, and in the past chlorinated solvents were used at one or more of our facilities, including a number we no longer own or operate. As at our current facilities, contamination at such formerly owned or operated properties can result and has resulted in liability to us, for which we have recorded appropriate reserves as needed. We believe that our operations are in compliance in all material respects with the environment, health, and safety regulations applicable to our facilities.

23


ITEM 1A.    RISK FACTORS
If any of the following risks actually occur, our business, financial condition, operating results, or cash flow could be materially and adversely affected. Additional risks or uncertainties not presently known to us, or that we currently believe are immaterial, may also impair our business operations.

Risks Relating to Our Business and the Industry in Which We Operate
Our business, financial condition, and results of operations may be adversely affected by global health epidemics, including the COVID-19 pandemic.
Any public health epidemic, including the COVID-19 pandemic, may affect our operations and those of third parties on which we rely, including our customers and suppliers. Our business, financial condition, and results of operations may be affected by: disruptions in our customers’ abilities to fund, develop, or bring to market products as anticipated; delays in or disruptions to the conduct of clinical trials; cancellations of contracts or confirmed orders from our customers; decreased demand for categories of products in certain affected regions; and inability, difficulty, or additional cost or delays in obtaining key raw materials, components, and other supplies from our existing supply chain; among other factors caused by a public health epidemic, including the COVID-19 pandemic.

While the COVID-19 pandemic has not had a material negative effect on our overall business, financial condition or results of operations to date, our customers and suppliers have in some cases experienced negative impacts due to disruptions in supply chains and disruptions to the operations of the FDA and other drug regulatory authorities, which resulted in, among other things, delays of inspections, reviews, and approvals of our customers’ products, as well as the volume and timing of orders from these customers. Such impacts may affect our business in the future. Governmental restrictions related to the COVID-19 pandemic, which continue to evolve, including travel restrictions, quarantines, shelter-in-place orders, business closures, new safety requirements or regulations, or restrictions on the import or export of certain materials, or other operational issues related to the COVID-19 pandemic may have an adverse effect on our business and results of operations.

We continue to monitor developments related to the COVID-19 pandemic and its effects on our business, operations, and financial condition. For purposes of our operational and financial planning, we have made, and update when appropriate, certain assumptions regarding the duration, severity, and global economic impact of the pandemic in different regions, and the need for continued manufacture and supply of COVID-19 vaccines and treatments, each of which remains uncertain. However, despite careful planning, our assumptions may not be accurate, as the extent to which COVID-19 may affect our future results will depend on future developments that are uncertain, including: the duration of the pandemic; emerging information concerning the severity and incidence of the virus and its variants; the emergence of additional virus variants; regional resurgences of the virus globally; the safety, efficacy, and availability of vaccines and treatments for COVID-19 (including its variants); the rate at which the population globally becomes vaccinated against COVID-19; the global economic impact of the pandemic; the actions of governments and regulatory authorities to contain the pandemic or control the supply of vaccines and treatments; and the actions the pharmaceutical industry, competitors, suppliers, customers, patients, and others may take to contain or address the pandemic’s direct and indirect effects.

Our Biologics segment, in particular, has reported substantial revenue from the testing, manufacturing, and packaging of COVID-19-related products for our customers. While this positive impact is expected to continue through at least the remainder of calendar 2022 and into calendar 2023, the duration and extent of future revenues from such testing, manufacturing, and packaging of COVID-19-related products is uncertain and dependent upon customer demand. See also "—Risks Related to Our Business and the Industry in Which We Operate—The continually evolving nature of the COVID-19 pandemic and the resulting public health response, including the changing demand for various COVID-19 vaccines and treatments from both patients and governments around the world, may affect sales of the COVID-19 products we manufacture."
In addition, the impact of the COVID-19 pandemic or any other public health epidemic could exacerbate other risks we face, including those described elsewhere in "Risk Factors."

The continually evolving nature of the COVID-19 pandemic and the resulting public health response, including the changing demand for various COVID-19 vaccines and treatments from both patients and governments around the world, may affect sales of the COVID-19 products we manufacture.

We manufacture or provide services for a variety of products intended for the prevention or treatment of COVID-19 and its symptoms and effects, including both vaccines and treatments. No single one of these products is material to our business. Certain of these products are subject to “take-or-pay” provisions that require the customer to either purchase a minimum
24


amount of product or pay any shortfall resulting from purchases not made. Such provisions should mitigate risks relating to any future uncertainty in the demand for these products.

The COVID-19-related products we develop and manufacture have not yet received full marketing approval from certain regulatory authorities around the world for certain patient populations, although some of these are being marketed and sold to such populations pursuant to an emergency use authorization (EUA) from the FDA or the equivalent authorization from non-U.S. regulatory authorities. Should any of these COVID-19-related products be denied any necessary regulatory approval, the demand for such product could decrease significantly and therefore decrease customer orders for additional development, manufacturing, or packaging of those products, although the financial effect on us may be mitigated by any take-or-pay provision in place with respect to that product. Additionally, the need for continued manufacture and supply of vaccines (including “booster” doses) and therapies to address the COVID-19 pandemic, including new and developing variants of COVID-19, is highly uncertain and subject to various political, economic, and regulatory factors that are outside of our control. Should the U.S. or other major regions worldwide determine that additional manufacture of COVID-19 vaccines, boosters, or therapies is no longer necessary, it could adversely affect our revenue and financial condition. In addition, highly-public political and social debate relating to the need for, efficacy of, or side effects related to one or more specific COVID-19 vaccines could contribute to changes in public perception of one or more COVID-19 vaccines manufactured by us, which could decrease demand for a COVID-19 related product we develop, manufacture, or package.
The demand for our offerings depends in part on our customers’ research and development and the clinical and market success of their products. Our business, financial condition, and results of operations may be harmed if our customers spend less on, or are less successful in, these activities. In addition, customer spending may be affected by, among other things, the COVID-19 pandemic or recessionary economic conditions caused in whole or in part by the pandemic, the Ukrainian-Russian war, or the rise in inflation worldwide.
Our customers are engaged in research, development, production, and marketing of pharmaceutical, biotechnology, and consumer health products. The amount of customer spending on research, development, production, and marketing, as well as the outcomes of such research, development, and marketing activities, have a large impact on our sales and profitability, particularly the amount our customers choose to spend on our offerings. Available resources, including funding for our biotechnology and other customers, the need to develop new products, and consolidation in the industries in which our customers operate may have an impact on such spending. Our customers and potential customers finance their research and development spending from private and public sources. A reduction in available financing for and spending by our customers, for these reasons or because of the direct or indirect effects of the COVID-19 pandemic, inflation, and the Ukrainian-Russian war or other regional or global conflicts, could have a material adverse effect on our business, financial condition, and results of operations. If our customers are not successful in attaining or retaining product sales due to market conditions, reimbursement issues, or other factors, our results of operations may be materially adversely affected.
We participate in a highly competitive market, and increased competition may adversely affect our business.
We operate in a market that is highly competitive. We compete with multiple companies as to each of our offerings and in every region of the globe in which we operate, including competing with other companies that offer advanced delivery technologies, outsourced dose form or biologics manufacturing, clinical trials support services, or development services to pharmaceutical, biotechnology, and consumer health companies globally. We also compete in some cases with the internal operations of those pharmaceutical, biotechnology, and consumer health customers that also have manufacturing capabilities and choose to source these services internally.
We face substantial competition in each of our markets. Competition is driven by proprietary technologies and know-how, capabilities, consistency of operational performance, quality, price, value, responsiveness, and speed. Some competitors have greater financial, research and development, operational, and marketing resources than we do. Competition may also increase as additional companies enter our markets or use their existing resources to compete directly with ours. Expanded competition from companies in low-cost jurisdictions, such as India and China, may in the future adversely affect our results of operations or limit our growth. Greater financial, research and development, operational, and marketing resources may allow our competitors to respond more quickly with strategic acquisitions, or with new, alternative, or emerging technologies. Changes in the nature or extent of our customers’ requirements may render our offerings obsolete or non-competitive and could adversely affect our results of operations and financial condition.
We are subject to product and other liability risks that could exceed our anticipated costs or adversely affect our results of operations, financial condition, liquidity, and cash flows.
We are subject to potentially significant product liability and other liability risks that are inherent in the design, development, manufacture, and marketing of our offerings. We may be named as a defendant in product liability lawsuits, which may allege that our offerings have resulted or could result in an unsafe condition or injury to consumers. Such lawsuits,
25


even those without merit, could be costly to defend and could result in reduced sales, significant liabilities, adverse publicity, and diversion of management’s time, attention, and resources.
Furthermore, product liability claims and lawsuits, regardless of their ultimate outcome, could have a material adverse effect on our business operations, financial condition, and reputation and on our ability to attract and retain customers. The availability of product liability insurance for companies in the pharmaceutical industry is generally more limited than insurance available to companies in other industries. We maintain product liability insurance with annual aggregate limits in excess of $25 million. There can be no assurance that a successful product liability or other claim would be adequately covered by our applicable insurance policies or by any applicable contractual indemnity or liability limitations.

Failure to comply with existing and future regulatory requirements, including changing regulatory standards or changing interpretations of existing standards, could adversely affect our results of operations and financial condition or result in claims from customers. In addition, changes to our procedures or additional procedures, implemented to comply with public health orders or best practice guidelines as a result of the COVID-19 pandemic, may increase our costs or reduce our productivity and thereby affect our business, financial condition, or results of operations.

The healthcare industry is highly regulated. We, and our customers, are subject to various local, state, federal, national, and transnational laws and regulations, which include the operating, quality, and security standards of the FDA, the DEA, various state boards of pharmacy, state health departments, the DHHS, similar bodies of the U.K., the E.U. and its member states, and other comparable agencies around the world, and, in the future, any change to such laws and regulations or the interpretation or application thereof could adversely affect us. Among other rules affecting us, we are subject to laws and regulations concerning cGMP and drug safety. As a result of the COVID-19 pandemic or other public health activity, new public health orders or best practice guidelines may increase our costs to operate or reduce our productivity, thereby affecting our business, financial condition, or results of operations.

Failure by us or by our customers to comply with the requirements of applicable laws and regulations or requests from regulatory authorities could result in warning letters, product recalls or seizures, monetary sanctions, injunctions to halt manufacture or distribution, restrictions on our operations, civil or criminal sanctions, or withdrawal of existing or denial of pending approvals, permits, or registrations, including those relating to products or facilities. In addition, any such failure relating to the products or services we provide could expose us to contractual or product liability claims as well as claims from our customers, including claims for reimbursement for lost or damaged active pharmaceutical ingredients, which cost could be significant.

In addition, any new offering or product classified as a pharmaceutical or medical device must undergo lengthy and rigorous clinical testing and other extensive, costly, and time-consuming procedures mandated by the FDA, the EMA, and other equivalent local, state, federal, national, and transnational regulatory authorities in the jurisdictions that regulate our offerings and products.
Although we believe that we comply in all material respects with applicable laws and regulations, there can be no assurance that a regulatory agency or tribunal would not reach a different conclusion concerning the compliance of our operations with applicable laws and regulations. In addition, there can be no assurance that we will be able to maintain or renew existing permits, licenses, or other regulatory approvals or obtain, without significant delay, future permits, licenses, or other approvals needed for the operation of our businesses. Any noncompliance by us or our customers with applicable law or regulation or the failure to maintain, renew, or obtain necessary permits and licenses could have an adverse effect on our results of operations and financial condition. Furthermore, loss of a permit, license, or other approval in any one portion of our business may have indirect consequences in another portion of our business if regulators or customers adjust their reviews of such other portion as a result or customers cease business with such other portion due to fears that such loss is a sign of broader concerns about our ability to deliver products or services of sufficient quality.
Failure to provide quality offerings to our customers could have an adverse effect on our business, and the market price of our Common Stock and may subject us to regulatory action or costly litigation.
Our results depend on our ability to execute and improve when necessary our quality management strategy and systems, and effectively train and maintain our workforce with respect to quality management. Quality management plays an essential role in determining and meeting customer requirements, preventing defects, and improving our offerings, and, despite our network of quality systems, a quality or safety issue, including with respect to a high-revenue product such as a COVID-19 vaccine or therapy, could have an adverse effect on our business, financial condition, stock price, or results of operations and may subject us to regulatory action, including a product recall, product seizure, injunction to halt manufacture or distribution, or restriction on our operations; monetary fines; or other civil or criminal sanctions. In addition, such an issue could subject us to
26


adverse publicity and costly litigation, including claims from our customers for reimbursement for the cost of lost or damaged active pharmaceutical ingredients or other related losses, the cost of which could be significant.

The services and offerings we provide are highly exacting and complex, and, if we encounter problems providing the services or support required, our business could suffer.

The offerings we provide are highly exacting and complex, due in part to complex and exacting manufacturing processes and strict regulatory requirements. From time to time, problems may arise in connection with facility operations or during preparation or provision of an offering, in both cases for a variety of reasons including, but not limited to, equipment malfunction, sterility variances or failures, failure to follow specific protocols and procedures, problems with raw materials, environmental factors, and damage to, or loss of, manufacturing operations due to fire, flood, or similar causes. Such problems could affect production of a particular batch or series of batches, require the destruction of or otherwise result in the loss of product or materials used in the production of product, or could halt facility production altogether. This could, among other things, lead to increased costs, lost revenue, damage to customer relations, reimbursement to customers for lost active pharmaceutical ingredients or other related losses, time and expense spent investigating the cause, lost production time, and, depending on the cause, similar losses with respect to other batches or products. Production problems in our biologic manufacturing operations could be particularly significant because the cost of raw materials is often appreciably higher than in our other businesses. If problems are not discovered before the product is released to the market, recall and product liability costs may also be incurred. In addition, such risks may be greater at facilities that are new or going through significant expansion or renovation. The risks associated with running a highly complex facility doing exacting work with substantial regulatory oversight are enhanced for our larger sites, like our Bloomington, Indiana, Harmans, Maryland, St. Petersburg, Florida, or Swindon U.K. sites, which generally generate much more revenue.

If we cannot keep pace with rapid technological advances, our services may become uncompetitive or obsolete, and our revenue and profitability may decline.

The healthcare industry is characterized by rapid technological change. Demand for our offerings may change in ways we may not anticipate because of evolving industry standards as well as a result of evolving customer needs that are increasingly sophisticated and varied and the introduction by others of new offerings and technologies that provide alternatives to our offerings. Several of our higher margin offerings are based on proprietary technologies. To the extent that such technologies are protected by patents, their related offerings may become subject to competition as the patents expire. Without the timely introduction of enhanced or new offerings and technologies, our offerings may become obsolete or uncompetitive over time, in which case our revenue and operating results would suffer. For example, if we are unable to respond to changes in the nature or extent of the technological or other needs of our pharmaceutical customers through enhancing our offerings, our competition may develop offerings that are more competitive than ours and we could find it more difficult to renew or expand existing agreements or obtain new agreements. Potential innovations intended to facilitate enhanced or new offerings generally will require a substantial investment before we can determine their commercial viability, and we may not obtain access to the innovations or have financial resources sufficient to fund all desired innovations.

Even if we succeed in creating or acquiring enhanced or new offerings from these innovations, they may still fail to result in commercially successful offerings or may not produce revenue in excess of the costs of development, and they may be rendered obsolete by changing customer preferences or the introduction by our competitors of offerings embodying new technologies or features. Finally, innovations may not be accepted quickly in the marketplace because of, among other things, entrenched patterns of clinical practice, the need for regulatory clearance, and uncertainty over market access or government or third-party reimbursement.

We and our customers depend on patents, copyrights, trademarks, know-how, trade secrets, and other forms of intellectual property protections, but these protections may not be adequate.

We rely on a combination of know-how, trade secrets, patents, copyrights, trademarks, and other intellectual property laws, nondisclosure and other contractual provisions, and technical measures to protect many of our offerings and intangible assets. These proprietary rights are important to our ongoing operations. There can be no assurance that these protections will provide uniqueness or meaningful competitive differentiation in our offerings or otherwise be commercially valuable or that we will be successful in obtaining additional intellectual property or enforcing our intellectual property rights against unauthorized users. Our exclusive rights under certain of our offerings are protected by patents, some of which will expire in the near term. When patents covering an offering expire, loss of exclusivity may occur, which may force us to compete with third parties, thereby negatively affecting our revenue and profitability.

27


Our proprietary rights may be invalidated, circumvented, or challenged. We may in the future be subject to proceedings seeking to oppose or limit the scope of our patent applications or issued patents. In addition, in the future, we may need to take legal actions to enforce our intellectual property rights, to protect our trade secrets, or to determine the validity or scope of the proprietary rights of others. Legal proceedings are inherently uncertain, and the outcome of such proceedings may be unfavorable to us. Any legal action regardless of outcome might result in substantial costs and diversion of resources and management attention.

There can be no assurance that our confidentiality agreements will not be breached, our trade secrets will not otherwise become known by competitors, or that we will have adequate remedies in the event of unauthorized use or disclosure of proprietary information. Even if the validity and enforceability of our intellectual property is upheld, an adjudicator might construe our intellectual property not to cover the alleged infringement. In addition, intellectual property enforcement may be unavailable or practically ineffective in some countries. There can be no assurance that our competitors will not independently develop technologies that are substantially equivalent or superior to our technology or that third parties will not design around our intellectual property claims to produce competitive offerings. The use of our technology or similar technology by others could reduce or eliminate any competitive advantage we have developed, cause us to lose sales, or otherwise harm our business.

While we continue to apply in the U.S. and certain other countries for registration of a number of trademarks, service marks, and patents, and also claim common law rights in various trademarks and service marks, there can be no assurance that third parties will not oppose our applications in the future. In addition, it is possible that in some cases we may be unable to obtain the registrations for trademarks, service marks, and patents for which we have applied, and a failure to obtain trademark and patent registrations in the U.S. or other countries could limit our ability to protect our trademarks and proprietary technologies and impede our marketing efforts in those jurisdictions.

License agreements with third parties control our rights to use certain patents, software, and information technology systems and proprietary technologies owned by third parties, some of which are important to our business. Termination of these license agreements for any reason could result in the loss of our rights to this intellectual property, causing an adverse change in our operations or the inability to commercialize certain offerings.

In addition, many of our branded pharmaceutical customers rely on patents to protect their products from generic competition. Because incentives exist in some countries, including the U.S., for generic pharmaceutical companies to challenge these patents, pharmaceutical and biotechnology companies are under the ongoing threat of challenges to their patents. If the patents on which our customers rely were successfully challenged and, as a result, the affected products become subject to generic competition, the market for our customers’ products could be significantly adversely affected, which could have an adverse effect on our results of operations and financial condition. We attempt to mitigate these risks by making our offerings available to generic as well as branded manufacturers and distributors, but there can be no assurance that we will be successful in marketing these offerings.

Our offerings or our customers’ products may infringe on the intellectual property rights of third parties.

From time to time, third parties have asserted intellectual property infringement claims against us and our customers, and there can be no assurance that third parties will not assert infringement claims against either us or our customers in the future. While we believe that our offerings do not infringe in any material respect upon proprietary rights of other parties, and that meritorious defenses would exist with respect to any assertion to the contrary, there can be no assurance that we could successfully avoid being found to infringe on the proprietary rights of others. Patent applications in the United States and certain other countries are generally not publicly disclosed until the patent is issued or published, and we and our customers may not be aware of currently filed patent applications that relate to our or their products, offerings, or processes. If patents later issue on these applications, we or they may be found liable for subsequent infringement. There has been substantial litigation in the pharmaceutical and biotechnology industries with respect to the manufacture, use, and sale of products that are the subject of conflicting patent rights.

Any claim that our offerings or processes infringe third-party intellectual property rights (including claims arising through our contractual indemnification of our customers), regardless of the claim’s merit or resolution, could be costly and may divert the efforts and attention of our management and technical personnel. We may not prevail against any such claim given the complex technical issues and inherent uncertainties in intellectual property matters. If any such claim results in an adverse outcome, we could, among other things, be required to: pay substantial damages (potentially including treble damages in the U.S.); cease the manufacture, use, or sale of the infringing offerings or processes; discontinue the use of the infringing technology; expend significant resources to develop non-infringing technology; license technology from the third party claiming infringement, which license may not be available on commercially reasonable terms or at all; and lose the opportunity
28


to license our technology to others or to collect royalty payments based upon successful protection and assertion of our intellectual property against others.

In addition, our customers’ products may be subject to claims of intellectual property infringement and such claims could materially affect our business if their products cease to be manufactured or they have to discontinue the use of the infringing technology.

Any of the foregoing could affect our ability to compete or have a material adverse effect on our business, financial condition, and results of operations.

Events that diminish, tarnish, or otherwise damage our brand may have an adverse effect on our future financial condition and results of operations.

We have built a strong brand in “Catalent,” with high overall and generally favorable awareness of the brand in our established markets and with target customers. Our brand identity is a competitive advantage for us in sales and marketing, which is evidenced by our customer mix among top branded drug, generics, biologics, and consumer health marketers. We have spent and continue to spend substantial time, money, and other resources to establish both our brand awareness and a favorable perception of our brand in relevant markets. Among other strategies, we participate in major international trade shows in our established markets and ensure visibility into our offerings through a comprehensive print and on-line advertising and publicity program. It is possible that a single event, or aggregation of several events, may diminish, tarnish, or otherwise damage our brand and adversely affect our future financial condition and results of operations.

For example, meaningful interruptions to our ability to reliably supply one or more customers with products on time, whether as a result of supply chain disruptions or manufacturing delays or defects, may diminish our customers’ confidence in our ability to timely meet our commitments, thereby damaging our brand. In addition, we are subject to various local, state, federal, national, and transnational laws and regulations, including the operating, quality, and security standards of the FDA, the DEA, and similar bodies of the U.K., the E.U., and other comparable agencies around the world. Highly public or significant negative reports or findings from a regulatory agency with respect to one or more manufacturing or quality defects in our operations, inspections of our facilities, or other routine reviews could cause negative public perception of our operations, negatively impacting our brand, and adversely affecting our financial condition and results of operations. In addition, many of the other risks we face, including those described elsewhere in "Risk Factors" could diminish, tarnish, or otherwise damage our brand.

Our future results of operations are subject to fluctuations in the costs, availability, and suitability of the components of the products we manufacture, including active pharmaceutical ingredients, excipients, purchased components, and raw materials. In addition, the COVID-19 pandemic and the ongoing supply-chain disruptions triggered by a combination of the pandemic and the Ukrainian-Russian war may interfere with the operations of certain of our direct or indirect suppliers or with international trade for these supplies, which may either raise our costs or reduce the productivity or slow the timing of our operations.

We depend on various active pharmaceutical ingredients, components, compounds, raw materials, and energy supplied primarily by third parties for our offerings. Our customers also frequently provide to us their active pharmaceutical or biologic ingredient for formulation or incorporation in the finished product and may supply other raw materials as well. It is possible that any of our or our customers’ supplier relationships could be interrupted due to changing regulatory requirements, import or export restrictions, natural disasters, international supply disruptions, including those caused by public health emergencies such as the COVID-19 pandemic, and the ongoing Ukrainian-Russian war, geopolitical issues, operational or quality issues at the suppliers’ facilities, and other events, or could be terminated in the future.

For example, gelatin, a critical component for manufacturing many of our softgel formats is only available from a limited number of sources. In addition, much of the gelatin we use is bovine-derived. Past concerns of contamination from bovine spongiform encephalopathy, or BSE, have narrowed the number of possible sources of particular types of gelatin. If there were a future disruption in the supply of gelatin, we may not be able to obtain an adequate alternative supply. If future restrictions were to emerge on the use of bovine-derived gelatin, any such restriction could hinder our ability to timely supply our customers with products and the use of alternative material could be subject to lengthy and uncertain formulation, testing, and regulatory approval.

In addition, certain of our inputs are currently sole-sourced, so any disruption related to such a supplier is more likely to have an impact on our operations. Replacing a sole-source supplier of a production input to a medicine requiring marketing approval may be impossible or time-consuming, due to the rigorous standards we are obliged to apply to any new supplier.
29



Any sustained interruption in our receipt of adequate supplies could have an adverse effect on our business and results of operations. In addition, while we have processes intended to reduce volatility in component and material pricing, we may not be able to successfully manage price fluctuations, and future price fluctuations or shortages may have an adverse effect on our results of operations.

Changes in market access or healthcare reimbursement for, or public sentiment towards our customers’ products in the United States or internationally, or other changes in applicable policies regarding the healthcare industry, could adversely affect our results of operations and financial condition by affecting demand for our offerings.

The healthcare industry has changed significantly over time, and we expect the industry to continue to evolve. Some of these changes, such as ongoing healthcare reform, including with respect to reforming drug pricing, adverse changes in governmental or private funding of healthcare products and services, legislation or regulations governing patient access to care and privacy, or the delivery, pricing, or reimbursement approval of pharmaceuticals and healthcare services or mandated benefits, may cause healthcare industry participants to change the amount of our offerings that they purchase or the price they are willing to pay for these offerings. In particular, it is possible that future legislation in the U.S. may affect or put a cap on future pricing of pharmaceutical and biotechnology products. While we are unable to predict the likelihood of changes to U.S. and other international laws affecting pharmaceutical and biotechnology products, any substantial revision of applicable healthcare legislation could have a material adverse effect on the demand for our customers’ products, which in turn could have a negative impact on our results of operations, financial condition, or business. Changes in the healthcare industry’s pricing, selling, inventory, distribution, or supply policies or practices, or in public or government sentiment for the industry as a whole, could also significantly reduce our revenue and results of operations. In particular, volatility in individual product demand may result from changes in public or private payer reimbursement or coverage.

Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.

We generated net operating losses (“NOLs”) in the past that have been, and continue to be, used to reduce taxable income. Utilization of our NOL carryforwards may be subject to a substantial limitation under Section 382 of the Internal Revenue Code of 1986, as amended (the “Internal Revenue Code), and comparable provisions of state, local, and foreign tax laws due to changes in ownership of our company that may occur in the future. Under Section 382 of the Internal Revenue Code and comparable provisions of state, local, and foreign tax laws, if a corporation undergoes an ownership change, generally defined as a greater than 50% change by value in its equity ownership over a three-year period, the corporation’s ability to carry forward its pre-change NOLs to reduce its post-change income may be limited. In addition, we acquired companies that generated pre-acquisition NOLs for tax purposes that will also be subject to limitation under Section 382 and comparable provisions of state, local, and foreign tax laws. We may experience ownership changes in the future as a result of future changes in our stock ownership. As a result, our ability to use our pre-change NOL carryforwards to reduce U.S. federal, state, local, and foreign taxable income we produce in the future years may be subject to limitations, which could result in increased future tax liability to us.

Changes to the estimated future profitability of the business may require that we establish an additional valuation allowance against all or some portion of our net deferred tax assets.

We have deferred tax assets for NOL carryforwards and other temporary differences. We currently maintain a valuation allowance for a portion of our U.S. net deferred tax assets and certain foreign net deferred tax assets. It is possible we may experience a decline in U.S. taxable income resulting from a decline in profitability of our U.S. operations, an increased level of debt in the U.S., or other factors. In assessing our ability to realize our deferred tax assets, we may conclude that it is more likely than not that some additional portion or all our deferred tax assets will not be realized. As a result, we may be required to record an additional valuation allowance against our deferred tax assets, which could adversely affect our effective income tax rate and therefore our financial results.

We depend on key personnel.

We depend on our executive officers and other key personnel, including our technical personnel, to operate and grow our business and to develop new and enhanced offerings and technologies. The loss of any of these officers or other key personnel or a failure to attract and retain suitably skilled technical personnel could adversely affect our operations.

In addition to our executive officers, we rely on 190 senior employees to lead and direct our business. Our senior leadership team is comprised of our subsidiaries’ executive officers and other vice presidents and directors who hold critical positions and possess specialized talents and capabilities that give us a competitive advantage in the market.
30



We employ more than 3,000 scientists and technicians whose areas of expertise and specialization cover subjects such as advanced delivery, biologics and gene and cell therapy formulation and manufacturing. Many of our sites and laboratories are located in competitive labor markets; therefore, global and regional competitors and, in some cases, customers and suppliers compete for the same skills and talent as we do.

We may acquire businesses and offerings that complement or expand our business or divest non-strategic businesses or assets. We may not be able to complete desired transactions, and such transactions, if executed, pose significant risks, including risks relating to our ability to successfully and efficiently integrate acquisitions or execute on dispositions and realize anticipated benefits therefrom. The failure to execute or realize the full benefits from any such transaction could have a negative effect on our operations and profitability.

Our future success may depend in part on opportunities to buy or otherwise acquire rights to other businesses or technologies, enter into joint ventures or otherwise enter into strategic arrangements with business partners that could complement, enhance, or expand our current business or offerings and services or that might otherwise offer us growth opportunities, or divest assets or an ongoing business. We face competition from other companies in pursuing acquisitions and similar transactions in the pharmaceutical and biotechnology industry. Our ability to complete transactions may also be limited by applicable antitrust and trade laws and regulations in the U.S. and other jurisdictions in which we or the operations or assets we seek to acquire carry on business. To the extent that we are successful in making acquisitions, we expend substantial amounts of cash, incur debt, or assume loss-making divisions as consideration. We or the purchaser of a divested asset or business may not be able to complete a desired transaction for any number of reasons, including a failure to secure financing.

Any acquisition that we are able to identify and complete may involve a number of risks, including, but not limited to, the diversion of management’s attention to integrate the acquired businesses or joint ventures, the possible adverse effects on our operating results during the integration process, the potential loss of customers or employees in connection with the acquisition, delays or reduction in realizing expected synergies, unexpected liabilities, and our potential inability to achieve our intended objectives for the transaction. In addition, we may be unable to maintain uniform standards, controls, procedures, and policies, which may lead to operational inefficiencies.

To the extent that we are not successful in completing desired divestitures, we may have to expend cash, incur debt, or continue to absorb the costs of loss-making or under-performing divisions. Any divestiture, whether we complete it or not, may involve numerous risks, including diversion of management’s attention, a negative impact on our customer relationships, costs associated with maintaining its business during the disposition process, and the costs of closing and disposing of the affected business or transferring remaining portions of the operations of the business to other facilities.

We provide services incorporating various advanced modalities, including protein and plasmid production and cell and gene therapies, and these modalities relate to relatively new modes of treatment that may be subject to changing public opinion, continuing research, and increased regulatory scrutiny, each of which may affect our customers’ abilities to conduct their businesses or obtain regulatory approvals for their therapies, and thereby adversely affect these offerings.

Cell and gene therapy, with or without the use of iPSCs or plasmids, remain relatively new means for treating disease and other medical conditions, with only a few cell and gene therapies approved to date in the U.S., the E.U., or elsewhere. Public perception may be influenced by claims that cell or gene therapies are unsafe, and cell or gene therapy may not gain the acceptance of the public or the medical community. In addition, ethical, social, legal, and cost-benefit concerns about cell or gene therapy, genetic testing, genetic research, and the use of stem cells or materials derived from viruses could result in additional regulations or limitations or even outright prohibitions on certain cell or gene therapies or related products. Various regulatory and legislative bodies have expressed an interest in, or have taken steps towards, further regulation of various biotechnologies, including cell and gene therapies. More restrictive regulations or claims that certain cell or gene therapies are unsafe or pose a hazard could reduce our customers’ use of our services. We can provide no assurance whether legislative changes will be enacted, regulations, policies, or guidance changed, or interpretations of existing strictures by agencies or courts changed, or what the impact of such changes, if any, may be.

We are subject to environmental, health, and safety laws and regulations, which could increase our costs or restrict our operations in the future.

Our operations are subject to a variety of environmental, health, and safety laws and regulations, including those of the EPA, OSHA, and equivalent local, state, and national regulatory agencies in the jurisdictions in which we operate. Any failure by us to comply with environmental, health, and safety requirements could result in the limitation or suspension of production or subject us to monetary fines, civil or criminal sanctions, or other future liabilities in excess of our reserves. In particular, we are subject to laws and regulations governing the destruction and disposal of raw materials, byproducts of our manufacturing
31


operations, and non-compliant products, the handling of regulated material included in our offerings, and the disposal of our products or their components at the end of their useful lives. In addition, compliance with environmental, health, and safety requirements could restrict our ability to expand our facilities or require us to acquire costly environmental or safety control equipment, incur other significant expenses, or modify our manufacturing processes. Our manufacturing facilities may use, in varying degrees, hazardous substances in their processes. These substances include, among others, chlorinated solvents, and in the past chlorinated solvents were used at one or more of our facilities, including a number we no longer own or operate. As at our current facilities, contamination at such formerly owned or operated properties can result and has resulted in liability to us. In the event of the discovery of new or previously unknown contamination either at our facilities, facilities we acquire in the future, or at third-party locations, including facilities we formerly owned or operated, the issuance of additional requirements with respect to existing contamination, or the imposition of other cleanup obligations for which we are responsible, we may be required to take additional, unplanned remedial measures for which we have not recorded reserves. We are conducting monitoring and cleanup of contamination at certain facilities currently or formerly owned or operated by us, and such activities may result in unanticipated costs or management distraction.

We are subject to labor and employment laws and regulations, which could increase our costs and restrict our operations in the future.

We have nearly 19,000 individuals providing services for us worldwide, including approximately 11,700 service providers in North America, 5,700 in Europe, 1,000 in South America, and 600 in the Asia-Pacific region. Certain employees at one of our North American facilities are represented by a labor organization, and national works councils or labor organizations are active at our European facilities and certain of our other facilities consistent with local labor environments and laws. Our management believes that our employee relations are satisfactory. However, further organizing activities, collective bargaining, or changes in the regulatory framework for employment may increase our employment-related costs or may result in work stoppages or other labor disruptions. Moreover, as employers are subject to various employment-related claims, such as individual and class actions relating to alleged employment discrimination and wage-hour and labor standards issues, such actions, if brought against us and successful in whole or in part, may affect our ability to compete or have a material adverse effect on our business, financial condition, and results of operations.

Certain of our pension plans are underfunded, and additional cash contributions we may make to increase the funding level will reduce the cash available for our business, such as the payment of our interest expense.

Certain of our current and former employees in the U.S., the U.K., Germany, France, Japan, Belgium, and Switzerland are participants in defined benefit pension plans that we sponsor. As of June 30, 2022, the underfunded amount of our pension plans on a worldwide basis was $28 million, primarily related to our pension plans in the U.K. and Germany. In addition, we have an estimated obligation of $38 million, as of June 30, 2022, related to our withdrawal from a multiemployer pension plan in which we formerly participated. In general, the amount of future contributions to the underfunded plans will depend upon asset returns, applicable actuarial assumptions, prevailing and expected interest rates, and other factors, and, as a result, the amount we may be required to contribute in the future to fund the obligations associated with such plans may vary. Such cash contributions to the plans will reduce the cash available for our business, including the funds available to pursue strategic growth initiatives or the payment of interest expense on our indebtedness.

Our global operations are subject to economic and political risks, that could affect the profitability of our operations or require costly changes to our procedures.

We conduct our operations in various regions of the world, including North America, South America, Europe, and the Asia-Pacific region. Global and regional economic and political developments affect businesses such as ours in many ways. Our operations are subject to the effects of global and regional competition. Our global operations are also affected by local economic environments, including inflation and recession. Political changes, some of which may be disruptive, and related hostilities can interfere with our supply chain, our customers, and some or all of our activities in a particular location. While some of these risks can be hedged using derivatives or other financial instruments and some are insurable, such mitigating measures may be unavailable, costly, or unsuccessful.

Beginning in fiscal 2022, much of the world, including the U.S. and the E.U., began to experience inflation levels not seen in more than 30 years. As a result, prices for many of our inputs have risen, in some cases dramatically. If inflation stays at elevated levels or increases, we may not be able to mitigate the impact of the increased costs we will bear through corresponding price increases to our customers, which could have an impact on our results of operations and financial condition.

As a global enterprise, fluctuations in the exchange rates of the U.S. dollar, our reporting currency, against other currencies could have a material adverse effect on our financial performance and results of operations.
32



As a company with significant operations outside of the U.S., certain revenues, costs, assets, and liabilities, including our euro-denominated 2.375% Senior Notes due 2028 (the “2028 Notes”), are denominated in currencies other than the U.S. dollar, which is the currency that we use to report our financial results. As a result, changes in the exchange rates of these or any other applicable currency to the U.S. dollar will affect our revenues, earnings, and cash flows. There has been, and may continue to be, volatility in currency exchange rates affecting the various currencies in which we do business. Such volatility and other changes in exchange rates could result in unrealized and realized exchange losses, despite any effort we may undertake to manage or mitigate our exposure to fluctuations in the values of various currencies.

Tax legislative or regulatory initiatives, new interpretations or developments concerning existing tax laws, or challenges to our tax positions could adversely affect our results of operations and financial condition.

We are a large multinational enterprise with operations in the U.S. and more than a dozen other countries across North and South America, Europe, and the Asia-Pacific region, and we do business with suppliers and customers in many additional regions. As such, we are subject to the tax laws and regulations of the U.S. federal, state, and local governments and of many jurisdictions outside of the U.S. From time to time, various legislative initiatives may be proposed that could adversely affect our tax positions, and existing legislation may be subject to additional regulatory changes or new interpretations. There can be no assurance that our effective tax rate or tax payments will not be adversely affected by these initiatives.

In addition, U.S. federal, state, local, and foreign tax laws and regulations are extremely complex and subject to varying interpretations. We are subject to regular examination of our income tax returns by various tax authorities. Examinations or changes in laws, rules, regulations, or interpretations by taxing authorities could result in adverse impacts to tax years open under statute or to our operating structures currently in place. It is possible that the outcomes from these examinations or changes in laws, rules, regulations, or interpretations by taxing authorities will have a material adverse effect on our financial condition or results of operations.

We use advanced information and communication systems to run our operations, compile and analyze financial and operational data, and communicate among our employees, customers, and counter-parties, and the risks generally associated with information and communications systems could adversely affect our results of operations. We continuously work to install new, and upgrade existing, systems and provide employee awareness training around phishing, malware, and other cyber security risks to enhance the protections available to us, but such protections may be inadequate to address malicious attacks or inadvertent compromises affecting data security or the operability of such systems.

We rely on information systems in our business to obtain, process, analyze, and manage data to:
facilitate the manufacture and distribution of thousands of inventory items in, to, and from our facilities;
receive, process, and ship orders on a timely basis;
manage the accurate billing and collections for more than one thousand customers;
create, compile, and retain testing and other product-, manufacturing-, or facility-related data necessary for meeting our and our customers’ regulatory obligations.
manage the accurate accounting and payment for thousands of vendors and our employees;
schedule and operate our global network of development, manufacturing, and packaging facilities;
document various aspects of our activities, including the agreements we make with suppliers and customers;
compile financial and other operational data into reports necessary to manage our business and comply with various regulatory or contractual obligations, including obligations under our bank loans and other indebtedness, the federal securities laws, the Internal Revenue Code, and other applicable state, local, and ex-U.S. tax laws; and communicate among our nearly 19,000 workers spread across dozens of facilities over four continents.

We face various security threats on a regular basis, including ongoing cyber security threats to and attacks on our information technology infrastructure. We deploy defenses against such threats and attacks and work to secure the integrity of our data systems using techniques, hardware, and software typical of companies of our size and scope. Despite our security measures, however, our information technology and infrastructure may be vulnerable to attacks by increasingly sophisticated intruders or others who try to cause harm to or interfere with our normal use of our systems. They are also susceptible to breach due to employee error, malfeasance, or other disruptions. Our suppliers, contractors, service providers, and other third parties with whom we do business also experience cyber threats and attacks that are similar in frequency and sophistication. In many cases, we have to rely on the controls and safeguards put in place by our suppliers, contractors, service providers, and other third parties to defend against, respond to, and report these attacks. We cannot know the potential impact of future cyber incidents, which vary widely in severity and scale. There can be no assurance that the various procedures and controls we
33


utilize to mitigate these threats will be sufficient to prevent disruptions to our systems, in part because (i) cyber-attack techniques change frequently and, at times, new techniques are not recognized until launched, and (ii) cyber-attacks can originate from a wide variety of sources. Our results of operations could be adversely affected if these systems are interrupted or damaged or fail for any extended period.

Risks Relating to Our Indebtedness

The size of our indebtedness and the obligations associated with it could adversely affect our ability to raise additional capital to fund our operations, limit our ability to react to changes in the economy or in our industry or to deploy capital to grow our business, expose us to interest-rate risk to the extent of our variable-rate debt, or prevent us from meeting our obligations under our indebtedness. These risks may be increased in a recessionary environment, particularly as sources of capital may become less available or more expensive.

As of June 30, 2022, we had $4.20 billion (U.S. dollar equivalent) of total indebtedness outstanding, consisting of $1.43 billion of secured indebtedness under our senior secured credit facilities and $2.77 billion of senior unsecured indebtedness, including $500 million aggregate principal amount of 5.000% U.S. dollar-denominated Senior Notes due 2027 (the “2027 Notes”), €825 million aggregate principal amount of the 2028 Notes, $550 million aggregate principal amount of U.S. dollar-denominated 3.125% Senior Notes due 2029 (the “2029 Notes”), and $650 million aggregate principal amount of U.S. dollar-denominated 3.500% Senior Notes due 2030 (the “2030 Notes” and, together with the 2027 Notes, the 2028 Notes, and the 2029 Notes, the “Senior Notes”). As of June 30, 2022, we also held $234 million in finance lease obligations. In addition, we had $721 million of unutilized capacity under our $725 million secured revolving credit commitments due to $4 million of outstanding letters of credit, which is part of our senior secured credit facilities (the “Revolving Credit Facility”).

The multi-billion-dollar size of our indebtedness could have important consequences for us, including:
increasing our vulnerability to adverse economic, industry, or competitive developments;
exposing us to the risk of increased interest rates because certain of our borrowings, including borrowings under our senior secured credit facilities, are at variable rates of interest;
exposing us to the risk of fluctuations in exchange rates because of our euro-denominated notes;
making it more difficult for us to satisfy our obligations with respect to our indebtedness, and any failure to comply with the obligations of any of our debt instruments, including restrictive covenants and borrowing conditions, could result in one or more events of default under the agreements governing such indebtedness or, through cross-defaults, in agreements governing other indebtedness;
restricting us from making strategic acquisitions or capital investments or causing us to make non-strategic divestitures;
limiting our ability to obtain additional financing for working capital, capital expenditures, product development, debt service requirements, acquisitions, and general corporate or other purposes; and
limiting our flexibility in planning for, or reacting to, changes in our business or market conditions and placing us at a competitive disadvantage compared to our competitors who have less indebtedness relative to their size and who, therefore, may be able to take advantage of opportunities that our higher level of indebtedness prevents us from exploiting.

Our total interest expense, net was $123 million, $110 million, and $126 million for fiscal 2022, 2021, and 2020, respectively. After taking into consideration our ratio of fixed-to-floating-rate debt, including as a result of our February 2021 interest-rate swap agreement with Bank of America N.A., and assuming that our Revolving Credit Facility is undrawn and LIBOR is above any applicable minimum floor, each change of 100 basis points in interest rates would result in a change of approximately $9 million in annual interest expense on the indebtedness under our senior secured credit facilities.

Our interest expense may continue to increase as policymakers combat the inflation that has taken hold since fiscal 2022 through interest-rate increases on benchmark financial products that can affect the interest rates on our variable-rate debt.

Despite our high indebtedness level, we and our subsidiaries are still capable of incurring significant additional debt, which could further exacerbate the risks associated with our substantial indebtedness.

We and our subsidiaries may be able to incur substantial additional indebtedness in the future. Although the agreements governing our indebtedness contain restrictions on the incurrence of additional indebtedness, these restrictions are subject to a number of significant qualifications and exceptions, and, under certain circumstances, the amount of indebtedness that we may incur while remaining in compliance with these restrictions could be substantial. In addition, as of June 30, 2022, we had approximately $721 million available to us for borrowing, subject to certain conditions, under our Revolving Credit Facility. If new debt is added to our subsidiaries’ existing debt levels, the risks associated with debt we currently face would increase.

34


Our debt agreements contain restrictions that limit our flexibility in operating our business.

The agreements governing our outstanding indebtedness contain various covenants that limit our ability to engage in specified types of transactions. These covenants limit the ability of Operating Company and those of its subsidiaries to which these covenants apply (which Operating Company’s Amended and Restated Credit Agreement, dated as of May 20, 2014 (as amended, the Credit Agreement”) calls restricted subsidiaries) to, among other things:
incur additional indebtedness and issue certain preferred stock;
pay certain dividends on, repurchase, or make distributions in respect of capital stock or make other restricted payments;
pay distributions from restricted subsidiaries;
issue or sell capital stock of restricted subsidiaries;
guarantee certain indebtedness;
make certain investments;
sell or exchange certain assets;
enter into transactions with affiliates;
create certain liens; and
consolidate, merge, or transfer all or substantially all of our assets and the assets of our subsidiaries on a consolidated basis.

A breach of any of these covenants could result in a default under one or more of these agreements, including as a result of cross-default provisions, and, in the case of our Revolving Credit Facility, permit the lenders to cease making loans to us.

Despite the limitations in our debt agreements, we retain the ability to take certain actions that may interfere with our ability to timely pay our substantial indebtedness.

The covenants in the Credit Agreement and in the several indentures governing our Senior Notes (collectively, the "Indentures") contain various exceptions to the limitations they otherwise impose on our ability and the ability of our restricted subsidiaries to take the various actions described in the prior risk factor. For example, if the Senior Notes have investment-grade ratings and we are not in default under these agreements, certain of these covenants will not apply, including the covenants restricting certain dividends and other payments, the covenants concerning the incurrence of indebtedness, and the covenants limiting guarantees of indebtedness by our restricted subsidiaries. In addition, the covenants restricting dividends and other distributions by us, purchases or redemption of certain equity securities, and prepayment, redemption, or repurchase of any subordinated indebtedness are subject to various exceptions.

We are currently using and may in the future use derivative financial instruments to reduce our exposure to market risks from changes in interest rates on our variable-rate indebtedness or changes in currency exchange rates, and any such instrument may expose us to risks related to counterparty credit worthiness or non-performance of these instruments.

We have executed and may enter into additional or new interest-rate swap agreements, currency swap agreements, or other hedging transactions in an attempt to limit our exposure to adverse changes in variable interest rates and currency exchange rates. Such instruments may result in economic losses if, for example, prevailing interest rates decline to a point lower than any applicable fixed-rate commitment. Any such swap will expose us to credit-related risks that, if realized, could adversely affect our results of operations or financial condition.

Risks Relating to Ownership of Our Common Stock

Our stock price has historically been and may continue to be volatile, and a holder of shares of our Common Stock may not be able to resell such shares at or above the price such stockholder paid, or at all, and could lose all or part of such investment as a result.

The trading price of our Common Stock has been and continues to be volatile. For the three years ended June 30, 2022, our Common Stock price as quoted on the NYSE ranged from $36.95 to $142.35. The trading price of our Common Stock may be adversely affected by any one or more of several factors, such as those listed above in “—Risks Relating to Our Business and Industry in Which We Operate and the following:
results of operations that vary from the expectations of securities analysts or investors;
results of operations that vary from those of our competitors;
changes in expectations as to our future financial performance, including financial estimates and investment recommendations by securities analysts or investors;
declines in the market prices of stocks generally, or those of pharmaceutical or other healthcare companies;
35


strategic actions by us or our competitors;
announcements by us or our competitors of significant contracts, new products, acquisitions, joint marketing relationships, joint ventures, other strategic relationships, or capital commitments;
changes in general economic or market conditions or trends in our industry or markets, such as increased inflation;
changes in business or regulatory conditions or regulatory actions taken with respect to our business or the business of any of our competitors or customers;
future sales of our Common Stock or other securities we may issue in the future;
investor perceptions of the investment opportunity associated with our Common Stock relative to other investment alternatives;
any decision by securities analysts to not publish research or reports about our business or to downgrade our stock or our sector;
the public response to press releases or other public announcements by us or third parties, including our filings with or information furnished to the SEC;
announcements relating to or developments in litigation;
guidance, if any, that we provide to the public, any change in this guidance, or any failure to meet this guidance;
the availability of an active trading market for our Common Stock;
public response to changes in the COVID-19 pandemic and public perceptions as to the need for manufacture of certain COVID-19-related products and our role in the successful manufacture of such products;
changes in the accounting principles we use to record our results or our application of these principles to our business; and
other events or factors, including those resulting from natural disasters, hostilities, acts of terrorism, geopolitical activity, public health crises, including pandemics, or responses to these events.

Broad market and industry fluctuations may adversely affect the market price of our Common Stock, regardless of our actual operating performance. In addition, price volatility may be greater if the public float or trading volume of our Common Stock is low, and the amount of public float on any given day can vary depending on the individual actions of our stockholders.

Following periods of market volatility, stockholders have been known to institute securities class action litigation in order to recover their resulting losses. If we become involved in securities litigation, it could have a substantial cost and divert resources and the attention of senior management from our business regardless of the outcome of such litigation.

Because we have no plan to pay cash dividends on our Common Stock for the foreseeable future, receiving a return on an investment in our Common Stock may require a sale for a net price greater than what was paid for it.

We currently intend to retain future earnings, if any, for future operations, expansion, and debt repayment and have no current plan to pay any cash dividend on our Common Stock for the foreseeable future. Any future decision to pay a dividend in respect of our Common Stock, and the amount and timing of any such dividend, will be at the sole discretion of our board of directors. Our board of directors may take into account, when deciding whether or how to pay a dividend, such factors as they may deem relevant, including general economic conditions, our financial condition and results of operations, our available cash and current and anticipated cash needs, possible future alternative deployments of our cash, our future capital requirements, and contractual, legal, tax, and regulatory restrictions and implications on the payment of dividends by us to our holders of shares of our Common Stock or by our subsidiaries to us. In addition, our ability to pay dividends is limited by covenants in the agreements governing our outstanding indebtedness and may be limited by covenants of any future indebtedness we or our subsidiaries incur. As a result, a holder of a share of our Common Stock may not receive any return on such investment unless it is sold for a price greater than that which was paid for it, taking into account any applicable commission or other costs of acquisition or sale.

Future sales, or the perception of future sales, of our Common Stock, by us or our existing stockholders could cause the market price for our Common Stock to decline.

The sale of shares of our Common Stock in the public market, or the perception that such sales could occur, could harm the prevailing market price of shares of our Common Stock. These sales, or the possibility that these sales may occur, also might make it more difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate.

The market price of shares of our Common Stock could drop significantly if the holders of our Common Stock sell their shares or are perceived by the market as intending to sell them. These factors could also make it more difficult for us to raise additional funds through future offerings of shares of our equity securities that we wish to issue. In the future, we may also issue our securities in connection with investments or acquisitions. The number of shares of our Common Stock issued or issuable in connection with an investment or acquisition could constitute a material portion of then-outstanding shares of our
36


Common Stock, subject to limitations on issuance of new shares without stockholder approval imposed by the NYSE or to restrictions set forth in the agreements governing our indebtedness, or the Stockholders’ Agreement between the Company and holders of our formerly outstanding Series A convertible preferred stock, par value $0.01 (the “Series A Preferred Stock”). Any issuance of additional securities in connection with investments, acquisitions, or otherwise may result in dilution to the holders of shares of our Common Stock.

Anti-takeover provisions in our organizational documents could delay or prevent a change of control.

Certain provisions of our current certificate of incorporation and bylaws may have an anti-takeover effect and may delay, defer, or prevent a merger, acquisition, tender offer, takeover attempt, or other change of control transaction that may otherwise be in the best interests of our stockholders, including transactions that might otherwise result in the payment of a premium over the market price for the shares held by our stockholders.
These provisions provide for, among other things:
the ability of our board of directors to issue one or more series of preferred stock;
advance notice for nominations of directors by stockholders and for stockholders to include matters to be considered at our annual meetings (though our board of directors has implemented shareholder proxy access); and
certain limitations on convening special stockholder meetings.

Provisions such as those just described, to the extent that they remain in effect, could make it more difficult for a third party to acquire us, even if the third-party’s offer may be considered beneficial by many of our stockholders. As a result, our stockholders may be limited in their ability to obtain a premium for their shares.

ITEM 1B.    UNRESOLVED STAFF COMMENTS
None.
37


ITEM 2.    PROPERTIES
Our principal executive offices are located at 14 Schoolhouse Road, Somerset, New Jersey. As of June 30, 2022, we had 58 facilities (5 geographical locations operate as multiple facilities because they support more than one reporting segment, with our Somerset location including both a manufacturing facility and our principal executive offices), comprising manufacturing operations, development centers, and sales offices contained in approximately 8 million square feet of manufacturing, laboratory, office and related space. Our manufacturing capabilities include all required regulatory, quality assurance and in-house validation space. The following table sets forth our facilities containing manufacturing, laboratory, office, and related space by reporting segment and geographic location as of June 30, 2022:
Geographic RegionBiologicsSoftgel and Oral Technologies
Oral and Specialty Delivery (2)
Clinical Supply ServicesCorporate
Total (1)
North America10963129
South America314
Europe6453119
Asia-Pacific246
Total16181110358
(1) Sites that are used by multiple segments are included once for each segment in this table.
(2) The facility in Somerset, New Jersey houses both an Oral and Specialty Delivery facility and our principal executive offices.
Two of our manufacturing facilities, located in Bloomington, Indiana and Harmans, Maryland, together generate a material portion of our net revenue. We believe these facilities are suitable for their intended purposes, with adequate capacity for current and projected demand for their contracted products.
We generally seek to own, rather than lease, our manufacturing facilities, although some facilities are leased. Our office space and warehouse facilities are often leased.
Additional information with respect to our leases and property, plant, and equipment is contained in Notes 16 and 19, respectively, to our Consolidated Financial Statements.

ITEM 3.    LEGAL PROCEEDINGS
From time to time, we may be involved in legal proceedings arising in the ordinary course of business, including, without limitation, inquiries and claims concerning environmental contamination as well as litigation and allegations in connection with acquisitions, product liability, manufacturing or packaging defects, and claims for reimbursement for the cost of lost or damaged active pharmaceutical ingredients, the cost of any of which could be significant. We intend to vigorously defend ourselves against any such litigation and do not currently believe that the outcome of any such litigation will have a material adverse effect on our financial statements. In addition, the healthcare industry is highly regulated and government agencies continue to scrutinize certain practices affecting government programs and otherwise.
From time to time, we receive subpoenas or requests for information relating to the business practices and activities of customers or suppliers from various governmental agencies or private parties, including from state attorneys general, the U.S. Department of Justice, and private parties engaged in patent infringement, antitrust, tort, and other litigation. We generally respond to such subpoenas and requests in a timely and thorough manner, and responses sometimes require considerable time and effort and can result in considerable costs being incurred. We expect to incur costs in future periods in connection with future requests.
ITEM 4.    MINE SAFETY DISCLOSURES
Not Applicable.

38


PART II
ITEM 5.    MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
The principal market for trading of our Common Stock is the NYSE. Our Common Stock trades under the symbol CTLT.
As of August 25, 2022, we had 11 holders of record of outstanding shares of our Common Stock. This number does not include beneficial owners whose shares were held in street name.
We did not declare or pay any dividend on our Common Stock in fiscal 2022 or fiscal 2021. We have no current plan to pay any dividend on our Common Stock. Any decision to declare and pay dividends in the future will be made at the sole discretion of our board of directors and will depend on, among other things, our results of operations, cash requirements, financial condition, contractual restriction, and other factors that our board of directors may deem relevant. Because we are a holding company and have no direct operations, we will only be able to pay dividends from funds we receive from our subsidiaries. In addition, our ability to pay dividends will be limited by covenants in our existing indebtedness and may be limited by the agreements governing other indebtedness we or our subsidiaries incur in the future. See Management’s Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources—Debt and Financing Arrangements—Debt Covenants.
Recent Sales of Unregistered Equity Securities
We did not sell any unregistered equity securities during the period covered by this Annual Report.
Purchases of Equity Securities
We did not purchase any of our equity securities during the period covered by this Annual Report.



39


Performance Graph
Set forth below is a line graph comparing the cumulative total shareholder return on our Common Stock from June 30, 2017 through June 30, 2022, based on the market price of our Common Stock and assuming reinvestment of dividends, with the cumulative total shareholder return of companies on the S&P 500 Index and S&P 500 Health Care Index. The graph assumes that $100 was invested in our Common Stock and in each index at the market close on June 30, 2017. The stock price performance of the following graph is not necessarily indicative of future stock performance.

ctlt-20220630_g2.jpg


40


ITEM 6.     [RESERVED]







41


ITEM 7.    MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our Consolidated Financial Statements and related notes, which appear elsewhere in this Annual Report. This section of the Annual Report generally discusses the fiscal years ended June 30, 2022 and 2021 and year-to-year comparisons between the fiscal years ended June 30, 2022 and 2021. The discussion of our results of operations for the fiscal year ended June 30, 2020 and a comparison of our results for the fiscal years ended June 30, 2021 and 2020 is included in Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations, of our Annual Report on Form 10-K for the fiscal year ended June 30, 2021, filed with the SEC on August 30, 2021 and is incorporated herein by reference. In addition to historical consolidated financial information, the following discussion contains forward-looking statements that reflect our plans, estimates, and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. You should carefully read “Special Note Regarding Forward-Looking Statements” in this Annual Report. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this Annual Report, particularly in Item 1A. Risk Factors.
Overview
We provide differentiated development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, vaccines, and consumer health products at over fifty facilities across four continents under rigorous quality and operational standards. Our oral, injectable, and respiratory delivery technologies, along with our state-of-the-art protein and cell and gene therapy manufacturing capacity, address a wide and growing range of modalities and therapeutic and other categories across the biopharmaceutical and consumer health industries. Through our extensive capabilities, growth-enabling capacity, and deep expertise in product development, regulatory compliance, and clinical trial and commercial supply, we can help our customers take products to market faster, including nearly half of new drug products approved by the FDA in the last decade. Our development and manufacturing platforms, our proven formulation, supply, and regulatory expertise, and our broad and deep development and manufacturing know-how enable our customers to advance and then bring to market more products and better treatments for patients and consumers. Our commitment to reliably supply our customers’ and their patients’ needs is the foundation for the value we provide; annually, we produce nearly 80 billion doses for nearly 8,000 customer products, or approximately 1 in every 23 doses of such products taken each year by patients and consumers around the world. We believe that through our investments in state-of-the-art facilities and capacity expansion, including investments in facilities focused on new treatment modalities and other attractive market segments our continuous improvement activities devoted to operational and quality excellence, the sales of existing and introduction of new customer products, and, in some cases, our innovation activities and patents, we will continue to attract premium opportunities and realize the growth potential from these areas.

In fiscal 2022, we operated in four segments, which also constitute the four reporting segments further described in "Business—Our Reporting Segments" contained elsewhere in this Annual Report: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. Immediately following the end of fiscal 2022, we adopted a new operating structure with two operating segments: (1) Biologics and (2) Pharma and Consumer Health (discussed further in Note 20, Subsequent Events to our Consolidated Financial Statements).
The COVID-19 Pandemic

Our response to COVID-19

Since the start of the COVID-19 pandemic, we have taken steps to protect our employees, ensure the integrity and quality of our products and services, and maintain business continuity for our customers and their patients who depend on us to manufacture and supply critical products to the market. To address the multiple dimensions of the pandemic, a senior, multi-disciplinary team regularly monitors the global situation, executing mitigation activities as required.

Among other things, we implemented measures to avoid or reduce infection or contamination in line with guidelines issued by the U.S. Centers for Disease Control and Prevention, the World Health Organization, and local authorities where we operate, re-emphasized good hygiene practices, reorganized our workflows where permitted to maximize physical distancing, required supervisor approval for employee travel, facilitated safer alternatives to travel to and from work, and employed in some cases remote-working strategies. We also frequently monitor our supply chain to identify risks, delays, and concerns that may affect our ability to deliver our services and products. During fiscal 2022, we did not identify any significant risk, delay, or concern that had a substantial effect on such delivery, in part because of our adoption of various procedures to minimize and manage supply disruptions to our ongoing operations, including through business continuity plans and careful attention to inventory levels to assure supply of needed inputs. Our existing procedures, which are consistent with cGMP and other
42


regulatory standards, are intended to assure the integrity of our supply against any contamination. We have a detailed response plan to manage impacts of the virus on employee health, site operations, and product supply, including immediate assessment of the health of employees reporting symptoms, comprehensive risk assessment of any impact to quality, additional cleaning protocols, and alternative shift patterns to compensate should fewer employees be available.

Continuing effects of the pandemic, combined with the Ukrainian-Russian war, are likely to result in further or more severe supply-chain disruptions in fiscal 2023 and potentially beyond. We continue to execute our mitigation strategies, but there can be no assurance of the continued effectiveness of these strategies.

Impact of COVID-19 on Our Business and Results of Operations

Throughout the pandemic, we have observed occasional customer delays and cancellations, increases in absenteeism of production employees in our facilities in certain affected regions, disruptions in certain clinical trials supported by our Clinical Supply Services segment, and delays in inspections and product approvals by the FDA and regulatory authorities globally.
We have also seen substantial demand and related revenue from COVID-19-related products, particularly in our Biologics segment. In part to meet this demand, we accelerated and enhanced certain of our capital improvement plans to expand capacity for manufacturing drug substance and drug product for protein-based biologics and cell and gene therapies, particularly at our drug product facilities in Bloomington, Indiana, Anagni, Italy, and our commercial-scale viral vector manufacturing facility in Harmans, Maryland and hired thousands of new employees. We also implemented various strategies to protect our financial condition and results of operations should we experience a reduction in demand for COVID-19 related products, such as inserting take-or-pay and minimum volume requirements in the contracts we executed for the manufacture of certain COVID-19 related products. However, the extent and duration of revenue associated with COVID-19-related products is uncertain and dependent, in important respects, on factors outside our control.
The future duration and extent of the COVID-19 pandemic and the future demand for COVID-19 vaccines and therapies is unknown. Public opinion regarding certain COVID-19 vaccines and therapies and the product owners and manufacturers continues to change and has affected the demand for certain products and services. In addition, the concentration of revenue from certain COVID-19 vaccine products enhances our operational risk with respect to quality, security, regulatory inspections and business disruption resulting from any unforeseen event that affects any of the facilities or communities in which we manufacture COVID-19 vaccines. We have implemented various mechanisms to protect our customers, their material and product, and our business continuity, including enhanced security measures at certain facilities and heightened cybersecurity controls.

See also “Risk Factors — Risks Related to Our Business and the Industry in Which We Operate — Our business, financial condition, and results of operations may be adversely affected by global health epidemics, including the COVID-19 pandemic” and “Risk Factors — Risks Related to Our Business and the Industry in Which We Operate — The continually evolving nature of the COVID-19 pandemic and the resulting public health response, including the changing demand for various COVID-19 vaccines and treatments from both patients and governments around the world, may affect sales of the COVID-19 products we manufacture” elsewhere in this Annual Report.
Critical Accounting Policies and Recent Accounting Pronouncements
The following disclosure supplements the descriptions of our accounting policies contained in Note 1 to our Consolidated Financial Statements regarding significant areas of judgment. Management made certain estimates and assumptions during the preparation of the Consolidated Financial Statements in accordance with U.S. GAAP. These estimates and assumptions affect the reported amount of assets and liabilities and disclosures of contingent assets and liabilities in the Consolidated Financial Statements. These estimates also affect the reported amount of net earnings during the reporting periods. Actual results could differ from those estimates. Because of the size of the financial statement elements to which they relate, some of our accounting policies and estimates have a more significant impact on the Consolidated Financial Statements than others.
Management has discussed the development and selection of these critical accounting policies and estimates with the audit committee of our board of directors. A discussion of some of our more significant accounting policies and estimates follows.
Revenue Recognition
We sell products and services directly to our pharmaceutical, biopharmaceutical, and consumer health customers. The majority of our business is conducted through manufacturing and commercial product supply, development services, and clinical supply services.
43


Our contracts with customers often include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require judgment. For our manufacturing and commercial product supply revenue, the contract generally includes the terms of the manufacturing services and related product quality assurance procedures to comply with regulatory requirements. Due to the regulated nature of our business, these contract terms are highly interdependent and, therefore, are considered to be a single combined performance obligation. For our development services and clinical supply services revenue, our performance obligations vary per contract and are accounted for as separate performance obligations. If a contract contains a single performance obligation, we allocate the entire transaction price to the single performance obligation. If a contract contains multiple performance obligations, we allocate consideration to each performance obligation using the “relative standalone selling price” as defined under Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers. Generally, we utilize observable standalone selling prices in our allocations of consideration. If observable standalone selling prices are not available, we estimate the applicable standalone selling price using an adjusted market assessment approach, representing the amount that we believe the market is willing to pay for the applicable service. Revenue is recognized over time using an appropriate method of measuring progress towards fulfilling our performance obligation for the respective arrangement. Determining the measure of progress that consistently depicts our satisfaction of performance obligations within each of our revenue streams across similar arrangements requires judgment.

Our customer contracts generally include provisions entitling us to a termination penalty when the customer terminates prior to the contract’s nominal end date. The termination penalties in these customer contracts vary but are generally considered substantive for accounting purposes and create enforceable rights and obligations throughout the stated duration of the contract. We account for a contract termination as a contract modification in the period in which the customer gives notice of termination. The determination of the contract termination penalty is based on the terms stated in the relevant customer agreement. As of the modification date, we update our estimate of the transaction price using the expected value method, subject to constraints, and recognize the amount over the remaining performance period under the contract. In the event of a contract termination, revenues are recognized to the extent that it is probable that a significant reversal will not occur when any uncertainty is subsequently resolved.
Long-lived and Other Definite-Lived Intangible Assets

We allocate the cost of an acquired company to the tangible and identifiable intangible assets and liabilities acquired, with the remaining cost recorded as goodwill. Intangible assets primarily include customer relationships, technology and trademarks. Valuing the identifiable intangible assets requires judgment. For example, we applied a multi-period, excess-earnings method to measure the core technology acquired in the Bettera Wellness acquisition, which included certain assumptions, such as (i) the estimated annual net cash flows (including application of an appropriate margin for forecasted revenue, revenue obsolescence rate, selling and marketing costs, return on working capital, contributory asset charges, and other factors), (ii) the discount rate that appropriately reflects the risk inherent in each future cash flow stream, and (iii) an assessment of the asset’s life cycle, (iv) as well as other factors. Intangible assets are generally amortized on a straight-line basis, reflecting the pattern in which the economic benefits are consumed, and are amortized over their estimated useful lives.

We assess the impairment of identifiable intangibles if events or changes in circumstances indicate that the carrying values of the assets may not be recoverable. Factors that could trigger an impairment review include the following:

significant under-performance relative to historical or projected future operating results;
significant changes in the manner of use of the acquired assets or the strategy of the overall business;
significant negative industry or economic trends; and
recognition of goodwill impairment charges.

If we determine that the carrying value of identifiable intangibles and/or long-lived assets may not be recoverable based on the existence of one or more of the above indicators of impairment, we measure recoverability of assets by comparing the respective carrying value of the assets to the current and expected future cash flows, on an un-discounted basis, to be generated from such assets. If such analysis indicates that the carrying value of these assets is not recoverable, we measure an impairment based on the amount in which the net carrying amount of the assets exceeds the fair values of the assets. See Notes 3, Business Combinations and Divestitures and 5, Other Intangibles, net to the Consolidated Financial Statements.
Goodwill and Indefinite-Lived Intangible Assets
We account for purchased goodwill and intangible assets with indefinite lives in accordance with ASC 350, Intangibles - Goodwill and Other. Under ASC 350, goodwill and intangible assets with indefinite lives are not amortized, but instead are tested for impairment at least annually. We perform an impairment evaluation of goodwill annually during the fourth quarter of our fiscal year or when circumstances otherwise indicate an evaluation should be performed. The evaluation may begin with a
44


qualitative assessment for each reporting unit to determine whether it is more-likely-than-not that the fair value of the reporting unit is less than its carrying value. If the qualitative assessment does not generate a positive response, or if no qualitative assessment is performed, a quantitative assessment, based upon discounted cash flows, is performed and requires management to estimate future cash flows, growth rates, and economic and market conditions. In fiscal 2022 and 2020, we proceeded immediately to the quantitative assessment, but in fiscal 2021 we began with the qualitative assessment. Accordingly, no sensitivity analysis was performed for fiscal 2021. The evaluations performed in fiscal 2020, 2021, and 2022 resulted in no impairment charge.
See Notes 4, Goodwill and 5, Other Intangibles, net to the Consolidated Financial Statements.
Income Taxes
In accordance with ASC 740, Income Taxes, we account for income taxes using the asset and liability method. The asset and liability method requires recognition of deferred tax assets and liabilities for expected future tax consequences of temporary differences that currently exist between tax bases and the corresponding financial reporting bases of our assets and liabilities. Deferred tax assets and liabilities are measured using enacted tax rates in the respective jurisdictions in which we operate. Deferred taxes are not provided on the undistributed earnings of subsidiaries outside of the U.S. when it is expected that these earnings will be permanently reinvested. In fiscal 2018, we recorded a provision for U.S. income taxes and foreign withholding taxes in relation to expected repatriations as a result of the 2017 U.S. Tax Cuts and Jobs Act (the ”2017 Tax Act”), but we have not made any provision for U.S. income taxes on the remaining undistributed earnings of foreign subsidiaries as those earnings are considered permanently reinvested in the operations of those foreign subsidiaries in the years after 2018.
The 2017 Tax Act imposed taxes on so-called “global intangible low-taxed income” (“GILTI”) earned by certain foreign subsidiaries of a U.S. company. In accordance with ASC 740, we made an accounting policy election to treat taxes due on future U.S. inclusions in taxable income related to GILTI as a current-period expense when incurred.
We assess the realizability of deferred tax assets by considering all available evidence, both positive and negative. We evaluate four possible sources of taxable income when assessing the realizability of deferred tax assets: 
carrybacks of existing NOLs (if and to the extent permitted by tax law);
future reversals of existing taxable temporary differences; 
tax planning strategies; and
future taxable income exclusive of reversing temporary differences and carryforwards.
We consider the need to maintain a valuation allowance on deferred tax assets based on management’s assessment of whether it is more likely than not that we would realize those deferred tax assets as a result of future reversals of existing taxable temporary differences and the ability to generate sufficient taxable income within the carryforward period available under the applicable tax law.
Unrecognized tax benefits are generated when there are differences between tax positions taken in a tax return and amounts recognized in the Consolidated Financial Statements. Tax benefits are recognized in the Consolidated Financial Statements when it is more likely than not that a tax position will be sustained upon examination. To the extent we prevail in matters for which liabilities have been established or are required to pay amounts in excess of our liabilities, our effective income tax rate in a given period could be materially affected. An unfavorable income tax settlement may require the use of cash and result in an increase in our effective income tax rate in the year it is resolved. A favorable income tax settlement would be recognized as a reduction in the effective income tax rate in the year of resolution.
Our accounting for income taxes involves the application of complex tax regulations in the U.S. and in each of the non-U.S. jurisdictions in which we operate, particularly European tax jurisdictions. The determination of income subject to taxation in each tax-paying jurisdiction requires us to review reported book income and the events occurring during the year in each jurisdiction in which we operate. In addition, the application of deferred tax assets and liabilities will have an effect on the tax expense in each jurisdiction. For those entities engaging in transactions with affiliates, we apply transfer-pricing guidelines relevant in many jurisdictions in which we operate and make certain informed and reasonable assumptions and estimates about the relative value of contributions by affiliates when assessing the allocation of income and deductions between consolidated entities in different jurisdictions. The estimates and assumptions used in these allocations can result in uncertainty in the measured tax benefit.
45


Factors Affecting our Performance
Fluctuations in Operating Results
Our annual financial reporting period ends on June 30. Excluding the impact from COVID-19, our revenue and net earnings are generally higher in the third and fourth quarters of each fiscal year, with our first fiscal quarter typically generating our lowest revenue of any quarter, and our last fiscal quarter typically generating our highest revenue. These fluctuations are primarily the result of the timing of our, and our customers’, annual operational maintenance periods at locations in Europe and the U.S., the seasonality associated with pharmaceutical and biotechnology budgetary spending decisions, clinical trial and research and development schedules, the timing of new product launches and length of time needed to obtain full market penetration, and, to a lesser extent, the time of the year some of our customers’ products are in higher demand.
Acquisition and Related Integration Efforts
Our growth and profitability are affected by the acquisitions we complete and the speed at which we integrate those acquisitions into our existing operating platforms. In fiscal 2020, we completed the acquisition of and integrated additional gene and cell therapy assets in the U.S. and Belgium. We also completed the acquisition of and integrated the Anagni facility in Italy. In fiscal 2021, we expanded our capacity and capabilities through five acquisitions for our Biologics segment and through the acquisition of a dry powder inhaler and spray dry manufacturing business from Acorda Therapeutics, Inc. (“Acorda”). In fiscal 2022, we acquired each of Bettera Wellness, a manufacturer of a consumer-preferred gummy and other formats for consumer health products, a commercial-scale cell therapy manufacturing facility in Princeton, New Jersey, and a manufacturing facility for biologic therapies and vaccines near Oxford, U.K.
Foreign Exchange Rates
Our operating network is global, and, as a result, we have substantial revenues and operating expenses that are denominated in currencies other than the U.S. dollar, the currency in which we report our financial results, and are therefore influenced by changes in currency exchange rates. In fiscal 2022, approximately 36% of our net revenue was generated from our operations outside the U.S. Foreign currencies for our operations include the British pound, European euro, Brazilian real, Argentine peso, Japanese yen, and the Canadian dollar.
Inflation
In fiscal 2022, we began to experience the effects of inflation, which increased to levels not seen in more than 30 years. In response, we began to implement various mitigation strategies, including in some cases increasing prices to customers or reducing other costs of operation, including through price renegotiations with suppliers. The effects of inflation, after accounting for these mitigation strategies, was immaterial to our financial results in fiscal 2022, but inflation is likely to continue for most or all of fiscal 2023, at least, and there can be no assurance that our mitigating strategies will continue to enjoy the same degree of success.
Trends Affecting Our Business
Industry
We participate in nearly every sector of the global pharmaceutical and biotechnology industry, which has been estimated to generate more than $1 trillion in annual revenue, including, but not limited to, the prescription drug and biologic sectors as well as consumer health, which includes the over-the-counter and vitamins and nutritional supplement sectors. Innovative pharmaceuticals, and biologics in particular, continue to play a critical role in the global market, while the share of revenue due to generic drugs and biosimilars is increasing in both developed and developing markets. Sustained developed market demand and rapid growth in emerging economies is driving consumer health product growth. Payors, both public and private, have sought to limit the economic impact of pharmaceutical and biologics product demand through greater use of generic and biosimilar drugs, access and spending controls, and health technology assessment techniques, favoring products that deliver truly differentiated outcomes.
New Molecule Development and R&D Sourcing
Continued strengthening in early-stage development pipelines for drugs and biologics, compounded by increasing clinical trial breadth and complexity, support our belief in the attractive growth prospects for development solutions. Large companies are in many cases reconfiguring their R&D resources, increasingly involving the use of strategic partners for important outsourced functions and new treatment modalities. Additionally, an increasing portion of compounds in development are from companies that do not have a full research and development infrastructure, and thus are more likely to need strategic development solutions partners.
46


Demographics
Aging population demographics in developed countries, combined with the global COVID-19 pandemic and health care reforms in many global markets that are expanding access to treatments to a greater proportion of the global population, will continue to drive increases in demand for pharmaceuticals, biologics, and consumer health products. Increasing economic affluence in developing regions will further increase demand for healthcare treatments, and we are taking active steps to allow us to participate effectively in these growth regions and product categories.
Finally, we believe the market access and payor pressures our customers face, global supply chain complexity, and the increasing demand for improved and new modality treatments will continue to escalate the need for advanced formulation and manufacturing, product differentiation, improved outcomes, and treatment cost reduction, all of which can often be addressed using our advanced delivery technologies.
Non-GAAP Metrics
As described in this section, management uses various financial metrics, including certain metrics that are not based on concepts defined in U.S. GAAP, to measure and assess the performance of our business, to make critical business decisions, and to assess our compliance with certain financial obligations. We therefore believe that presentation of certain of these non-GAAP metrics in this Annual Report will aid investors in understanding our business.
EBITDA from operations
Management measures operating performance based on consolidated earnings from operations before interest expense, expense for income taxes, and depreciation and amortization, adjusted for the income attributable to non-controlling interests (EBITDA from operations). EBITDA from operations is not defined under U.S. GAAP, is not a measure of operating income, operating performance, or liquidity presented in accordance with U.S. GAAP, and is subject to important limitations.
We believe that the presentation of EBITDA from operations enhances an investor’s understanding of our financial performance. We believe this measure is a useful financial metric to assess our operating performance across periods and use this measure for business planning purposes. In addition, given the significant investments that we have made in the past in property, plant, and equipment, depreciation and amortization expenses represent a meaningful portion of our cost structure. We believe that disclosing EBITDA from operations provides investors with a useful tool for assessing the comparability between periods of our ability to generate cash from operations sufficient to pay taxes, service debt, and undertake capital expenditures without consideration of non-cash depreciation and amortization expense. We present EBITDA from operations in order to provide supplemental information that we consider relevant for readers of the Consolidated Financial Statements, and such information is not meant to replace or supersede U.S. GAAP measures. Our definition of EBITDA from operations may not be the same as similarly titled measures used by other companies. The most directly comparable measure to EBITDA from operations defined under U.S. GAAP is net earnings. Included in this Management’s Discussion and Analysis is a reconciliation of net earnings to EBITDA from operations.
In addition, we evaluate the performance of our segments based on segment earnings before non-controlling interest, other (income) expense, impairments, restructuring costs, interest expense, income tax expense, stock-based compensation, gain (loss) on sale of subsidiary, and depreciation and amortization (Segment EBITDA).
Adjusted EBITDA
Under the Credit Agreement and in the Indentures, the ability of Operating Company to engage in certain activities, such as incurring certain additional indebtedness, making certain investments, and paying certain dividends, is tied to ratios based on Adjusted EBITDA (which is defined as Consolidated EBITDA in the Credit Agreement and “EBITDA” in the Indentures). Adjusted EBITDA is a covenant compliance measure in our Credit Agreement and Indentures, particularly those covenants governing debt incurrence and restricted payments. Adjusted EBITDA is based on the definitions in the Credit Agreement, is not defined under U.S. GAAP, is not a measure of operating income, operating performance, or liquidity presented in accordance with U.S. GAAP, and is subject to important limitations. Because not all companies use identical calculations, our presentation of Adjusted EBITDA may not be comparable to other similarly titled measures of other companies.
In addition, we use Adjusted EBITDA as a performance metric that guides management in its operation of and planning for the future of the business and drives certain management compensation programs. Management believes that Adjusted EBITDA provides a useful measure of our operating performance from period to period by excluding certain items that are not representative of our core business, including interest expense and non-cash charges like depreciation and amortization.
47


The measure under U.S. GAAP most directly comparable to Adjusted EBITDA is net earnings. In calculating Adjusted EBITDA, we add back certain non-cash, non-recurring, and other items that are deducted when calculating EBITDA from operations and net earnings, consistent with the requirements of the Credit Agreement. Adjusted EBITDA, among other things:
does not include non-cash stock-based employee compensation expense and certain other non-cash charges;
does not include cash and non-cash restructuring, severance, and relocation costs incurred to realize future cost savings and enhance operations;
adds back any non-controlling interest expense, which represents minority investors’ ownership of non-wholly owned consolidated subsidiaries and is, therefore, not available; and
includes estimated cost savings that have not yet been fully reflected in our results.
Adjusted Net Income and Adjusted Net Income per Share
We use Adjusted Net Income and Adjusted Net Income per share (which we sometimes refer to as Adjusted EPS”) as performance metrics. Adjusted Net Income is not defined under U.S. GAAP, is not a measure of operating income, operating performance, or liquidity presented in accordance with U.S. GAAP, and is subject to important limitations. We believe that providing information concerning Adjusted Net Income and Adjusted Net Income per share enhances an investor’s understanding of our financial performance. We believe that these measures are useful financial metrics to assess our operating performance from period to period by excluding certain items that we believe are not representative of our core business, and we use these measures for business planning and executive compensation purposes. We define Adjusted Net Income as net earnings adjusted for (1) earnings or loss from discontinued operations, net of tax, (2) amortization attributable to purchase accounting, and (3) income or loss from non-controlling interest in majority-owned operations. We also make adjustments for other cash and non-cash items (as shown above, in “—Adjusted EBITDA”), partially offset by our estimate of the tax effect of such cash and non-cash items. Our definition of Adjusted Net Income may not be the same as similarly titled measures used by other companies. Adjusted Net Income per share is computed by dividing Adjusted Net Income by the weighted average diluted shares outstanding.
Use of Constant Currency
As exchange rates are an important factor in understanding period-to-period comparisons, we believe the presentation of results on a constant currency basis in addition to reported results helps improve investors’ ability to understand our operating results and evaluate our performance in comparison to prior periods. Constant currency information compares results between periods as if exchange rates had remained constant period-over-period. We use results on a constant currency basis as one measure to evaluate our performance. In this Annual Report, we calculate constant currency by calculating current-year results using prior-year foreign currency exchange rates. We generally refer to such amounts calculated on a constant currency basis as excluding the impact of foreign exchange. These results should be considered in addition to, not as a substitute for, results reported in accordance with U.S. GAAP. Results on a constant currency basis, as we present them, may not be comparable to similarly titled measures used by other companies and are not measures of performance presented in accordance with U.S. GAAP.
Summary Two-Year Key Financial Performance Metrics
Discussion of the year-over-year changes for the fiscal year ended June 30, 2021 compared to the fiscal year ended June 30, 2020 and the results of operations and cash flows for the fiscal year ended June 30, 2020, is included in Item 7, Management's Discussion and Analysis of Financial Condition and Result of Operations of our Annual Report on Form 10-K for the fiscal year ended June 30, 2021, filed with the SEC on August 30, 2021, and is incorporated herein by reference.
The below tables summarize our results in fiscal 2022 and 2021 with respect to several financial metrics we use to measure performance. Refer to the discussions below regarding performance and the use of key financial metrics and “—Non-GAAP Metrics—Use of Constant Currency” concerning the measurement of revenue at constant currency.
48


ctlt-20220630_g3.jpg ctlt-20220630_g4.jpg
Fiscal Year Ended June 30, 2022 compared to the Fiscal Year Ended June 30, 2021
Results for the fiscal year ended June 30, 2022 compared to the fiscal year ended June 30, 2021 were as follows:
(Dollars in millions)Fiscal Year Ended  
 June 30,
FX ImpactConstant Currency
Increase (Decrease)
20222021Change $
Change % *
Net revenue $4,828 $3,998 $(84)$914 23 %
Cost of sales3,188 2,646 (48)590 22 %
Gross margin 1,640 1,352(36)324 24 %
Selling, general, and administrative expenses 844 687 (6)163 24 %
Gain on sale of subsidiary(1)(182)— 181 (99)%
Other operating expense41 19 (1)23 110 %
Operating earnings756 828 (29)(43)(5)%
Interest expense, net 123 110 (1)14 12 %
Other expense, net 28 (7)32 1,227 %
Earnings before income taxes605 715 (21)(89)(12)%
Income tax expense86 130 (6)(38)(30)%
Net earnings$519 $585 $(15)$(51)(9)%
* Change % calculations are based on amounts prior to rounding.
Net Revenue
2022 vs. 2021
Year-Over-Year ChangeFiscal Year Ended  
 June 30,
Net Revenue
Organic20 %
Impact of acquisitions%
Impact of divestitures(2)%
Constant currency change23 %
Foreign currency translation impact on reporting(2)%
Total % change21 %
49


Net revenue increased by $914 million, or 23%, excluding the impact of foreign exchange, compared to the fiscal year ended June 30, 2021. Net revenue increased 20% organically on a constant-currency basis, primarily related to (i) broad-based strength across our Biologics offerings, in particular demand for our drug product and drug substance offerings for COVID-19 related programs, (ii) increased demand for our customers' prescription products, (iii) a continued rebound in our consumer health products, particularly in cough, cold, and over-the-counter pain relief products, and (iv) growth in development services in our Softgel and Oral Technologies segment.
Net revenue increased 5% inorganically as a result of acquisitions, which was partially offset by a 2% decrease in net revenue due to the sale of Catalent USA Woodstock, Inc. and related assets (collectively, the “Blow-Fill-Seal Business”) in fiscal 2021. Inorganic net revenue resulted from our acquisitions of Skeletal Cell Therapy Support SA (“Skeletal”), Delphi Genetics SA (“Delphi”) and the manufacturing and packaging assets of Acorda in fiscal 2021, as well as RheinCell Therapeutics GmbH (“RheinCell”), Bettera Wellness and a cell therapy commercial manufacturing facility and its operations in Princeton, New Jersey (“Princeton”) from Erytech Pharma S.A. (“Erytech”) in fiscal 2022.
Gross Margin
Gross margin increased by $324 million, or 24%, in fiscal 2022 compared to fiscal 2021, excluding the impact of foreign exchange, primarily as a result of the strong margin profile for all Biologics segment offerings, including demand across our drug product and drug substance offerings for COVID-19 related programs. Additional factors for such growth included increased demand for prescription products, a continued rebound in demand for consumer health products in our Softgel and Oral Technologies segment, and a favorable impact from prior-year recall charges in our Oral and Specialty Delivery segment. Margin growth was offset in part by a $47 million increase in depreciation expense, a one-time non-cash $7 million fair value inventory adjustment associated with our Bettera Wellness acquisition and an unfavorable impact from remediation activities at our Brussels facility.
On a constant-currency basis, gross margin, as a percentage of net revenue, increased 30 basis points to 34.1% in the fiscal year ended June 30, 2022, compared to 33.8% in the prior year, primarily due to the higher margin profile associated with our Biologics segment.
Selling, General, and Administrative Expense
Selling, general, and administrative expense increased by $163 million, or 24%, in fiscal 2022 compared to fiscal 2021, excluding the impact of foreign exchange, which includes $46 million in net incremental expenses from acquired and divested companies. The year-over-year increase in selling, general, and administrative expenses was primarily due to a $19 million increase in employee health and welfare costs, a $15 million increase in information technology spend, $14 million in employee-related costs primarily incurred for wages and bonuses, a $13 million increase in amortization and depreciation, $10 million of incremental bad debt expense, an $8 million increase in travel and entertainment, and a $5 million increase in integration costs associated with acquisitions.

Other Operating Expense
Other operating expense for the fiscal years ended June 30, 2022 and 2021 was $41 million and $19 million, respectively. The year-over-year increase was due to a $22 million increase in fixed asset impairment charges primarily associated with dedicated equipment for a product that we no longer manufacture in our respiratory and specialty platform and certain obsolete equipment in our Biologics segment.
Interest Expense, net
Interest expense, net, of $123 million in fiscal 2022 increased by $14 million, or 12%, compared to fiscal 2021, excluding the impact of foreign exchange. The savings from repayment of our formerly outstanding term loans and early redemption of our U.S. dollar-denominated 4.875% Senior Notes due 2026 (the “2026 Notes”) in fiscal 2021 were fully offset by increases in interest expense from our most recent tranche of term loans, the 2029 Notes, and the 2030 Notes.
For additional information concerning our debt and financing arrangements, including the changing mix of debt and equity in our capital structure, see “—Liquidity and Capital Resources—Debt and Financing Arrangements” and Note 7, Long-Term Obligations and Short-Term Borrowings to the Consolidated Financial Statements.
Other Expense, net    
50



Other expense, net of $28 million for fiscal 2022 was primarily driven by $33 million of foreign currency losses and $4 million of financing charges related to our outstanding term loans, partially offset by a $2 million gain related to the change in fair value of the derivative liability arising from the dividend-adjustment mechanism of our formerly outstanding Series A Preferred Stock.

Other expense, net of $3 million for fiscal 2021 was primarily driven by an $11 million premium on early redemption of the 2026 Notes, a write-off of $4 million of previously capitalized financing charges related to our repayment of term loans and our redeemed 2026 Notes, $3 million of financing charges related to our outstanding term loans, and a net foreign currency translation loss of $5 million. Those losses were partially offset by a gain of $17 million related to the fair value of the derivative liability associated with our previously outstanding Series A Preferred Stock.
Provision for Income Taxes

Our provision for income taxes for the fiscal year ended June 30, 2022 was $86 million relative to earnings before income taxes of $605 million. Our provision for income taxes for the fiscal year ended June 30, 2021 was $130 million relative to earnings before income taxes of $715 million. The decreased income tax provision for the current-year period over the prior-year period was largely the result of a decrease in pretax income, a $69 million income tax benefit for U.S. foreign tax credits resulting from an amendment to prior-year returns, and the tax benefit associated with the establishment of a net deferred tax asset expected to arise as a result of recently enacted tax reform in Switzerland and related transition rules (collectively, “Swiss Tax Reform”). This decrease was partially offset by certain deemed income inclusion in the U.S., a $26 million income tax charge for establishing a valuation allowance against the net deferred tax assets of certain Belgian operations, and a $62 million valuation allowance against the aforementioned tax benefit related to Swiss Tax Reform. The provision for income taxes in each of fiscal 2022 and 2021 was also affected by the geographic distribution of our pretax income, the tax impact of permanent differences, restructuring, special items, and other discrete tax items that may have unique tax implications depending on the nature of the item.
Segment Review
The below charts depict the percentage of net revenue from each of our four reporting segments for the previous two years. Refer below for discussions regarding the segments net revenue and EBITDA performance and to “—Non-GAAP Metrics” for a discussion of our use of Segment EBITDA, a measure that is not defined under U.S. GAAP.
ctlt-20220630_g5.jpg
51


Our results on a segment basis for the fiscal year ended June 30, 2022 compared to the fiscal year ended June 30, 2021 were as follows:
(Dollars in millions)Fiscal Year Ended  
 June 30,
FX ImpactConstant Currency
Increase (Decrease)
20222021Change $
Change % (1)
Biologics
Net revenue $2,549 $1,928 $(35)$656 34 %
Segment EBITDA 798 608 (14)204 34 %
Softgel and Oral Technologies
Net revenue 1,246 1,012 (32)266 26 %
Segment EBITDA 292 237 (8)63 27 %
Oral and Specialty Delivery
Net revenue 650 686 (12)(24)(3)%
Segment EBITDA 192 160 (6)38 24 %
Clinical Supply Services
Net revenue 400 391 (6)15 %
Segment EBITDA 110 108 (3)%
Inter-segment revenue elimination (17)(19)%
Unallocated Costs(2)
(286)(292)*
Combined totals
Net revenue $4,828 $3,998 $(84)$914 23 %
EBITDA from operations $1,106 $1,114 $(26)$18 %
(1)    Change % calculations are based on amounts prior to rounding.
*    Not meaningful    
(2)    Unallocated costs include restructuring and special items, stock-based compensation, gain (loss) on sale of subsidiary, impairment charges, certain other corporate-directed costs, and other costs that are not allocated to the segments as follows:
 Fiscal Year Ended  
 June 30,
(Dollars in millions)20222021
Impairment charges and gain/loss on sale of assets(a)
$(31)$(9)
Stock-based compensation(54)(51)
Restructuring and other special items (b)
(55)(31)
Gain on sale of subsidiary (c)
182 
       Other expense, net (d)
(28)(3)
Non-allocated corporate costs, net(119)(87)
Total unallocated costs$(286)$
(a)    For the fiscal year ended June 30, 2022, impairment charges are primarily due to fixed asset impairment charges associated with dedicated equipment for a product that we no longer manufacture in our respiratory and specialty platform and obsolete equipment in our Biologics platform.
(b)    Restructuring and other special items for the fiscal year ended June 30, 2022 include (i) transaction and integration costs primarily associated with the Princeton acquisition, and the Bettera Wellness, Delphi, Hepatic Cell Therapy Support SA (“Hepatic”), Acorda and RheinCell transactions and (ii) unrealized losses on venture capital investments. Restructuring and other special items during the fiscal year ended June 30, 2021 include (1) transaction costs for the sale of our Blow-Fill-Seal Business, (2) transaction and integration costs associated with the acquisition of our facility in Anagni, Italy, the Acorda, Masthercell Global Inc. (“MaSTherCell”), Delphi, Hepatic, and Skeletal transactions and the acquisition of Société d’infrastructures, de services et d’énergies SA, and (3) restructuring costs associated with the closure of our Clinical Supply Services facility in Bolton, U.K. Refer to Note 3, Business Combinations and Divestitures for further details on the transactions listed above.
52


(c)    For the fiscal years ended June 30, 2022 and 2021, gain on sale of subsidiary is due to the divestiture of our Blow-Fill-Seal Business, which was formerly part of our Oral and Specialty Delivery segment. Refer to Note 3, Business Combinations and Divestitures for further details on the sale of the Blow-Fill-Seal Business.
(d)    Refer to Note 15, Other Expense, net for details of financing charges and foreign currency adjustments recorded within Other Expense, net in our Consolidated Financial Statements.
Provided below is a reconciliation of net earnings to EBITDA from operations:
 Fiscal Year Ended  
 June 30,
(Dollars in millions)20222021
Net earnings$519 $585 
Depreciation and amortization378 289 
Interest expense, net123 110 
Income tax expense86 130 
EBITDA from operations$1,106 $1,114 
Biologics segment
2022 vs. 2021
Year-Over-Year ChangeFiscal Year Ended  
 June 30,
Net RevenueSegment EBITDA
Organic34 %35 %
Impact of acquisitions— %(1)%
Constant currency change34 %34 %
Foreign exchange translation impact on reporting(2)%(2)%
Total % change32 %32 %
Net revenue in our Biologics segment increased by $656 million, or 34%, excluding the impact of foreign exchange, compared to the fiscal year ended June 30, 2021. The increase was driven across all segment offerings by strong end-market demand for our global drug product, drug substance, and cell and gene therapy offerings, primarily related to demand for COVID-19-related programs.
Biologics Segment EBITDA increased by $204 million, or 34%, excluding the impacts of foreign exchange and acquisitions, compared to the fiscal year ended June 30, 2021, Excluding the impact of acquisitions, Segment EBITDA increased 35%, compared to the fiscal year end June 30, 2021. The increase was driven across all segment offerings by strong end-market demand for our drug product, drug substance, and cell and gene therapy offerings, primarily related to demand for COVID-19-related programs, and partially offset by an unfavorable impact from remediation activities at our Brussels facility.

We completed the acquisition of RheinCell in August 2021. In April 2022, we completed the acquisition of Princeton. For the fiscal year ended June 30, 2022, these acquisitions had an immaterial impact on our net revenue and decreased Segment EBITDA on an inorganic basis by 1% compared to the corresponding prior-year period.
Softgel and Oral Technologies segment
53


2022 vs. 2021
Year-Over-Year ChangeFiscal Year Ended  
 June 30,
Net RevenueSegment EBITDA
Organic10 %12 %
Impact of acquisitions16 %15 %
Constant currency change26 %27 %
Foreign exchange translation impact on reporting(3)%(4)%
Total % change23 %23 %
Net revenue in our Softgel and Oral Technologies segment increased by $266 million, or 26%, excluding the impact of foreign exchange, compared to the fiscal year ended June 30, 2021. Net revenue increased 10%, compared to the fiscal year ended June 30, 2021, excluding the impact of acquisitions. The increase in organic revenue primarily relates to strong end-market demand for prescription products, a continued rebound in consumer health products, particularly in cough, cold, and over-the-counter pain relief products, and growth in development services.
Softgel and Oral Technologies Segment EBITDA increased by $63 million, or 27%, excluding the impact of foreign exchange, compared to the fiscal year ended June 30, 2021. Segment EBITDA increased 12%, compared to the fiscal year ended June 30, 2021, excluding the impact of acquisitions. The increase in organic Segment EBITDA, similar to that of net revenue, was primarily driven by an increase in demand for prescription products, a continued rebound in consumer health products, particularly in cough, cold, and over-the-counter pain relief products, and the margin generated from strong development revenue growth.
We completed the Bettera Wellness acquisition in October 2021, which increased net revenue and Segment EBITDA on an inorganic basis by 16% and 15%, respectively, during the fiscal year ended June 30, 2022, compared to the corresponding prior-year period. For the fiscal year ended June 30, 2022, we recorded a one-time non-cash inventory fair value adjustment for $7 million resulting from our Bettera Wellness purchase accounting, which unfavorably impacted Segment EBITDA.
Oral and Specialty Delivery segment
2022 vs. 2021
Year-Over-Year ChangeFiscal Year Ended  
 June 30,
Net RevenueSegment EBITDA
Organic%43 %
Impact of acquisitions%(7)%
Impact of divestitures(10)%(12)%
Constant currency change(3)%24 %
Foreign exchange translation impact on reporting(2)%(4)%
Total % Change(5)%20 %
Net revenue in our Oral and Specialty Delivery segment decreased by $24 million, or 3%, excluding the impact of foreign exchange, compared to the fiscal year ended June 30, 2021. Net revenue increased 6%, compared to the fiscal year ended June 30, 2021, excluding the impact of acquisitions and divestitures, primarily driven by demand for the segment’s orally disintegrating Zydis commercial products and demand for early-phase development programs.
Oral and Specialty Delivery Segment EBITDA increased by $38 million, or 24%, excluding the impact of foreign exchange, compared to the fiscal year ended fiscal year ended June 30, 2021. Segment EBITDA increased 43%, compared to the fiscal year ended June 30, 2021, excluding the impact of acquisitions and divestitures. The increase in organic Segment EBITDA from the corresponding prior-year period was primarily driven by increased demand for the segment’s orally disintegrating Zydis commercial products and a favorable impact from prior-year recall charges in our respiratory and specialty platform.
We completed the Acorda transaction in February 2021. For the fiscal year ended June 30, 2022, this acquisition increased our net revenue by 1% and unfavorably impacted Segment EBITDA on an inorganic basis by 7% compared to the corresponding prior-year period.

54


We completed the Blow-Fill-Seal Business divestiture in March 2021. For the fiscal year ended June 30, 2022, this divestiture decreased our net revenue and Segment EBITDA on an inorganic basis by 10% and 12%, respectively, compared to the corresponding prior-year period.
Clinical Supply Services segment
2022 vs. 2021
Fiscal Year Ended  
 June 30,
Year-Over-Year ChangeNet RevenueSegment EBITDA
Organic%%
Constant currency change4 %5 %
Foreign exchange translation impact on reporting(2)%(3)%
Total % Change%%
Net revenue in our Clinical Supply Services segment increased by $15 million, or 4%, excluding the impact of foreign exchange, compared to the fiscal year ended June 30, 2021. The increase was driven by growth in our manufacturing and packaging and storage and distribution offerings in the North America and Asia Pacific regions.
Clinical Supply Services Segment EBITDA increased by $5 million, or 5%, excluding the impact of foreign exchange, compared to the fiscal year ended June 30, 2021, primarily due to growth in the Asia Pacific region and operational efficiencies in our Western Europe facilities.
Liquidity and Capital Resources
Sources and use of Cash
Our principal source of liquidity has been cash flow generated from operations and the net proceeds of capital market activities. The principal uses of cash are to fund operating and capital expenditures, business or asset acquisitions, interest payments on debt, and any mandatory or discretionary principal payment on our debt. As of June 30, 2022, and following the September 2021 execution of Amendment No. 6 (the “Sixth Amendment”) to the Credit Agreement, we had available a $725 million Revolving Credit Facility that matures in May 2024, the capacity of which is reduced by the amount of all outstanding letters of credit issued under the senior secured credit facilities and those short-term borrowings referred to as swing-line borrowings. At June 30, 2022, we had $4 million of outstanding letters of credit and no outstanding borrowing under our Revolving Credit Facility.
We believe that our cash on hand, cash from operations, and available borrowings under our Revolving Credit Facility will be adequate to meet our future liquidity needs for at least the next twelve months, including the amounts expected to become due with respect to our pending capital projects. We have no significant maturity under any of our bank or note debt until the July 2027 maturity of our 2027 Notes.
On August 9, 2022, we entered into a purchase agreement to acquire Metrics Contract Services ("Metrics") and will pay approximately $475 million in cash, subject to customary adjustments. Metrics is an oral solids development and manufacturing business specializing in handling highly potent compounds at its facility in Greenville, North Carolina. We intend to fund this acquisition using a combination of cash on hand, existing senior secured credit facilities, and, depending on market conditions, potentially new debt financing. The closing of the acquisition is not contingent on any financing activity.
55


Cash Flows
Fiscal Year Ended June 30, 2022 Compared to the Fiscal Year Ended June 30, 2021
The following table summarizes our consolidated statements of cash flows for the fiscal year ended June 30, 2022 compared with the fiscal year ended June 30, 2021:
 Fiscal Year Ended  
 June 30,
 
(Dollars in millions)20222021
Change $ 
Net cash provided by (used in):
Operating activities$439 $433 $
Investing activities$(1,884)$(649)$(1,235)
Financing activities$1,031 $142 $889 
Operating Activities
For the fiscal year ended June 30, 2022, cash provided by operating activities was $439 million, an increase of $6 million compared to $433 million for the prior year. This increase in cash flow from operating activities was primarily due to an increase in operating income, excluding the gain derived from the sale of the Blow-Fill-Seal business in March 2021, a favorable impact from a decline in the rate of trade receivables growth, and a favorable impact from a decline in the rate of inventory growth, which was partially offset by an unfavorable impact from the increase in contract assets.
Investing Activities
For the fiscal year ended June 30, 2022, cash used in investing activities was $1.88 billion, compared to $649 million during fiscal 2021. The increase in cash used in investing activities was primarily driven by a $1.05 billion increase in cash used for business acquisition activities, partially offset by a $52 million decline in the purchase of marketable securities and a $26 million decrease in cash used for purchases of property, plant, and equipment compared to the prior year. Another key driver in the year-over-year change was the lack of proceeds from sale of any subsidiary, as no subsidiary was sold in the current year, compared to $290 million in proceeds from the sale of subsidiaries received in fiscal 2021.
Financing Activities
For the fiscal year ended June 30, 2022, cash provided by financing activities was $1.03 billion, which increased $889 million compared to cash provided by financing activities of $142 million during the fiscal year ended June 30, 2021. The increase in cash provided by financing activities was primarily driven by a $934 million year-over-year increase in cash received from the issuance of debt, partially offset by the July 2020 exercise of an over-allotment option on 1.2 million additional shares by the underwriter for the equity offering in June 2020, resulting in net proceeds of $82 million.
Debt and Financing Arrangements
Senior Secured Credit Facilities and Sixth Amendment to the Credit Agreement
In September 2021, we completed the Sixth Amendment to the Credit Agreement. Pursuant to the Sixth Amendment, we incurred an additional $450 million aggregate principal amount of U.S. dollar-denominated term loans (the “Incremental Term B-3 Loans) and amended the quarterly amortization payments from 0.25% to 0.2506% of the principal amount outstanding for the Incremental Term B-3 Loans and the other term loans outstanding under the Credit Agreement, all of which are U.S. dollar-denominated (together with the Incremental Term B-3 Loans, the “Term B-3 Loans”). The Incremental Term B-3 Loans otherwise feature the same principal terms as the previously drawn Term B-3 Loans, including an interest rate of one-month LIBOR (subject to a floor of 0.50%) plus 2.00% per annum and a maturity date of February 2028. The proceeds of the Incremental Term B-3 Loans, after payment of the offering fees and expenses, were used in part to fund a portion of the consideration paid at the closing of the Bettera Wellness acquisition.

The Sixth Amendment also provided for incremental revolving credit commitments under the Revolving Credit Facility. The applicable rate for all loans drawn under the Revolving Credit Facility is one-month LIBOR plus 2.25%, and such rate can be reduced to one-month LIBOR plus 2.00% in future periods based on a measure of Operating Company's total leverage ratio. The maturity date for the Revolving Credit Facility is May 17, 2024.

56


Pursuant to the terms of the Credit Agreement, the interest rates under the Term B-3 Loans and loans drawn under the Revolving Credit Facility will be based on a replacement benchmark interest rate when LIBOR is no longer available.
The availability of capacity under the Revolving Credit Facility is reduced by the aggregate value of all outstanding letters of credit under the Credit Agreement. As of June 30, 2022, we had $721 million of unutilized capacity under the Revolving Credit Facility, due to $4 million of outstanding letters of credit.
Further information concerning the senior secured credit facilities, including the Term B-3 Loans and the Revolving Credit Facility, can be found in Note 7, Long-Term Obligations and Short-Term Borrowings to the Consolidated Financial Statements
5.000% Senior Notes due 2027
In June 2019, Operating Company completed a private offering of the 2027 Notes. The 2027 Notes are fully and unconditionally guaranteed, jointly and severally, by all of the wholly owned U.S. subsidiaries of Operating Company that guarantee its senior secured credit facilities. The 2027 Notes were offered in the U.S. to qualified institutional buyers in reliance on Rule 144A under the Securities Act and outside the U.S. only to non-U.S. investors pursuant to Regulation S under the Securities Act. The 2027 Notes will mature on July 15, 2027 and bear interest at the rate of 5.000% per annum. Interest is payable semi-annually in arrears on January 15 and July 15 of each year, beginning on January 15, 2020. The proceeds of the 2027 Notes after payment of the offering fees and expenses were used to repay in full the outstanding borrowings under Operating Company's then-outstanding term loans under its senior secured credit facilities that would otherwise have matured in May 2024.
2.375% Euro-denominated Senior Notes due 2028
In March 2020, Operating Company completed a private offering of the 2028 Notes. The 2028 Notes are fully and unconditionally guaranteed, jointly and severally, by all of the wholly owned U.S. subsidiaries of Operating Company that guarantee its senior secured credit facilities. The 2028 Notes were offered in the U.S. to qualified institutional buyers in reliance on Rule 144A under the Securities Act and outside the U.S. only to non-U.S. investors pursuant to Regulation S under the Securities Act. The 2028 Notes will mature on March 1, 2028 and bear interest at the rate of 2.375% per annum. Interest is payable semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2020. The proceeds of the 2028 Notes after payment of the offering fees and expenses were used to repay in full the outstanding borrowings under Operating Company's euro-denominated term loans under its senior secured credit facilities, that would otherwise have matured in May 2024, and repay in full our Euro-denominated 4.75% Senior Notes due 2024, which would otherwise have matured in December 2024, plus any accrued and unpaid interest thereon, with the remainder available for general corporate purposes.
3.125% Senior Notes due 2029

In February 2021, Operating Company completed a private offering of the 2029 Notes. The 2029 Notes are fully and unconditionally guaranteed, jointly and severally, by all of the wholly owned U.S. subsidiaries of Operating Company that guarantee its senior secured credit facilities. The 2029 Notes were offered in the U.S. to qualified institutional buyers in reliance on Rule 144A under the Securities Act and outside the U.S. only to non-U.S. investors pursuant to Regulation S under the Securities Act. The 2029 Notes will mature on February 15, 2029 and bear interest at the rate of 3.125% per annum payable semi-annually in arrears on February 15 and August 15 of each year, beginning on August 15, 2021. The proceeds of the 2029 Notes after payment of the offering fees and expenses were used to repay in full the outstanding borrowings under the 2026 Notes, plus any accrued and unpaid interest thereon, with the remainder available for general corporate purposes.
3.500% Senior Notes due 2030
In September 2021, Operating Company completed a private offering of the 2030 Notes. The 2030 Notes are fully and unconditionally guaranteed, jointly and severally, by all of the wholly owned U.S. subsidiaries of Operating Company that guarantee its senior secured credit facilities. The 2030 Notes were offered in the U.S. to qualified institutional buyers in reliance on Rule 144A under the Securities Act and outside the U.S. only to non-U.S. investors pursuant to Regulation S under the Securities Act. The 2030 Notes will mature on April 1, 2030 and bear interest at the rate of 3.500% per annum payable semi-annually in arrears on April 1 and October 1 of each year, beginning on April 1, 2022. The proceeds of the 2030 Notes, after payment of the offering fees and expenses, were used to fund a portion of the consideration paid at the closing of the Bettera Wellness acquisition.
57


Deferred Purchase Consideration
In connection with the acquisition of Catalent Indiana, LLC in October 2017, $200 million of the $950 million aggregate nominal purchase price was payable in $50 million installments on each of the first four anniversaries of the closing date. The Company made the installment payments in October 2018, October 2019, October 2020, and the final payment was made in October 2021.
Debt Covenants
Senior Secured Credit Facilities
The Credit Agreement contains covenants that, among other things, restrict, subject to certain exceptions, Operating Company’s (and Operating Company’s restricted subsidiaries’) ability to incur additional indebtedness or issue certain preferred shares; create liens on assets; engage in mergers and consolidations; sell assets; pay dividends and distributions or repurchase capital stock; repay subordinated indebtedness; engage in certain transactions with affiliates; make investments, loans, or advances; make certain acquisitions; enter into sale and leaseback transactions; amend material agreements governing Operating Company’s subordinated indebtedness; and change Operating Company’s lines of business.
The Credit Agreement also contains change-of-control provisions and certain customary affirmative covenants and events of default. The Revolving Credit Facility requires compliance with a net leverage covenant when there is a 30% or more draw outstanding at a period end. As of June 30, 2022, Operating Company was in compliance with all material covenants under the Credit Agreement.
Subject to certain exceptions, the Credit Agreement permits Operating Company and its restricted subsidiaries to incur certain additional indebtedness, including secured indebtedness. None of Operating Company’s non-U.S. subsidiaries nor its dormant Puerto Rico subsidiary is a guarantor of the loans.
Under the Credit Agreement, Operating Company’s ability to engage in certain activities such as incurring certain additional indebtedness, making certain investments, and paying certain dividends is tied to ratios based on Adjusted EBITDA (which is defined as “Consolidated EBITDA” in the Credit Agreement). Adjusted EBITDA is based on the definitions in the Credit Agreement, is not defined under U.S. GAAP, and is subject to important limitations. See “—Non-GAAP Metrics” for further details on Adjusted EBITDA.
As market conditions warrant, we may from time to time seek to purchase our outstanding debt in privately negotiated or open-market transactions, by tender offer or otherwise. Subject to any limitation contained in the Credit Agreement, any purchase made by us may be funded by the use of cash on hand or the incurrence of new secured or unsecured debt. The amount involved in any such purchase transaction, individually or in the aggregate, may be material. Any such purchase may involve a substantial amount of one particular class or series of debt, with the attendant reduction in the trading liquidity of such class or series.
The Senior Notes
The Indentures contain certain covenants that, among other things, limit the ability of Operating Company and its restricted subsidiaries to incur or guarantee more debt or issue certain preferred shares; pay dividends on, repurchase, or make distributions in respect of their capital stock or make other restricted payments; make certain investments; sell certain assets; create liens; consolidate, merge, sell; or otherwise dispose of all or substantially all of their assets; enter into certain transactions with their affiliates, and designate their subsidiaries as unrestricted subsidiaries. These covenants are subject to a number of exceptions, limitations, and qualifications as set forth in the Indentures. The Indentures also contain customary events of default including, but not limited to, nonpayment, breach of covenants, and payment or acceleration defaults in certain other indebtedness of Operating Company or certain of its subsidiaries. Upon an event of default, either the holders of at least 30% in principal amount of each of the then-outstanding Senior Notes or the applicable Trustee under the Indentures, may declare the applicable Senior Notes immediately due and payable; or in certain circumstances, the applicable Senior Notes will automatically become immediately due and payable. As of June 30, 2022, Operating Company was in compliance with all material covenants under the Indentures.
Liquidity in Foreign Subsidiaries
As of June 30, 2022 and 2021, the amounts of cash and cash equivalents held by foreign subsidiaries were $377 million and $351 million, respectively, out of total consolidated cash and cash equivalents of $449 million and $896 million, respectively. These balances are dispersed across many international locations around the world.
58


Adjusted EBITDA and Adjusted Net Income per Share
The below tables summarize our fiscal 2022 and 2021 results with respect to certain financial metrics we use to measure performance throughout the fiscal year. Refer to Non-GAAP Metrics” for further details regarding Adjusted EBITDA and Adjusted net income per share.
ctlt-20220630_g6.jpg
A reconciliation between Adjusted EBITDA and net earnings, the most directly comparable measure under U.S. GAAP, which also shows the adjustments from EBITDA from operations, follows:
Fiscal Year Ended
(In millions)June 30, 2022June 30, 2021
Net earnings$519 $585 
Interest expense, net123 110 
Income tax expense
86 130 
Depreciation and amortization378 289 
EBITDA from operations1,106 1,114 
Stock-based compensation54 51 
Impairment charges and gain/loss on sale of assets31 
Financing-related expenses and other 18 
Restructuring costs10 10 
Acquisition, integration, and other special items46 21 
Gain on sale of subsidiary(1)(182)
Foreign exchange loss (gain) (included in other, net) (1)
31 (4)
Inventory fair value step-up charges— 
Other adjustments (2)
(3)(17)
Adjusted EBITDA$1,285 $1,020 
Favorable (unfavorable) FX impact (23)
Adjusted EBITDA - constant currency$1,308 

(1)    Foreign exchange loss of $31 million for the fiscal year ended June 30, 2022 includes: (a) $12 million of unrealized gains related to foreign trade receivables and payables, (b) $11 million of unrealized losses on the unhedged portion of our euro-denominated debt, and (c) $34 million of unrealized losses on inter-company loans. The foreign exchange adjustment was also affected by the exclusion of realized foreign currency exchange rate gains from the settlement of inter-company loans of $2 million. Inter-company loans exist between our subsidiaries and do not reflect the ongoing results of our trade operations.
Foreign exchange gain of $4 million for the fiscal year ended June 30, 2021 includes: (a) $13 million of unrealized losses related to foreign trade receivables and payables, (b) $3 million of unrealized losses on the unhedged portion
59


of the euro-denominated debt, and (c) $25 million of unrealized gains on inter-company loans. The foreign exchange adjustment was also affected by the exclusion of realized foreign currency exchange rate losses from the settlement of inter-company loans of $5 million. Inter-company loans exist between our subsidiaries and do not reflect the ongoing results of our trade operations.
(2)    Primarily represents the gain recorded on the change in the estimated fair value of the derivative liability related to our formerly outstanding Series A Preferred Stock.
A reconciliation between Adjusted Net Income and net earnings, the most directly comparable measure under U.S. GAAP, follows. The table also provides a calculation of Adjusted Net Income per each basic share and each diluted share.
ctlt-20220630_g7.jpg
Fiscal Year Ended
(In millions, except per share data)June 30, 2022June 30, 2021
Net earnings519 $585 
Amortization (1)
123 93 
Stock-based compensation54 51 
Impairment charges and gain/loss on sale of assets31 
Financing-related expenses18 
Restructuring costs10 10 
Acquisition, integration, and other special items46 21 
(Gain) on sale of subsidiary(1)